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Abstract 
 
The gene underlying the classic neurodegenerative lysosomal storage disorder 
(LSD) juvenile neuronal ceroid lipofuscinosis (JNCL) in humans, CLN3, 
encodes a polytopic membrane spanning protein of unknown function. Several 
studies using simpler models have been performed in order to further 
understand this protein and its pathological mechanism. Schizosaccharomyces 
pombe provides an ideal model organism for the study of CLN3 function, due to 
its simplicity, genetic tractability and the presence of a single orthologue of 
CLN3 (Btn1p), which exhibits a functional profile comparable to its human 
counterpart. In this study, this model was used to explore the effect of different 
mutations in btn1 as well as phenotypes arising from complete deletion of the 
gene. Different btn1 mutations have different effects on the protein function, 
underlining different phenotypes and affecting the levels of expression of Btn1p. 
So far, there is no cure for JNCL and therefore it is of great importance to 
identify novel lead compounds that can be developed for disease therapy. To 
identify these compounds, a drug screen with btn1Δ cells based on their 
sensitivity to cyclosporine A, was developed. Positive hits from the screen were 
validated and tested for their ability to rescue other specific phenotypes also 
associated with the loss of btn1. The same hits were also tested in JNCL 
patient fibroblasts and in a zebrafish model of the disease. Promising results 
were obtained for three compounds: alloxazine, prochlorperazine dimaleate and 
E-64, with the latest being the one with the most potential for developing 
therapeutic tools. Yeast models for other LSDs (Chédiak Higashi Syndrome, 
Niemann-Pick disease type C2 and congenital CLN10 disease) were also 
characterised in terms of cellular phenotypes and the compounds described 
above were also tested in these models. Overlapping phenotypes were 
observed on all the yeast models, suggesting at least one common pathway 
between these LSDs. 
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1 Introduction 
 
Juvenile CLN3 disease is one type of a group of diseases known as the 
neuronal ceroid lipofuscinosis (NCL), and is caused by mutations in the CLN3 
gene. CLN3 encodes a polytopic membrane spanning protein of unknown 
function. It is conserved and all evidence obtained so far suggests the same 
function in simple yeast as in human cells. Work done in fission yeast has 
shown that complete loss of the CLN3 orthologue, Btn1p, has multiple effects 
within the cell. Current therapeutic strategies for other types of NCL caused by 
enzyme defects are not applicable to juvenile CLN3 disease (JNCL), and new 
strategies or tools are urgently required for treatment of this disease. 
This first chapter consists of an introductory description of different topics that 
are relevant for a better understanding of this project. First an overview of the 
lysosomal storage disorders (LSDs) group is presented, including a more 
detailed description of all types of NCL, particularly juvenile CLN3 disease. 
Descriptions of two other LSDs (Chédiak-Higashi Syndrome and Niemann Pick 
type C disease) are also included. Second, all previous work that has been 
done with fission yeast and the CLN3 orthologue, Btn1p, will be described. Last, 
the aims of this project will be presented.  
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1.1 Lysosomal storage disorders 
In simple terms, lysosomal storage disorders (LSDs) are rare monogenic 
diseases characterised by biological defects that lead to the accumulation of 
unmetabolised compounds in lysosomes. Until the present date, 70 disorders 
have been identified as part of this group, with a collective prevalence varying 
between 1 in 5000 and 1 in 1000 live births (Aerts et al. 2011). Most LSDs are 
inborn errors of metabolism that originate from a defective catabolism and 
consequent intralysosomal accumulation of endogenous undegraded 
molecules. The majority of LSDs results from loss of activity of a lysosomal 
catabolic enzyme, which may be related to a defective protein synthesis or 
folding, enzyme activation or membrane protein defects (Jeyakumar et al. 
2005). Niemman Pick type C and several NCL, among others, fall into this latter 
category. However, the broad clinical spectrum of LSDs are clearly not simply 
an effect of the intralysosomal compound storage, but a consequence of 
defects in signalling pathways that affect the cell far beyond the lysosome, both 
structurally and biochemically (Vellodi 2005). This is becoming more apparent 
as the lysosome is no longer considered to be a waste recycling centre but play 
a central role in several cellular functions such as energy metabolism, lipid 
homeostasis, membrane repair and defence against pathogens, among others 
(Settembre et al. 2012). The pathophysiology of LSDs varies between the 
different disorders depending on the underlying defect, the type of storage 
compound and how this storage affects the cell metabolism (Gieselmann 2006). 
The majority of affected individuals with any type of LSD often show 
abnormalities at a neurological level that can lead to neurodegeneration 
(Walkley 1998).   
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1.1.1 Neuronal ceroid lipofuscinosis 
The neuronal ceroid lipofuscinosis (NCL) are neurodegenerative disorders 
grouped together on a clinical basis, with onset usually in childhood (Mole et al. 
1999). Children with NCL can start manifesting symptoms at any age, even 
before birth. The order of onset of the symptoms varies between the different 
types of NCL, but the main symptoms are common to all types. These include 
seizures and blindness, as well as progressive decline of cognitive and motor 
functions, eventually leading to a premature death. 
NCL are the most common of this type of diseases, with an incidence that can 
be as high as 7 in 100,000 births in some countries (Kyttälä et al. 2006). NCL 
are characterised by accumulation of autofluorescent ceroid and lipofuscin-like 
pigments in lysosomes. The ceroid pigment accumulates in disease, particularly 
in diseases caused by lysosomal dysfunction (Sulzer et al. 2008), whereas 
lipofuscin is an age-associated pigment that accumulates in the brains of all 
individuals as they get older, but in NCL cases this accumulation occurs much 
earlier (Seehafer & Pearce 2006). This storage material is not an obvious result 
of a defect in a single catabolic step. The major protein component of the 
storage material varies according to the NCL type, but in the majority of cases it 
is the subunit c of mitochondrial adenosine triphosphate (ATP) synthase (Haltia 
2006). This storage material has a characteristic pattern when examined under 
the electron microscope (EM), which varies according to the type of NCL (e.g. a 
fingerprint-like pattern for juvenile CLN3 disease). Most patient cells show this 
accumulation, but characteristically this leads to death only in neurons. The 
reason why this happens is unknown, however it is thought that this is due to 
the increased energy and metabolism requirements of neurons, which may 
make them more sensitive to the accumulated material or other underlying 
molecular defects (Goebel & Lake 1998).  
There are many types of NCL, traditionally classified according to the age of 
onset and the order of appearance of clinical symptoms, but recently modified 
according to the underlying genetic defect (Mole et al. 2011). The term Batten 
disease can be used to describe all forms of NCL, or more specifically, the 
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juvenile type. A brief description of each NCL is included below, and a table 
summarising all of these types is also presented (Table 1.1). 
 
Congenital CLN10 disease 
The congenital form of NCL, known as congenital CLN10 disease, is the most 
aggressive form of all NCLs and the one with the earliest onset. This disease 
was firstly identified in 1941 (Norman & Wood 1941) and has been described in 
11 patients to date. CLN10 disease is a very rare form of NCL although many 
cases may be undiagnosed due to spontaneous abortions and stillborn unviable 
foetuses (Anderson et al. 2013). This disease is caused by at least seven 
different mutations in the CTSD gene, which encodes for cathepsin D (Warrier 
et al. 2013). Cathepsin D is a lysosomal protease of the pepsin family (Rawlings 
& Barrett 1995) that is involved in several biological processes such as 
apoptosis, cell invasion, proteolytic degradation and other brain biological 
functions such as aging or even homeostasis of neuronal structures (Koike et 
al. 2000; Steinfeld et al. 2006). It is suggested that the neuronal death seen in 
this form of NCL occurs due to defects in the macroautophagy-lysosomal 
degradation pathway (Kohan et al. 2011). More interestingly, CLN3 has been 
suggested to affect the transport and proteolytic maturation of cathepsin D, due 
to its effect on vesicular trafficking and in lysosomal pH, respectively (Golabek 
et al. 2000; Fossale et al. 2004). This establishes a link between these two 
proteins. 
The protein constituents of the storage material in CLN10 disease are mainly 
saposins A and D, and the material has a granular ultrastructure resembling 
granular osmiophilic deposits (GRODs). Individuals with congenital onset show 
different phenotypes, such as microcephaly at time of birth, cerebral and 
cerebellar atrophy, seizures, spasticity, low set ears and broad nasal bridge in 
some cases, and have postnatal respiratory insufficiency, leading to death 
within hours to weeks after birth (Siintola et al. 2006).  Missense mutations in 
CTSD can also cause a NCL disease with later ages of onset, where affected 
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individuals have a normal early development but start to manifest ataxia and 
visual defects in early childhood, with a progressive decline that will eventually 
lead to loss of psychomotor functions and death (Steinfeld et al. 2006). In these 
cases there is an evident reduction of the proteolytic activity of cathepsin D, and 
the amount of protein present in the cells is markedly reduced. It is therefore 
proposed that the level of residual enzyme activity in individuals with CTSD 
mutations is critical for the clinical manifestation of the CLN10 disease 
Mutations in the cathepsin D gene are also present in other animals, where 
phenotypes associated with the CLN10 disease are evident: sheep, mice and 
fruit fly (Drosophila melanogaster) (Koike et al. 2000; Tyynelä et al. 2000; 
Myllykangas et al. 2005). The CTSD gene is also conserved in fission yeast 
(see below, section 1.2.2). 
 
Infantile CLN1 disease 
The gene underlying infantile CLN1 disease, PPT1 (or CLN1) encodes for the 
palmitoyl-protein thiosterase protein (PPT1) and was identified in 1995 (Vesa et 
al. 1995). In individuals with the mutated gene, there is no detectable enzyme 
activity in the brain. PPT1 removes thioester-linked fatty acids from cysteine 
residues in proteins and facilitates their degradation and/or recycling in the 
lysosome (Das et al. 1998). Therefore cysteine-containing fatty acyl thioesters 
accumulate intracellularly in cells with defective PPT1. PPT1 has been 
associated with different cellular functions: cholesterol metabolism, neuronal 
maturation, calcium homeostasis, endocytosis, among other, and it also has an 
antiapoptotic effect by decreasing the rate of activation of Ras oncogenes (Cho 
& Dawson 2000; Ahtiainen et al. 2006; Ahtiainen et al. 2007). The 
neurodegeneration that occurs in the cases of infantile CLN1 disease was 
reported as being a result of neuronal apoptosis via endoplasmic reticulum (ER) 
stress-induced caspase-12 activation and high production of reactive oxygen 
species (ROS) (Kim et al. 2006). The PPT1 gene is conserved in many 
eukaryotic species, such as Caenorhabditis elegans, D. melanogaster and 
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Schizosaccharomyces pombe (Korey & MacDonald 2003; Cho & Hofmann 
2004; Porter et al. 2005). 
Classic infantile CLN1 disease is a rare disorder, with an incidence of 1 in 100 
000 births, but it is a devastating condition (Haltia et al. 1973). Symptoms 
appear before the age of 18 months and include: cerebellar atrophy, 
microcephaly, ataxia, blindness, seizures, frequent convulsions and a 
progressive psychomotor deterioration that starts at about 1 year of age. By 3 
years of age they are diagnosed with brain death, which persists until death 
between 10-14 years of age (Haltia et al. 1973; Santavuori et al. 1973). 
Histologically, the storage material is similar to that of congenital CLN10 
disease, with a GROD-like characteristic pattern and composition of mainly 
saposins A and D (Tyynelä et al. 1993). 
Nonsense biallelic mutations in the CLN1 gene result in infantile CLN1 disease; 
however, other type of mutations in this gene can cause forms of NCL with later 
onset. For instance, heterozygous mutations in the PPT1 gene were reported to 
underlie a type of NCL clinically consistent with juvenile NCL but with an 
ultrastructural profile similar to the infantile form, granular deposits consisted of 
saposins (Mitchison et al. 1998; Kalviainen et al. 2007). Furthermore, some 
missense mutations in the PPT1 gene result in phenotypes clinically similar to 
the late infantile and juvenile forms of NCL, with disease onset at 2-4 years and 
after 5 years of age, respectively. However, the storage material observed in 
these cases is once again GROD-like (Das et al. 1998). PPT1 deficiency can 
also be associated with adult-onset NCL where symptoms start occurring as 
late as in the third decade of life of the patients (van Diggelen et al. 2001; 
Ramadan et al. 2007). It is suggested that if there is sufficient enzyme function, 
even at low levels, this is enough to ameliorate the NCL phenotype and delay 
the onset of the disease. These findings are supportive for a therapeutic 
strategy that includes enzyme replacement therapy. In fact, recent work in 
PPT1 knockout mice injected from birth with purified recombinant PPT1 showed 
that the treatment was well tolerated and resulted in signiﬁcant improvements in 
survival, motor performance and brain pathology of the mice (Hu et al. 2012). 
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Late infantile NCL 
There are different forms of late infantile NCL (LINCL), according to the gene 
that underlies the disease: CLN2, CLN5, CLN6, CLN7 or CLN8.  
Classic late infantile NCL (cLINCL, CLN2 disease) is caused by mutations in 
the CLN2 gene (also known as tripeptidyl peptidase 1, or TPP1) (Sleat et al. 
1997). TPP1 is a lysosomal peptidase, and mutations in the encoding gene lead 
to its retention in the ER and posterior degradation (Steinfeld et al. 2004). It is 
also thought that TPP1 may play a fundamental role in the degradation of 
subunit c of the mitochondrial ATP synthase, which accumulates in cLINCL as 
curvilinear bodies (Ezaki et al. 2000). The onset of symptoms in classic CLN2 
disease is between 2 and 4 years of age, and death of patients occurs between 
7 and 15 years of age (Sleat et al. 2008). Individuals show several symptoms, 
such as: speech impediments, epilepsy, mental deterioration and ataxia, 
followed by loss of vision and motor functions by the age of 10 years (Steinfeld 
et al. 2002). Mutations in CLN2 have on occasions also caused infantile NCL 
with an earlier onset before the first year of age, or more commonly a protracted 
form, with a juvenile age of onset (Ju et al. 2002; Bessa et al. 2008).  
A second type of LINCL is CLN5 disease, previously known as Finnish variant 
LINCL (vLINCL), and is caused by mutations in the CLN5 gene (Savukoski et 
al. 1998). This gene encodes a lysosomal glycoprotein of unknown function 
which traffics through the ER and Golgi apparatus to the lysosomes, and 
although originally reported as a membrane associated form, is now thought to 
be soluble (Isosomppi et al. 2002; Vesa et al. 2002; Larkin et al. 2013). When 
mutated, the CLN5 protein may not traffic to lysosomes (Schmiedt et al. 2010). 
CLN5 was also shown to interact directly with two other NCL proteins, TPP1 
and CLN3 (Vesa et al. 2002). In CLN5 disease, patients start manifesting 
symptoms at a slightly later age than in CLN2 disease (between 4 and 7 years 
of age) and the survival time is longer (up to 30 years of age) (Santavuori 1982; 
Moore et al. 2008). Symptoms vary between motor clumsiness, mental 
retardation, progressive visual failure, ataxia and myoclonic seizures 
(Savukoski et al. 1998). CLN5 disease patients can have mixed ultrastructural 
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patterns of inclusions: curvilinear, fingerprint and rectilinear; all containing 
subunit c of ATP synthase (Moore et al. 2008; Xin et al. 2010). Late infantile 
CLN5 disease is also manifested by Border Collie dogs (Melville et al. 2005). 
Certain mutations in CLN5 have been reported to underlie later forms of NCL, 
such as juvenile and adult forms (Sleat et al. 2009; Xin et al. 2010). 
Another variant form of LINCL is CLN6 disease, once known as Lake-
Cavanagh disease. This type is caused by mutations in the CLN6 gene, which 
encodes a putative transmembrane protein that localises to the ER (Gao et al. 
2002; Wheeler et al. 2002; Mole et al. 2004). CLN6 is highly conserved across 
vertebrates, with a orthologue in mice and in sheep (Broom & Zhou 2001; Gao 
et al. 2002; Tammen et al. 2006). Variant late infantile CLN6 disease is 
characterised by storage bodies containing subunit c of ATP synthase that can 
adopt a curvilinear, rectilinear or fingerprint profile (Moore et al. 2008). The 
disease course is similar to cLINCL; however, patients start manifesting 
symptoms slightly later, at 5 to 7 years of age, and survive until their second 
decade of life (Siintola et al. 2005; Moore et al. 2008). Symptoms include 
seizures and motor impairments in an early stage, and loss of vision later. 
A third type of LINCL, late infantile CLN7 disease, was first recognised in 
Turkish patients (Topçu et al. 2004). This variant form is caused by mutations in 
the major facilitator superfamily domain containing 8 (MFSD8 or CLN7) gene, 
which encodes a polytopic membrane protein with 12 membrane-spanning 
domains that is mainly localised in the lysosomes. MFSD8 belongs to a 
transporter superfamily and is conserved in vertebrates (Siintola et al. 2007). 
Compared to the classic form of CLN2 disease, patients with this variant show a 
slower but more severe course of the disease, with a higher frequency of 
seizures accompanied by a cerebral and cerebellar atrophy (Aiello et al. 2009). 
Other symptoms include motor impairment, ataxia, seizures and developmental 
regression (Topçu et al. 2004). Mutations in CLN7 can also underlie juvenile 
NCL (Kousi et al. 2009).  
The CLN8 gene was initially identified as the gene underlying progressive 
epilepsy with mental retardation (EPMR) (Ranta et al. 1999). It is now known 
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that EPMR (or Northern epilepsy) is a form of LINCL (more specifically a 
mutation-specific phenotype) with a more protracted course. The age of onset is 
between 5 and 10 years of age, when patients start manifesting seizures 
followed by a slow deterioration of mental capacities (Herva et al. 2000). Other 
mutations cause a more typical late infantile CLN8 disease. EM studies show 
that the storage bodies contain subunit c of ATP synthase and can have a 
fingerprint, curvilinear or rectilinear ultrastructural profile (Allen et al. 2012). 
CLN8 is a predicted transmembrane protein, which is located in the ER and 
traffics between the ER and the ER-Golgi intermediate compartments (Lonka et 
al. 2000). The function of CLN8 remains elusive but it has been associated with 
an indirect role of in protecting neurons from damage (Vantaggiato et al. 2009). 
Furthermore, a mutation in CLN8 underlies a NCL-like phenotype in English 
Setter dogs (Katz et al. 2005). 
 
Adult NCL 
The basis of adult-onset NCL is quite complex, since genes with different 
effects on the disease phenotype have been identified, all leading to an adult 
onset form of NCL (or ANCL). In general, the term adult NCL comprises a group 
of rare and genetically heterogeneous disorders with disease onset varying 
from 10 to 50 years of age (Berkovic et al. 1988). There are cases of ANCL 
where the genetic cause is still unknown. 
The form entitled adult CLN6 disease (or Kufs disease type A) is an autosomal 
recessive disease caused by mild mutations in the CLN6 gene, the same gene 
that is associated with disease onset in late infancy (Arsov et al. 2011). This 
form of NCL is characterised by progressive myoclonic epilepsy and ataxia, 
which start around the third decade of life, and no retinal degeneration 
(Berkovic et al. 1988). Storage material is mainly located in the neurons and 
can have three different profiles: fingerprint, rectilinear and GROD-like (Burneo 
et al. 2003).  
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Kufs type B disease is another type of ANCL. This type of Kufs disease differs 
from type A because it is mainly characterised by dementia, cerebellar signs, 
several motor deficiencies and behavioural disturbances, rather than epilepsy 
(Burneo et al. 2003). One gene, underlying the adult CLN13 disease, CTSF (or 
CLN13), was recently identified in some of these cases. CTSF encodes 
cathepsin F, a lysosomal protease (Smith et al. 2013). 
Another form of ANCL is known as adult CLN4 disease or Parry disease. It is 
autosomal dominant and caused by mutations in the deoxyribonucleic acid 
(DNA) J homologue subfamily C member 5 (DNAJC5 or CLN4) gene that 
encodes for cysteine-string protein α (CSPα), a highly conserved protein that is 
involved in the rescue of unfolded synaptic proteins (Cadieux-Dion et al. 2013). 
Mutations in DNAJC5 reduce the amount of functional CSPα affecting its 
location in neuronal cells, which might lead to dysfunction at a presynaptic level 
and to the neurodegeneration seen in affected individuals. There is also 
accumulation of misfolded proteins that are resistant to proteolysis in the 
neurons’ lysosomes (Noskova et al. 2011). The age of onset of symptoms in the 
affected individuals varies between 25 and 46 years of age and includes 
seizures, cognitive deterioration with loss of speech, cerebral atrophy, motor 
deficiencies (including Parkinsonism in some cases) and predominantly 
dementia, with no retinal degeneration (Nijssen et al. 2002; Burneo et al. 2003; 
Noskova et al. 2011). The storage material is arranged in three different 
ultrastructural profiles: fingerprint, rectilinear and GROD-like (Josephson et al. 
2001).  
Other more rare types of ANCL have been described. For instance, a 
homozygous mutation in the GRN gene (also known as CLN11), which encodes 
progranulin, has been identified in ANCL patients (Smith et al. 2012). 
Progranulin has been associated with several roles, such as inflammation, 
tumourigenesis and tissue repair (Bateman & Bennett 2009). Heterozygous 
mutations in this same gene are better known to cause frontotemporal lobar 
degeneration, the second most common early-onset dementia (Yu et al. 2010). 
In this CLN11 disease, affected individuals show visual failure and convulsions 
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in the second decade of life, followed by ataxia, cerebellar atrophy and early 
deterioration of cognitive capacities (Smith et al. 2012). Storage material with a 
rectilinear profile was identified in a progranulin-deficient mouse model (Petkau 
et al. 2012). 
In a mass spectrometry-based assay, mutations in further genes were shown to 
cause adult forms of NCL: two missense mutations in the CLN5 gene and a 
missense mutation in the N-sulphoglucosamine sulphohydrolase (SGSH) gene, 
which more usually underlies mucopolysaccharidoses III A (Sleat et al. 2009). 
Another study also showed that mutations in CLN5 cause ANCL (Xin et al. 
2010).  
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1.1.2 Juvenile CLN3 disease 
The juvenile form of NCL (JNCL), now known as juvenile CLN3 disease, is the 
most common form of NCL accounting for about 50% of all known NCL cases. 
The incidence of juvenile CLN3 disease can be as high as 7 births per 100,000 
in Scandinavia (Uvebrant & Hagberg 1997). 
Children with juvenile CLN3 disease start manifesting symptoms between the 
ages of 4 to 10 years. Symptoms start with visual impairment, followed by 
seizures and cognitive, speech and motor decline, progressively leading to 
death, usually in the second or third decade of life (Consortium 1995). Most 
patients also show behavioural problems with angry outbursts, physical 
violence, and features of depression. Magnetic resonance imaging 
examinations show cerebral and cerebellar atrophy (Mole et al. 2005).  
The juvenile CLN3 disease is characterised by the presence of lipofuscin with a 
fingerprint ultrastructural pattern (Palmer et al. 1992). These fingerprint profiles 
are often seen within large membrane-bound lysosomal vacuoles in the 
patients’ blood lymphocytes, but they are also found in neuronal tissues. 
Subunit c of ATP synthase complex is found in high concentrations in patients’ 
lysosomes, being the main protein component of the accumulated material in 
juvenile NCL. 
Juvenile CLN3 disease, like the majority of NCL disorders, is an autosomal 
recessive inherited condition, caused by mutations in the human gene CLN3 
(Consortium 1995). CLN3 encodes a polytopic membrane protein with 438 
amino acids. The proposed topology of the CLN3 protein consists of six 
transmembrane domains and a lumenal amphipathic helix (Nugent et al. 2008; 
Ratajczak et al. 2014) (Figure 1.1.1).  
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Figure 1.1.1 Proposed topologies of Btn1p showing the 
position of different mutations 
Proposed topology of Btn1p according to (A) Nugent et al and (B) Ratjaczak et al. Positions 
E295 and G187, where p.E295K and p.G187A mutations occur, are shown in the diagram by 
oval shapes. The region deleted in the 1-kb deletion is represented in light grey (Nugent et al. 
2008; Ratajczak et al. 2014). 
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Over 50 mutations have been described in CLN3 to date (NCL resource 
mutation database - http://www.ucl.ac.uk/ncl). The most common mutation, 
present in almost all patients, is a 1-kb intragenic deletion that removes two 
internal exons within the CLN3 gene, and that can be found on both disease 
alleles or in compound heterozygosity with a different mutation (Consortium 
1995; Munroe et al. 1997). This deletion is known to result in at least two 
different transcripts: one predicted to encode a truncated protein of just over 
100 amino acids and another lacking three internal exons. Thus, two mutant 
proteins may be expressed in cells of juvenile CLN3 disease patients 
(Kitzmuller et al. 2008). Previously it had been thought that these patients had 
lost all function of CLN3; however it was later shown that patients with this 
mutation have a mutation-specific phenotype since partial function of CLN3 
remains in all cells (Haines et al. 2009). Moreover, the mutant protein is able to 
rescue the enlarged lysosomes that arise from complete or severe loss of CLN3 
function (Kitzmuller et al. 2008). Furthermore, the existence of subclinical eye 
features was reported in healthy carriers of the 1-kb deletion (Gottlob et al. 
1988). 
Other mutations have been detected in CLN3. These mutations can be in 
compound heterozygosity with the 1-kb deletion. The majority are missense 
mutations, but other types have also been found:  nonsense mutations, small 
deletions, small insertions, intronic and splice-site mutations (Munroe et al. 
1997). Approximately 80% of mutations in CLN3 cause truncation of the protein 
resulting in prematurely truncated products (Kousi et al. 2012). The 
p.Glu295Lys is one of the mutations associated with the mildest form of juvenile 
CLN3 disease in patients also carrying the 1-kb disease allele, with blindness 
as a clinical symptom for several decades, before the remaining symptoms start 
to manifest (Wisniewski et al. 1998; Aberg et al. 2009). Another mutation, 
p.Gly187Ala, is predicted to cause complete loss of CLN3 function, perhaps 
through disruption of protein folding and eventual degradation (Haines et al. 
2009). There is evidence of correlation between genotype and phenotype in the 
CLN3 disease. For example, it has been reported that mutations in the lumenal 
regions, including the amphipathic helix, have the most significant impact on the 
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CLN3 function (Haines et al. 2009). Similarly, any mutation that will affect the 
protein structure will give rise to a classic juvenile NCL phenotype, whereas a 
more protracted disease course will be underlined by other mutations, 
presumably affecting less important CLN3 residues (Mole et al. 2005). 
Remarkably, several individuals whose only symptoms are visual failure, even 
in late adulthood, have recently been shown to harbour mutations in CLN3 
(Coppieters et al. 2014; Wang et al. 2014). This relationship between disease 
severity and the underlying mutation suggests that certain protein regions are 
more important for its activity than others. This makes it very important to further 
elucidate the protein function and predict which are the important regions, in 
order to reach a therapeutic goal. This will be further discussed later in the 
Discussion Chapter. 
CLN3 is the most highly conserved of the NCL genes, and it has been 
described in all eukaryotic species, except plants (Mole et al. 2005) (Figure 
1.1.2). This high conservation between species suggests an important role for 
this protein at the cellular level. The fact that the protein is greatly conserved 
also provides several simpler models for juvenile CLN3 disease. Organisms 
that have been used as models for the study of CLN3 include: the budding 
yeast Saccharomyces cerevisiae, fission yeast Schizosaccharomyces pombe, 
the nematode worm Caenorhabditis elegans, fruit fly Drosophila melanogaster, 
zebrafish Danio rerio and at least four different mouse models. In budding yeast, 
the orthologue of CLN3 is Btn1p. Btn1p is composed of 408 amino acids, and is 
59% similar and 39% identical to the human protein (Pearce & Sherman 1997). 
The fission yeast orthologue has the same denomination, Btn1p, but is slightly 
smaller, with 396 amino acids, and is 48% similar and 30% identical to its 
human orthologue (Gachet et al. 2005). C. elegans has three CLN3 gene 
orthologues: cln-3.1, cln-3.2, and cln-3.3, all with distinct expression patterns 
(de Voer et al. 2001). The fruit fly model of juvenile CLN3 disease is a gain-of-
function system, and the Drosophila cln3 is 60% similar to the human gene. 
Overexpression of cln3 causes degeneration and roughening of the fly eyes, 
duplicated macrochaetae on the thorax, thickening of wing veins and increased 
apoptosis in the wings (Tuxworth et al. 2009). A zebrafish model of CLN3 
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disease was generated by a Cln3-targeted morpholino approach. These fish 
show a spontaneous tail flicking phenotype, locomotion impairments with no 
movement, smaller eyes and premature death (Claire Russell and Kim Wager; 
personal communication). Finally, there are four mouse models with different 
deletions and insertions in the Cln3 gene. The first one was generated by 
targeted disruption of exons 1 to 6 of Cln3. These mice show accumulation of 
autofluorescent material in neurons, cortical atrophy and neurodegeneration 
(Mitchison et al. 1999). The second mouse model is also a knockout model, 
created by disruption of exons 7 and 8 of Cln3, and they also show storage 
material and neurodegeneration (Katz et al. 1999). The other two models are 
knock-in mice. One is a Cln3ex7-8 knock-in mouse, a genetic model of the 
common 1-kb deletion found in juvenile NCL patients, where exons 7 and 8 
have been deleted.  This mouse shows degeneration in the retina, cerebral 
cortex and cerebellum, neurological problems and suffers from a premature 
death (Cotman et al. 2002). The last mouse is another knock-in reporter model 
of the disease, where exons 1 to 8 of Cln3 are replaced with -galactosidase 
reporter. These mice show autofluorescent inclusions and neurological 
impairment, such as tremors, susceptibility to seizures and deficient motor 
functions (Eliason et al. 2007). All of these models contributed to important 
findings regarding the function of CLN3, and this is discussed below. 
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Figure 1.1.2  Conservation of CLN3 between several species 
Diagram of CLN3 amino acid conservation between human, mouse, Danio rerio (zebrafish), 
Drosophila melanogaster (fruit fly) and Schizosaccharomyces pombe (fission yeast). Each 
amino acid is represented by a letter and ‘-‘ represents the lack of those amino acids in the 
organism. Asterisks and grey rectangles represent residues that are known to be mutated in the 
human CLN3. The regions in black are regions that are exactly the same between the species; 
regions in grey correspond to regions where the amino acids are very similar respective to their 
properties. Lines above the amino acids correspond to the predicted transmembrane domains 
domains of the CLN3 protein according to the topology proposed by Nugent et al.. All mutated 
residues are highly conserved between species, as well as the transmembrane regions. 
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Table 1.1 Summary of different types of NCL 
NCL type Gene / Protein Protein function 
Congenital CLN10 disease  CTSD / cathepsin D Lysosomal protease 
Infantile CLN1 disease CLN1 / PPT1 Lysosomal thioesterase  
Late infantile CLN2 disease CLN2 / TPP1 Lysosomal peptidase 
Late infantile CLN5 disease CLN5  Lysosomal glycoprotein 
Late infantile CLN6 disease CLN6  ER transmembrane 
protein 
Late infantile CLN7 disease CLN7 / MFSD8 Membrane transporter 
protein 
Late infantile CLN8 disease 
or EPMR 
CLN8  Predicted 
transmembrane protein 
Juvenile CLN3 disease CLN3  Predicted 
transmembrane protein 
Adult CLN6 disease or Kufs 
disease type A 
CLN6  ER transmembrane 
protein 
Adult CLN13 disease or 
Kufs disease type B 
CTSF / cathepsin F Lysosomal protease 
Adult CLN4 disease or 
Parry disease 
DNAJC5 / CSPα Involved in protein folding 
Adult CLN11 disease GRN / progranulin Cell growth regulator 
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CLN3 function 
The exact function of CLN3 is still unknown and thought to be complex. Over 
the years, several important cellular roles have been associated with this 
protein such as autophagy, cytoskeletal organization, lysosomal homeostasis, 
lipid modification, apoptosis, trafficking, amino acid transport and metabolism. 
All of these functions are discussed below, together with a summary of the 
current information available on the CLN3 localisation and trafficking. 
 
CLN3 localisation and trafficking 
CLN3 has been reported at different locations in mammalian cells. These 
different locations include lysosomal or late endosomal compartments (Järvelä 
et al. 1998; Järvelä et al. 1999; Kida et al. 1999; Kyttälä et al. 2004) including 
the lysosomal membrane (Ezaki et al. 2003), the Golgi apparatus (Kida et al. 
1999; Kremmidiotis et al. 1999; Getty et al. 2013), the trans-Golgi network 
(TGN) (Tecedor et al. 2013), the endoplasmic reticulum (Kida et al. 1999), the 
nucleus (Margraf et al. 1999), the mitochondria (Katz et al. 1997) and in 
membrane lipid rafts (Rakheja et al. 2004). CLN3 has also been located in 
synaptosomes (Luiro et al. 2001). These studies were all done with 
overexpressed CLN3 as the amount of endogenous protein is too low to be 
detected using antibodies. 
Further work concerning CLN3 localisation was carried out in simpler disease 
models, again by studying ectopic expression with a GFP tag. Btn1p, the yeast 
orthologue of CLN3, is located in the perimeter membrane of vacuoles (the 
yeast organelles equivalent to mammalian lysosomes) and prevacuolar 
compartments, both in S. cerevisiae and S. pombe (Croopnick et al. 1998; 
Pearce et al. 1999b; Gachet et al. 2005). Additionally, Btn1p was observed in 
the Golgi apparatus at steady state with trafficking via the endocytic system to 
the vacuoles, in S. pombe (Gachet et al. 2005; Codlin & Mole 2009) and S. 
cerevisiae (Kama et al. 2011). 
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The effect of different mutations on the localisation of CLN3 has been reported 
in several studies. The presence of the common deletion in CLN3 has been 
shown to prevent exit of the protein from the ER and subsequent targeting to 
the endosomal/lysosomal compartments (Järvelä et al. 1999). Similarly, work 
done in the fission yeast model of juvenile CLN3 disease, showed that the 
missense mutation p.Gly187Ala (or p.Gly136Ala in Btn1p) and other mutations 
in the predicted second lumenal loop of Btn1p (according to (Nugent et al. 
2008) affect trafficking to the vacuoles and retain Btn1p in the ER (Codlin & 
Mole 2009; Haines et al. 2009). Other missense mutations in CLN3 were also 
studied. Work using mammalian cells showed that these mutations do not seem 
to affect CLN3 trafficking, since mutant CLN3 was observed in the same 
compartments as the wild-type protein, in the endosomal-lysosomal pathway 
(Järvelä et al. 1999; Haskell et al. 2000). However, recent work done in our 
group with fission yeast showed different results. In this study, mutations in the 
Btn1p C-terminal cysteine residues led to internalisation of the protein into the 
vacuoles (Haines et al. 2009).  
CLN3 undergoes several post-translational modifications. CLN3 is N-
glycosylated in two sites (asparagine residues 71 and 85) that are not essential 
for targeting CLN3 to the lysosomes, since the presence of mutations in these 
sites does not affect the lysosomal sorting of CLN3 (Storch et al. 2007). The C-
terminal of CLN3 contains a farnesylation motif (Pullarkat & Morris 1997). The 
inhibition of farnesylation in this motif appears to impair the sorting efficiency of 
CLN3 in early endosomes and subsequently increases the amount of CLN3 in 
the plasma membrane (Storch et al. 2007). Two other motifs are essential for 
CLN3 sorting to the lysosome both in neuronal and non-neuronal cells: one is 
located in the C-terminal and consists of a methionine and a glycine separated 
by nine amino acids [M(X)9G] (from 409 to 419), and the other is a dileucine 
motif (in hydrophobic amino acids 253 and 254) that resembles classic 
lysosomal targeting motifs in the second cytosolic loop domain of CLN3, LI 
(Kyttälä et al. 2004).  
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Lysosome homeostasis 
As mentioned above, CLN3 is localised in the membrane of late endosomes 
and lysosomes. Therefore, it is plausible that it exerts some functional roles in 
these organelles. Evidence of CLN3 function in lysosomal homeostasis has 
been reported in several studies. The lysosomal pH in fibroblasts is increased in 
several NCL, including the juvenile form (Holopainen et al. 2001). This is 
thought to result from a decrease in the vacuolar H+ ATPase complex (v-
ATPase) activity, reported in other study (Ramirez-Montealegre & Pearce 
2005). It is also thought that this decreased activity in the lysosomes disturbs 
the catalytic activity of lysosomal proteins and subsequently leads to 
accumulation of lipopigments, characteristically seen in NCL (Holopainen et al. 
2001).  
It was reported that the activities of several lysosomal enzymes are increased in 
Juvenile NCL patients (Sleat et al. 1998). Similarly, work done in a knockout 
mouse model of this disease showed that the activity of the lysosomal acid 
phosphatase LAP/ACP2 was significantly increased in the mice brain (Pohl et 
al. 2007). In the same study, this lysosomal phosphatase was reported as being 
present at high levels in juvenile NCL patient fibroblasts. This may reflect 
compensatory effects occurring in the cell that are initiated at the lysosome. 
The level of expression of CLN3 is thought to influence lysosome size in 
mammalian and yeast cells: in HeLa cells depleted for CLN3 by the action of 
small interfering ribonucleic acid (siRNA) lysosomes are larger than in control 
cells and overexpression of CLN3 decreases their size (Kitzmuller et al. 2008). 
Similar effects were seen in induced pluripotent stem cells derived from patient 
fibroblasts and in S. pombe (Gachet et al. 2005; Lojewski et al. 2014). 
Additionally, fibroblasts from patients containing the 1-kb common deletion 
when treated with siRNA against CLN3 showed an increase in lysosomes size. 
This result corroborates the finding that the 1-kb deletion retains some function 
and is not a null mutation (Kitzmuller et al. 2008).  
Alterations in lysosomal pH have also been reported in both yeast models of 
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juvenile CLN3 disease (S. cerevisiae and S. pombe), but with contradictory 
effects. Fission yeast cells show the same phenotype as mammalian cells: 
when btn1 is deleted vacuoles are larger and less acidic than in wild-type cells, 
and overexpression of btn1 increases acidity (Gachet et al. 2005). In contrast, 
in budding yeast, cells deleted for BTN1 have more acidic vacuoles, thought to 
be due to an increase in v-ATPase activity (Chattopadhyay et al. 2000). In 
fission yeast, ectopic expression of btn1 is able to compensate for v-ATPase 
function in cells deleted for genes encoding v-ATPase subunits, suggesting that 
its contribution to vacuole acidification is not only via an effect on the v-ATPase 
activity (see more details below, section 1.2.3) (Codlin et al. 2008a). This 
rescue may be due to an effect that Btn1p exerts on the activity of other ion 
transporters or channels, or as a direct consequence of its own activity.  
 
Trafficking, endocytosis and autophagy 
CLN3 dysfunction has been associated with defects in membrane trafficking 
routes and endocytosis. HeLa cells treated with CLN3 siRNA show a defect in 
trafficking of the cation-independent mannose 6-phosphate receptor (CI-MPR). 
This defect results in an impediment in the ability of CI-MPR to exit the TGN, 
where it accumulates (Metcalf et al. 2008). Furthermore, there was a reduction 
in the maturation rate and cellular activity of lysosomal cathepsins B and D, 
which suggests that CLN3 plays an essential role in trafficking and delivery of 
lysosomal enzymes, affecting the ability of lysosomes to perform their functions. 
Another study performed in cultured human embryonal kidney cells confirmed 
that the maturation process of cathepsin D is deficient when CLN3 function is 
inhibited (Golabek et al. 2000). The lysosomal degradation of the amyloid-β 
protein precursor was also affected in the absence of CLN3. Furthermore, 
processing and transport of cathepsin D are also disrupted in a knock-in mouse 
model of juvenile CLN3 disease (Fossale et al. 2004). However, these effects 
on cathepsin D activity are not as low as the levels required to directly induce 
disease resembling CLN10 disease. 
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In S. pombe, it was found that the post-Golgi trafficking of vacuolar protein 
sorting 10 protein (Vps10p), the sorting receptor of the vacuole hydrolase 
carboxypeptidase Y (Cpy1p), is impaired in btn1Δ cells (where btn1 is deleted). 
This leads to a defect in the sorting of Cpy1p so that it is secreted from the cell. 
The fact that Vps10p is not able to traffic from the Golgi to the TGN might be 
due to a direct effect that Btn1p exerts on the Golgi compartment, where it is 
located at steady state and which undergoes striking morphological changes in 
the absence of Btn1p (Codlin & Mole 2009).  
Studies in different CLN3 models reported defects in the endocytic process: S. 
pombe btn1Δ cells (Codlin et al. 2008b), knock-in mice neuronal precursor cells 
(Fossale et al. 2004) and juvenile NCL patient fibroblasts (Luiro et al. 2004). In 
a recent study with brain endothelial cells, CLN3 was reported to mediate the 
transport of microdomain-associated proteins, caveolin-1 and multidrug 
resistance protein 1, MDR1, from the TGN to the plasma membrane. Therefore, 
all functions associated with these proteins such as drug efflux, endocytosis 
and regulation of cell volume, were impaired in CLN3-null cells (Tecedor et al. 
2013). Another recent study performed in endothelial brain cells from a knock-in 
juvenile NCL mouse model revealed that these cells have defects in the ADP-
ribosylation factor 1-cell division control protein 42 homologue (ARF1-Cdc42) 
pathway (Schultz et al. 2014). These defects have a direct impact on the fluid-
phase endocytic process and other cellular processes such as filopodia 
formation and cell migration. 
In a study with the S. cerevisiae model of juvenile CLN3 disease, it was 
revealed that the expression of BTN2 (orthologue of the human Hook1) is 
elevated in BTN1Δ cells (Pearce et al. 1999b). Furthermore, Btn2p is involved 
in the regulation of the endocytic SNARE complex in yeast and mediates 
retrograde sorting of proteins from late endosomes back to Golgi compartments 
(Kama et al. 2007; Kama et al. 2011). The orthologue of Hook1 in Drosophila 
regulates endocytosis of surface ligands (Kramer & Phistry 1996, 1999) In 
fibroblasts from juvenile NCL patients; CLN3 overexpression induces 
aggregation of Hook1 and a weak interaction between these two proteins was 
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found (Luiro et al. 2004). Additionally, Hook1 has been shown to physically 
interact with endocytic Rab7, Rab9 and Rab11, suggesting a role for Hook1 in 
membrane trafficking.  
There is also evidence of autophagy disruption in a knock-in mouse model of 
juvenile CLN3 disease at the level of autophagic vacuole maturation. In these 
murine cells the levels of the autophagy marker LC3-II were increased, 
lysosomes and autophagic vacuoles were less mature than in wild-type mice, 
and there was accumulation of subunit c of mitochondrial ATP synthase in 
vacuoles (Cao et al. 2006). Another recent study showed an upregulation of the 
Akt-mTOR (mammalian target of rapamycin) signalling pathway and decreased 
acidity in juvenile NCL patient fibroblasts, both leading to macroautophagy and 
disrupted endocytosis (Vidal-Donet et al. 2013). The increased lysosomal pH 
affects the maturation of autophagosomes and impairs endocytosis. 
 
Cytoskeletal organization  
Since CLN3 and Hook1 may interact (see above), and Hook1 interacts with 
microtubules (Walenta et al. 2001), it is plausible that CLN3 function may be 
related to cytoskeletal organization (Luiro et al. 2004). In fact, gene expression 
profiling of embryonic cortical neurons of a knockout mouse model revealed a 
downregulation of dynactin (Luiro et al. 2006). Dynactin interacts with 
microtubules, suggesting a microtubule-related defect in this mouse model. In 
other studies, an interaction between CLN3 and the plasma membrane fodrin 
cytoskeleton was reported, since this structure has an abnormal appearance in 
patient fibroblasts and in brain cells from a knockout mouse model (Uusi-Rauva 
et al. 2008; Getty et al. 2011). A recent study showed that cells from a knockout 
mouse model have defects at a cytoskeletal level, due to alterations in the 
cytoskeleton-associated nonmuscle myosin-IIB activity (Getty et al. 2011). 
These mice fibroblasts appeared longer and thinner than those from wild-type 
mice. 
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Work using the S. pombe model of juvenile CLN3 disease also contributes to 
this idea that CLN3 (or Btn1p) function is linked to the cytoskeleton. Severe 
defects in the F-actin cytoskeleton were reported in yeast btn1 cells at a high 
temperature of growth (Codlin et al. 2008b). F-actin is depolarized which leads 
to an abnormal cell morphology. Moreover, at the same temperature, btn1 
yeast cells adopt a curved morphology and show bundling of microtubules 
(Haines et al. 2009). 
 
Amino acid transport 
Lysosomes isolated from lymphoblasts of juvenile NCL patients show defective 
transport of arginine, leading to a depletion of arginine in patient lysosomes 
(Ramirez-Montealegre & Pearce 2005). Arginine transport into the lysosomes is 
v-ATPase-dependent. Therefore, it is proposed that CLN3 has a role in the 
regulation of intracellular levels of arginine possibly due to decreased v-ATPase 
activity. The same phenotype was also seen in S. cerevisiae cells deleted for 
BTN1 (Kim et al. 2003). In these cells transport of arginine into vacuoles also 
requires a functional v-ATPase. Levels of vacuolar arginine are depleted and 
there is no transport of this amino acid into the vacuole. These defects are 
rescued by expression of Btn1p and human CLN3, suggesting a potential role 
of CLN3 (and Btn1p) in the transport and/or regulation of the transport of amino 
acids into the lysosome (or vacuole). However, more recently it was shown that 
mutations in CLN3 (and BTN1) predispose cells to keep low levels of arginine, 
since high levels are toxic to cells with no BTN1 (Vitiello et al. 2007). 
Additionally, in the same study, it was also shown that the decreased level of 
intracellular arginine is not a result of altered arginine uptake, arginine efflux or 
incorporation into peptides. The altered metabolism of arginine was also studied 
in brains of a knockout mouse model of juvenile CLN3 disease. In this study, no 
differences in brain arginine levels were observed between wild-type and 
knockout mouse (Chan et al. 2009). However, a decrease in arginine transport 
into cerebellar granule cells was observed. Additionally, there was an alteration 
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in the production of nitric oxide, which is synthesized from arginine and 
therefore dependent on its availability. Nitric oxide is involved in many 
physiological processes in the brain, suggesting that imbalances in arginine 
(and consequently nitric oxide) brain levels can have great implications in 
neuronal function and survival.  
Another study in S. pombe showed several metabolic abnormalities in the 
btn1Δ strain: increased glycolytic flux and glycolysis and amino acid changes 
(Pears et al. 2010). These phenotypes suggest that Btn1p has a role in the 
control of glycolytic rate and that vacuolar dysfunction may reflect the 
concentration of amino acids. This hypothesis is corroborated by the 
observation of high levels of glycogen storage in mammalian cells depleted for 
CLN3. In yeast cells, the increase in glycolytic flux may originate from increased 
activity of the v-ATPase as a compensatory mechanism for the increased 
vacuole pH in btn1Δ cells (mentioned above); or simply to meet energy 
demands of btn1Δ cells in which oxidative phosphorylation is suppressed.   
 
Other functions  
Another proposed function for CLN3 is an anti-apoptotic activity, reported in 
several studies. Overexpression of CLN3 reduced drug-mediated apoptosis in 
at least three studies (Puranam et al. 1999; Persaud-Sawin et al. 2002; 
Narayan et al. 2006a). However, in a more recent study the ectopic 
overexpression of cln3 in the wing of Drosophila increased apoptosis, opposing 
the previous idea of a CLN3 anti-apoptotic activity (Tuxworth et al. 2009). In the 
same study, it was revealed that cln3 expression activates the Jun N-terminal 
kinase (JNK) signalling pathway and inhibits the Notch signalling pathway. 
Several studies proposed that CLN3 confers resistance to oxidative stress. 
Cells from the knock-in Cln3∆ex7/8 mouse showed abnormally elongated 
mitochondria and a reduced survival rate after being exposed to hydrogen 
peroxide, implying an increased sensitivity to oxidative stress and a defective 
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energy metabolism in these cells (Fossale et al. 2004). Similarly, the fruit fly 
model of juvenile CLN3 disease was reported as being hypersensitive to 
oxidative stress generated by hydrogen peroxide, diethylmaleate and paraquat 
(Tuxworth et al. 2011). Overexpression of cln3 in this model conferred 
resistance to this type of stress. In the same study, CLN3 was also shown to 
interact with JNK and FOXO stress signalling pathways, promoting stress 
resistance. Additionally, a study in SH-SY5Y neuroblastoma cells revealed that 
overexpressed CLN3 confers resistance to ER stress induced by treatment with 
tunicamycin (Wu et al. 2014). In another recent study, mitochondrial 
abnormalities such as increased distension, disruption of the internal 
architecture and loss of cristae were observed in neural progenitor cells from 
juvenile NCL patients (Lojewski et al. 2014). In an older study, other 
mitochondrial defects were reported in a knockout mouse model: lower 
mitochondrial oxygen consumption due to reduced activities of respiratory chain 
complexes in this organelle and a larger mitochondrial size when compared to 
wild-type mice (Luiro et al. 2006). 
Another proposed function of CLN3 is as a lipid catalyst or modifier. CLN3 was 
proposed to be a palmitoyl-protein Δ-9 desaturase, since a possible fatty acid 
desaturase domain was identified in a study using the Pfam server (Narayan et 
al. 2006b). This enzymatic activity is deficient in a knockout mouse model of 
juvenile CLN3 disease and in cultured SH-SY5Y neuroblastoma cells treated 
with Cln3 siRNA. However the motif is not conserved in yeast btn1 (Kitzmuller 
et al. 2008). CLN3 has been related to the production of the 
bis(monoacylglycerol)phosphate phospholipid, since it is reduced in extracts 
from juvenile NCL patient brains (Hobert & Dawson 2007).  
Finally, CLN3 interacts with a neuronal calcium-binding protein, Calsenilin, in 
vitro, and regulates intracellular levels of free calcium (Ca2+) in SH-SY5Y cells 
(Chang et al. 2007). This interaction was reported as being essential for 
supressing Ca2+-induced cell death in neurons. In fact, the level of intracellular 
calcium is increased in SH-SY5Y cells treated with CLN3 siRNA (An Haack et 
al. 2011); and a calcium channel antagonist, amlodipine, was reported as being 
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able to reverse elevated calcium levels in rat cortical neurons treated with 
siRNA against CLN3 (Warnock et al. 2013).  
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1.1.3 Chédiak-Higashi syndrome and Niemann-Pick type C disease 
Two further lysosomal storage disorders will be briefly described: the Chédiak-
Higashi syndrome (CHS) and the Niemann-Pick type C disease (NPC). Yeast 
strains for both of these diseases were characterised during this study (Results 
Chapter 4). 
Chédiak-Higashi syndrome (CHS) is a rare autosomal recessive disorder 
caused by mutations in the lysosomal trafficking regulator protein (LYST). 
Human LYST gene (also known as CHS1) was identified following identification 
of its murine orthologue, beige (Barbosa et al. 1996). LYST is known to be a 
large cytosolic- and microtubule-associated protein, however its exact function 
remains unknown. LYST has been associated with lysosomal homeostasis, 
more specifically fission and/or fusion of lysosomes (Holland et al. 2014). 
Symptoms of CHS include partial albinism of hair and eyes, progressive 
neurologic defects, severe immunodeficiency with impaired activity of natural 
killer cells and increasing susceptibility to infections (Higashi 1954; Barrat et al. 
1996). Death typically occurs in childhood, in the first decade of life, in a 
disease stage denominated ‘accelerated phase’, characterised by lymphocytic 
infiltration of various body organs. However, some patients with a mild disease 
course can survive until adulthood (Karim et al. 2002). The hallmark of CHS is 
the presence of abnormally large organelles (including lysosomes) and vesicles 
in different types of cells, such as granulocytes (Burkhardt et al. 1993; Karim et 
al. 1997). These defects may result from a defective trafficking of proteins 
involved in the genesis of these components (Faigle et al. 1998) or a problem in 
membrane remodelling. CHS can be treated by bone marrow transplantation, 
but since this does not apply to the central nervous system, patients eventually 
develop neurologic defects (Kaplan et al. 2008).  
There is a orthologue of LYST in fission yeast, lvs1 (large vacuoles size). This 
gene was identified after a BLAST (Basic Local Alignment Search Tool) search, 
as a protein containing a single BEACH domain, similar to the human 
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counterpart (Fred Chang, unpublished data). Other phenotypes observed in this 
yeast strain are discussed in this study (Results Chapter 4). 
 
Niemann-Pick disease type C (NPC) is one of the three Niemann-Pick diseases 
(types A-C) and has a prevalence as high as 1/120,000 live births in Western 
Europe (Vanier & Millat 2003). It is an autosomal recessive LSD with a highly 
variable clinical phenotype. NPC can be caused by mutations in two genes: 
NPC1, in approximately 95% of cases, and NPC2 (or HE1) (Carstea et al. 1997; 
Naureckiene et al. 2000). NPC1 is predicted to be a glycoprotein that localises 
to the limiting membrane of late endosomes and can be transiently associated 
with lysosomes and TGN (Higgins et al. 1999). NPC2 is a soluble glycoprotein 
present in the lumen of lysosomes that binds to mannose-6-phosphate receptor 
and to cholesterol, regulating their levels in the lysosomes (Ko et al. 2003; 
Vance 2006).  
The exact functions of NPC1 and NPC2 proteins are still unknown, but different 
studies have reported their involvement in the transport of cholesterol and other 
cargo in the late endosomes and lysosomes. In a recent study, a model of 
“hydrophobic handoff” of cholesterol between NPC1 and NPC2 was proposed 
(Wang et al. 2010). In this model, NPC2 accepts cholesterol in the lysosomal 
lumen, binds it and then directly transfers it to membrane-bound NPC1, for a 
consequent export from the lysosome membrane. Low density lipoprotein 
(LDL)-derived cholesterol is exported from lysosomes (or late endosomes) to 
the TGN for esterification or to the plasma membrane for efflux (Ioannou 2000). 
However, the mechanism responsible for this efflux is still unknown: NPC1 may 
act as a molecular pump, directly responsible for cholesterol efflux, or it may 
promote this trafficking process via membrane vesicles or sterol carrier proteins, 
such as oxysterol-binding protein (Yu et al. 2014). Cells with mutant NPC1 have 
been shown to have low levels of calcium in their lysosomes, caused by 
sphingosine storage and preceding cholesterol storage (Lloyd-Evans et al. 
2008). Therefore, it is possible that NPC1 is involved in the efflux of 
sphingosine from lysosomes.  
Chapter 1 Introduction 
 44 
The clinical presentation of NPC is highly variable, with age of onset varying 
from the perinatal period to adulthood. Symptoms can be hepatic, psychiatric or 
neurologic (Vanier & Millat 2003). Patients with the 'classic' late-infantile/juvenile 
form of NPC start manifesting symptoms between 3 and 5 years of age. They 
progressively develop neurologic abnormalities, such as: ataxia, seizures, 
spasticity, and loss of speech and other intellectual abilities.  
Death usually occurs in their teenage years but they can survive until their 
thirties (Vanier & Millat 2003). At a cellular level, NPC patients present 
excessive storage of endocytosed unesterified cholesterol, sphingomyelin and 
glycolipids in the lysosomal/late endosomal system, accumulated due to 
impaired cholesterol intracellular transport (Pentchev et al. 1985). This 
accumulation occurs in all tissues except the brain (Vance 2006). 
The S. cerevisiae orthologue of NPC1 is Ncr1p. Yeast cells lacking Ncr1p have 
mitochondrial dysfunctions such as sensitivity to oxidative stress, and a reduced 
chronological lifespan (survival of non-dividing stationary cells) (Vilaca et al. 
2014). S. pombe has a predicted orthologue of NPC2, but not NPC1. The 
npc2Δ strain had not been characterised prior to this study (Results Chapter 4). 
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1.2 Fission yeast: a model for juvenile CLN3 disease 
Schizosaccharomyces pombe is a genetically tractable unicellular eukaryote 
with only 5123 genes arranged in 3 chromosomes (Robinow 1977; Wood et al. 
2002) (http://www.pombase.org/). Fission yeast has a rod-like shape, grows by 
increasing its length and divides via the formation of a septum in the medial 
region of the region of the cell, where the division in two daughter cells occur 
(Forsburg & Rhind 2006) (see Figure 1.2.1 for examples of fission yeast cells 
with and without septa). These cells have a short generation time, with each 
cycle lasting 2 to 4 hours (Moreno et al. 1991). Together these characteristics 
make S. pombe an ideal model for the study of eukaryotic cell biology and gene 
function. Furthermore, fission yeast genes can be easily tagged, mutated and 
deleted.  
S. pombe cells are usually haploid and can have two mating types: h+ and h-. 
h+/h- heterozygous diploid zygotes can be created when a pair of haploid cells 
of opposite mating types mate after a period of starvation (Moreno et al. 1991). 
These zygotes undergo meiosis forming haploid spores that only germinate 
when in adequate nutritional conditions. Haploid fission yeast cells are 
commonly used as models in laboratory since only one copy of the gene is 
present in this organism, and this excludes any issue regarding dominant or 
recessive alleles or mutations expressed in diploid organisms.  
S. pombe and Saccharomyces cerevisiae are not closely related despite being 
from the same fungi division (Hedges 2002). S. pombe is functionally and 
genetically more similar to mammalian cells than S. cerevisiae, making it the 
favourite yeast to study processes such as the cell cycle, genetic recombination, 
chromosome structure, translation, meiosis, mitosis and RNA splicing (Moreno 
et al. 1991; Wood et al. 2002; Forsburg & Rhind 2006). The use of fission yeast 
in this project, instead of budding yeast, is mainly due to the fact that several 
phenotypes, associated with vacuole function and cell morphology, have 
already been described and developed in S. pombe (see below, section 1.2.3). 
Furthermore, it has numerous dynamic vacuoles making it a better model 
Chapter 1 Introduction 
 46 
system to study LSDs. Therefore those phenotypes can be used in this project 
in order to further elucidate the molecular mechanisms of Btn1p, CLN3 and 
juvenile CLN3 disease. 
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1.2.1 Function of yeast vacuoles 
S. pombe contains many small circular vacuoles (around 50 to 80 per cell), 
contrary to budding yeast (with 2 to 4 large vacuoles) (Bone et al. 1998) (see 
Figure 1.2.1). However, vacuole function is the same in both strains. Therefore, 
much of what is known about the vacuoles in fission yeast was predicted from 
studies in S. cerevisiae and then confirmed in S. pombe.  
Vacuoles, like lysosomes, are acidic compartments containing several 
hydrolytic enzymes. They are responsible for degradation of macromolecules, 
and are also involved in osmoregulation, pH homeostasis and act as storage 
reservoirs for metabolites and amino acids (Klionsky et al. 1990). When S. 
pombe is placed in an aqueous environment, its vacuoles fuse with each other 
creating larger structures that occupy a great portion of the cell’s volume (Bone 
et al. 1998). S. cerevisiae YPT7 gene, encoding for a guanosine-5'-
triphosphate(GTP)ase protein of the Rab family, initiates vacuoles fusion, in a 
process called docking (Price et al. 2000). Similarly, the S. pombe Ypt7p is also 
responsible for the vacuolar fusion in these cells (Bone et al. 1998). ypt7Δ 
fission yeast cells have much smaller vacuoles than wild-type cells. Other 
factors can also influence vacuole size in fission yeast. Mutations in genes 
involved in vacuolar H+ ATPase function and in vps34 (a phosphoinositide-3-
Kinase) cause an increase in vacuole size (Iwaki et al. 2004). The same 
phenotype is observed in btn1Δ (see above, section 1.1.2). Vacuole size can be 
measured after labelling the vacuole membrane with the lipophilic dye N-(3-
triethylammoniumpropyl)-4-(6-(4-(diethylamino) phenyl) hexatrienyl) pyridinium 
dibromide (FM4-64). The presence of multiple vacuoles in S. pombe makes it a 
suitable organism for the study of NCLs, since lysosomes play a pivotal role in 
these disorders.  
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Figure 1.2.1  Fission yeast 
Schizosaccharomyces pombe cells stained with calcofluor in the left panel and with FM4-64 in 
the right panel, showing their cell walls/septa and vacuoles, respectively. Bold arrows indicate 
septated yeast cells. Scale bars – 10µm.  
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1.2.2 NCL genes in S. pombe  
At least three NCL genes have predicted orthologues in S. pombe: CLN1, CLN3 
and CLN10. 
The S. pombe CLN1 orthologue is called pdf1 (palmitoyl protein thioesterase- 
dolichol pyrophosphate phosphatase fusion 1) and encodes the orthologue of 
Ppt1p fused to dolichol pyrophosphate phosphatase 1 (Dolpp1p). The deletion 
of the entire open reading frame of pdf1 is nonviable for the cells. However, 
cells with mutations in the ppt1 domain are viable, but sensitive to growth in the 
presence of sodium orthovanadate and elevated pH (Cho & Hofmann 2004). 
These phenotypes can be rescued by the ectopic expression of human PPT1 
indicating that these proteins are functional orthologues. 
The orthologue of CLN10/CTSD in S. pombe is sxa1. This gene encodes for an 
aspartyl protease that is 40% identical and 22% similar to the human protein. 
Little is known about this yeast protein, except that it is involved in the mating 
response (Imai & Yamamoto 1992). Phenotypes of the sxa1Δ strain were 
characterised in this study and are described in Results Chapter 4. 
Finally, the fission yeast orthologue of CLN3 is btn1. As previously mentioned, 
Btn1p is 30% identical and 48% similar to human CLN3. Several phenotypes 
have been associated to the loss of btn1 (or mutant Btn1p) in yeast cells.  This 
is discussed in the section below. 
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1.2.3 Btn1p, the orthologue of CLN3 
All evidence supports the same function of CLN3 and its yeast orthologue 
Btn1p. Ectopic expression of the human CLN3 gene can rescue all tested 
phenotypes that arise in btn1 yeast cells that are deleted for btn1 (see below). 
Moreover, there are several highly conserved regions between CLN3 and Btn1p, 
and the hydropathy profiles of these proteins are similar (Nugent et al. 2008). 
The majority of amino acids that are affected by the described missense 
mutations in CLN3 are also conserved in S. pombe (Gachet et al. 2005; 
Kitzmuller et al. 2008).  
Several studies in fission yeast have shown multiple effects of complete loss of 
Btn1p function in btn1 cells. Btn1p is thought to be involved in vacuole 
homeostasis, cytokinesis, cell wall arrangement, cytoskeletal organisation, 
endocytosis, growth regulation, response to stress and trafficking. Some of 
these phenotypes were described above (section 1.1.2) and others are 
discussed below. A diagram representing the complexity of localisation of 
BTn1p and btn1 phenotypes is shown at the end of this subchapter (Figure 
1.2.2). 
 
Localisation and trafficking of Btn1p 
Ectopically expressed Btn1p tagged with green fluorescent protein (GFP) was 
first shown to be located in vacuoles of fission yeast cells, more specifically in 
the membrane of these organelles. Tagged Btn1p was tracked and observed to 
follow a trafficking route through small pre-vacuolar and endosomal 
compartments to the vacuolar membrane, within 3 hours of promoter 
repression, in a Ypt7p-dependent manner (Gachet et al. 2005). It was also 
shown that Btn1p exerts some function in its pre-vacuolar localisation, since in 
ypt7 cells that are also deleted for btn1, the vacuoles were still larger and 
more alkaline than those of ypt7 cells, where Btn1p is unable to traffic to the 
vacuoles. More recently, at steady-state, Btn1p was found to be located in the 
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Golgi complex and its loss showed a striking effect on the number of the Golgi 
compartments, their morphology and location within the cell (Codlin & Mole 
2009). The absence of Btn1p also affected trafficking through the Golgi. Thus, 
Btn1p protein, in S. pombe, is required for correct sorting and trafficking of 
molecules to or through the Golgi. The fact that Btn1p affects the Golgi, which is 
important for the correct trafficking and sorting of proteins and molecules, can 
explain the wide diversity of phenotypes that occur in btn1 cells. 
  
Defective vacuole homeostasis 
As mentioned before, btn1 cells have larger and less acidic vacuoles than 
wild-type cells, suggesting an imbalance in vacuole homeostasis. Growth of 
btn1 cells in acidic media led to a reduction in vacuole size, establishing a link 
between size and pH in these organelles (Gachet et al. 2005). Defects affecting 
vacuolar (and lysosomal) function will probably affect the autophagic process 
and/or the trafficking of proteins that may be involved in neurotransmission in 
humans (Kim et al. 2003; Gachet et al. 2005). 
 
Cytokinesis delay and cell wall defects 
btn1 cells are longer at division, have a slower growing rate and a higher 
septation index than wild-type cells (Gachet et al. 2005). This leads to a higher 
number of binucleate cells and suggests an abnormal cell cycle and a delay in 
the cytokinesis process in these cells. The secondary septum seen in some 
btn1 cells is significantly thicker than in wild-type cells, as are other regions of 
the cell wall on the sides of the cells (Codlin et al. 2008a). btn1 cells show 
defects in the cell wall glucan composition, noticeable by sensitivity to -
glucanase zymolyase-20T. A similar defect was observed in cells containing v-
ATPase mutants, vma1 or vma3. Growth in acidic media was sufficient to 
rescue the zymolase sensitivity in all of these strains (btn1, vma1 and 
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vma3) suggesting that this phenotype is pH-dependent and that defects in the 
vacuole homeostasis and cell wall composition are linked. On the other hand, 
the cytokinesis delay phenotype is pH-independent (it is not rescued by growth 
in acidic media) indicating that Btn1p acts in at least two different and 
independent pathways. 
 
Defective growth at 37ºC, cytoskeletal organization and endocytosis  
In a study of Codlin et al (2008), it was shown that the presence of Btn1p is 
essential for growth of yeast cells at 37C (Codlin et al. 2008b). At this 
temperature, btn1 cells have a pear-like shape, swell and eventually lyse after 
2 to 3 cell cycles. Phenotypes such as cytokinesis delay and zymolase 
sensitivity become more severe in btn1 cells grown at 37C. Moreover, their 
normal bipolarized growth is disturbed after 7 hours of growth, with an inability 
to set up growth at a new end following division, and with deposition of the cell 
wall being position and structurally affected. Therefore, btn1 cells grow in a 
monopolar manner from one tip only. This defect was shown to be due to a 
failure in the polarization of sterol-rich membrane domains and the formation 
and polarization of F-actin patches to the cell tips after cytokinesis. The 
localisation of Btn1p is dependent on the actin cytoskeleton and is altered at 
37ºC, where it localises near the cell tips and the septum. The defect that btn1 
cells show in the actin cytoskeleton may affect the trafficking and activity of the 
membrane v-ATPase. Since this protein is crucial for maintaining the vacuole 
pH, the actin phenotype may be linked and modulate the acidification of 
vacuoles, as seen in these btn1 cells.  
In the same study, it was also shown that the endocytosis process is defective 
in btn1 cells grown at high temperature, both in material uptake and in 
trafficking to the vacuole (Codlin et al. 2008b). In this case, the uptake of FM4-
64 was severely reduced after 7 hours at 37ºC. A similar defect in neurons 
could affect the movement, release and uptake of neurotransmitters, leading to 
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neurodegeneration.  
 
Effects of different mutations in Btn1p function 
In a recent study, four different phenotypes that have been characterised in 
btn1 cells were selected as marker phenotypes to further understand the 
effect of mutations in Btn1p (Haines et al. 2009). These phenotypes were: 
enlarged vacuoles and cytokinesis delay with an increased septation index at 
25C, and monopolar growth and cell curving at 37C. All of these phenotypes 
were rescued by expression of Btn1p and CLN3. Only the enlarged vacuoles 
phenotype was rescued by ectopic expression of the mutant btn1 containing the 
equivalent to the human 1-kb common deletion. This corroborated the fact that 
this mutation does not completely abolish CLN3/Btn1p function. On the other 
hand, the cell curving phenotype was rescued only by a mutant protein carrying 
the equivalent to the p.Glu295Lys human mutation, which was found in patients 
with a very mild form of juvenile NCL (Wisniewski et al. 1998; Aberg et al. 
2009), as previously mentioned. This suggests that further studies of the 
molecular basis of this mutation may reveal a novel target for therapies to delay 
onset of symptoms in juvenile CLN3 disease. Three of these phenotypes 
(enlarged vacuoles, increased septation index and cell curving at 37C) were 
investigated again in this study and are discussed in Results Chapter 1. 
 
Summary 
Taken together, all of the phenotypes described in btn1 cells, associated with 
the high degree of sequence identity between the human gene CLN3 and the 
yeast btn1, and the fact that CLN3 can compensate for loss of Btn1p, makes S. 
pombe a good candidate for the elucidation of the still unknown function of 
CLN3. Therefore, instead of using human or mammalian cells, one can use a 
simple model as fission yeast to overexpress, delete and model the effect of 
disease-causing or targeted mutations in btn1. This study of ectopic and 
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variable expression of Btn1p will be directly relevant to comprehend the function 
of human CLN3. Furthermore, therapeutic approaches for CLN3 disease can 
also be studied in S. pombe in the first instance before translation to higher 
eukaryotic organisms.  
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Figure 1.2.2  Complex picture of Btn1p localisation and function 
in a fission yeast cell 
Diagram of a fission yeast cell summarising the complexity of Btn1p, with regard to its 
localisation and function(s). Btn1p/CLN3 has been proposed to be localised in the Golgi 
apparatus, and/or in the endolysosomal pathway including the vacuole (both represented in the 
picture in blue boxes). This protein has also been reported to have multiple effects in the cell: it 
affects the vacuolar pH and size, probably when it is localised in this organelle; on the other 
hand, it affects the Golgi complex size, structure and number and the cellular post-Golgi 
trafficking, probably when Btn1p is localised here. Other phenotypes may be affected from both 
locations or one of them: increased septation index, cell wall integrity and morphology, heat 
tolerance, glycolytic process, and others not represented in this figure. GA – Golgi apparatus: 
VAC – vacuole. This diagram was adapted from (Bond et al. 2013). 
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1.3 Project aims 
So far, there is no cure for juvenile CLN3 disease and there is no available 
treatment for people manifesting the disease, mainly due to the fact that CLN3 
is an intracellular membrane protein, not suitable for enzyme replacement 
therapy. However, the fact that most patients retain some function of CLN3 
suggests that therapeutic methods that mimic the missing function, or improve 
the existing one, could be used to increase the quality of life of these patients 
and prevent or even halt the disease progression(Kitzmuller et al. 2008). 
Therefore, it is of great interest to identify novel lead compounds that revert 
phenotypes associated with juvenile CLN3 disease and that can be developed 
to treat the disease. However, screening for compounds in mammalian cells is 
not yet feasible, since no robust cellular phenotypes associated with juvenile 
NCL have been described to date. Therefore, in this study the identification of 
these compounds was done in a simple eukaryotic model, S. pombe, to simplify 
and accelerate the process. Although the work done in fission yeast is 
complementary, it is undoubtedly more far-reaching than candidate approaches 
in mammalian cells or other model systems. 
The aims of this project were: 
 To create yeast strains carrying endogenously expressed btn1 and 
btn1 containing the equivalent of disease-causing mutations, and 
investigate the localisation and the impact of these mutations on 
Btn1p function. 
 To find a robust and striking phenotype in the btn1 strain suitable for 
a high-throughput screening approach. 
 To identify potential therapeutic compounds in a library of 1280 Food 
and Drug Administration (FDA)-approved compounds, and test their 
ability to rescue phenotypes of S. pombe btn1 cells, juvenile CLN3 
disease patient fibroblasts and a zebrafish model of the disease. 
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 To characterise yeast strains modelling three other lysosomal storage 
disorders (Chédiak-Higashi syndrome, Niemann-Pick disease type 
C2 and congenital CLN10 disease) in terms of phenotypes and 
investigate the efficacy of potential therapeutic compounds in these 
strains.  
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2 Materials & Methods 
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2.1 List of reagents 
All the reagents used in this work, are summarised below, with details of the 
respective manufacturers: 
Adenine : Sigma Aldrich 
Agar : Formedium   
Agarose : Sigma Aldrich 
Alloxazine : Sigma Aldrich 
Amino acid supplements : Formedium 
Ammonium chloride (NH4Cl) : Sigma Aldrich 
Ammonium sulfate : Sigma Aldrich 
Ampicillin : Sigma Aldrich 
D-(-)-threo-2-amino-1-[p-nitrophenyl]-1,3-propanediol (ANP) : Sigma Aldrich 
Biotin : Sigma Aldrich 
BisBenzimide H33342 trihydrochloride (Hoechst) : Sigma-Aldrich 
Bovine serum albumin (BSA) : VWR 
Calcium chloride dihydrate (CaCl2.2H2O) : Sigma Aldrich 
Calcofluor : Sigma Aldrich 
Chloroquine diphosphate salt : Sigma Aldrich 
Citric acid : Sigma Aldrich 
Copper (II) sulfate pentahydrate (CuSO45H2O) : Sigma Aldrich  
Cyclosporine A (CsA) : Sigma Aldrich 
Dimethyl sulfoxide (DMSO) : Sigma Aldrich 
DNA 1kb ladder : Molecular Probes, Invitrogen 
Dropout mix : Formedium 
Dulbecco's modified eagle's medium (DMEM) : LMCB 
E-64 : Sigma Aldrich 
Ethidium bromide : Sigma Aldrich 
Ethylenediamine tetraacetic acid (EDTA) : Sigma Aldrich 
Foetal bovine serum (FBS) : Sigma Aldrich 
5-fluoroorotic acid (FOA) : Formedium 
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FM4-64 : Molecular Probes, Invitrogen 
Geneticin (G418) : Sigma Aldrich 
Glucose : Formedium 
Glycerol : BDH Prolabo, VWR 
Herring sperm DNA : Sigma Aldrich 
Histidine : Sigma Aldrich 
Hydrogen chloride (HCl) : Sigma Aldrich 
Inositol : Sigma Aldrich 
Iron (III) chloride hexahydrate (FeCl36H2O) : Sigma Aldrich 
Leucine : Formedium 
Lithium acetate : Sigma Aldrich 
Lysogeny broth (LB) : LMCB  
LysoSensor yellow/blue dextran : Molecular Probes, Invitrogen 
Magnesium chloride (MgCl2) : Sigma Aldrich  
Magnesium chloride hexahydrate (MgCl26H2O) : Sigma Aldrich 
Manganese sulfate (MnSO4) : Sigma Aldrich 
Molybdate dihydrate (MoO42H2O) : Sigma Aldrich 
Nicotinic acid : Sigma Aldrich 
Deoxyribonucleotide (dNTP) mix : Promega 
Orthoboric acid (H3BO3) : BDH GPR 
Pantothenic acid : Sigma Aldrich 
Paraformaldehyde (PFA) : Sigma Aldrich 
Penicillin streptomycin (PenStrap) : Sigma Aldrich 
Polyethylene glycol (PEG) 4000 : Sigma Aldrich 
Phosphate buffered saline (PBS) : LMCB  
Potassium chloride : Sigma Aldrich 
Potassium hydrogen phthalate : Sigma Aldrich 
Potassium iodide : Sigma Aldrich 
Prochlorperazine dimaleate : Sigma Aldrich 
Propidium iodide : Sigma Aldrich 
N-propyl-galate : Sigma Aldrich 
RNase : Sigma Aldrich 
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Saponin : Sigma Aldrich 
di-Sodium hydrogen phosphate (Na2HPO4) : Sigma Aldrich 
Sodium sulfate (Na2SO4) : Sigma Aldrich 
T4 DNA ligase : Promega 
Tris : Sigma Aldrich 
Triton X-100 : BDH Prolabo, VWR  
Trypsin : Sigma Aldrich 
Uracil : Formedium 
Yeast extract (YE) : Formedium 
Yeast nitrogen base : Formedium 
Zinc sulphate heptahydrate (ZnSO4.7H2O) : Sigma Aldrich 
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2.2 Table of yeast strains 
Table 2.1. Table of yeast strains 
Strain Genotype Source 
wild-type (wt) 972  h
-
 Laboratory stock 
btn1Δ h-, btn1::NatMx, leu1-32, 
ura4D18, his3
-
,  ade6-
210,  
This study 
btn1::ura h
-
, btn1::ura4, leu1-32, 
ura4D18, his3
-
, ade6-210 
Laboratory stock 
nmt3 h
-
, btn1::nmt3 gfp-btn1 This study 
nmt41 h
-
, btn1::nmt41 gfp-btn1 This study 
GFP-btn1 h
-
, btn1::gfp-btn1, leu1-
32, ura4D18, his3
-
, ade6-
210 
This study 
1kbΔ h
-
, btn1::gfp-btn1(1kbD), 
leu1-32, ura4D18, his3
-
, 
ade6-210 
This study 
E240K h
-
, btn1::gfp-
btn1(E240K), leu1-32, 
ura4D18, his3
-
, ade6-210 
This study 
G136A h
-
, btn1::gfp-
btn1(G136A), leu1-32, 
ura4D18, his3
-
, ade6-210 
This study 
btn1Δ+prep42GFPbtn1 h-, btn1::NatMx, leu1-32, 
ura4D18, his3
-
,  ade6-
210  
Laboratory stock 
btn1Δ+prep42 h-, btn1::NatMx, leu1-32, 
ura4D18, his3
-
,  ade6-
210 
Laboratory stock 
lvs1Δ h-, lvs1::kanMX6, leu1-
32, ura4D18, his3
-
,  
ade6-210  
Fred Chang laboratory 
sxa1Δ SPAC26A3.01, 
sxa1::kanMX 
Bioneer library 
npc2Δ SPAPB8E5.04c, 
npc2::kanMX 
Bioneer library 
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2.3 Fission yeast methods 
The majority of yeast methods was done according to (Moreno et al. 1991). 
2.3.1 Media  
Yeast extract with supplements (YES) 
Yeast extract  5g 
Glucose   30g 
Supplements stock (50X)   2ml 
Agar (for solid medium)   20g 
H2O    to 1 l 
Autoclaved. 
For experiments with CsA, this chemical was added to a final concentration of 
0.1 mg/ml in 1% DMSO as a carrier. (CsA stocks were prepared in DMSO in 
100 mg/ml, and stored at -20ºC until use). For experiments with G418, the 
chemical was added to a final concentration of 100 mg/L. (G418 stock was 
prepared in 1 M Tris.HCl, pH 8, in a final concentration of 50mg/ml, and stored 
at  -20ºC until use). 
Supplements stock (500X) 
Adenine 1.875g 
Histidine 1.875g 
Leucine 1.875g 
Uracil 1.875g 
H2O  to 50ml 
Diluted to 50X stock in sterile H2O, filter sterilised and stored at 4ºC until use. 
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Minimal media (MM) 
Ammonium Chloride (NH4Cl) 5g 
Potassium hydrogen phtalate 3g 
Na2HPO4      2.2g 
Adenine        500mg 
Uracil        250mg 
Leucine (if required)        250mg 
Histidine        250mg 
Agar (for solid medium)   20g 
H2O       to 0.9 l 
Autoclaved. 
 
Before use, the following were added to the initial solution: 
20% Glucose      100ml 
Salts stock (50X)     20ml 
Vitamins stock (1000X)  1ml 
Minerals stock (10.000X)      0.1ml 
 
In the experiments with compounds, they were added to the MM or YES 
medium to a final concentration of 10 M diluted in DMSO at the appropriate 
concentration (according to manufacturer’s instructions). 
For spot assays, ANP and chloroquine were added to a final concentration of 
0.75 or 1 mM, and 0.1 mM, respectively. Stocks were prepared as following: 
ANP (100 mM)                                   2.122g (in 20ml of DMSO) 
Chloroquine diphospate salt (10 mM)  0.26g (in 50ml H2O) 
Both stored at -20ºC until use. 
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Salts stock (50X) 
MgCl2.6H2O      53.3g 
CaCl2.2H2O         0.735g 
KCl   50g 
Na2SO4 2g 
H2O    to 1 l 
Filter sterilised and stored at 4ºC until use. 
Vitamins stock (1000X) 
Nicotinic acid 1g 
Inositol 1g 
Biotin    1mg 
Pantothenic acid     0.1g 
H2O            to 100ml 
Filter sterilised and stored at 4ºC until use. 
Minerals stock (10.000X) 
H3BO3     0.5g 
MnSO4     0.4g 
ZnSO4.7H2O     0.4g 
FeCl3.6H2O     0.2g 
MoO4.2H2O       0.16g 
KI     0.1g 
CuSO4.5H2O       0.04g 
Citric acid 1g 
H2O            to 100ml 
Filter sterilised and stored at 4ºC until use. 
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5-fluoroorotic acid (FOA) media 
Bottle 1: FOA      437mg 
              Uracil     50mg 
              Dropout Mix       750mg 
              Aminoacid supplements (-ura)250mg 
              Yeast Nitrogen Base       850mg 
              Ammonium sulphate   2.5g 
              H2O          to 250ml 
Sonicated and warmed to 50ºC. 
Bottle 2: Glucose   8.5g 
               Bacto Agar 12g 
               H2O          to 300ml 
Autoclaved immediately and poured to 250ml. 
Contents of Bottle 2 were added to Bottle 1, mixed and poured onto plates. 
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2.3.2 Growth of yeast cells 
To create stock collections of strains these were frozen at -80ºC. Cells were 
scraped from solid media after growth for 1 or 2 days, and mixed in 1ml of YES 
containing 20% (v/v) glycerol in a sterile cryotube. Tubes were briefly vortexed 
and stored at -80ºC. To re-isolate strains, a small amount of frozen stock was 
scraped and streaked onto a suitable plate and then incubated at 30°C for 1 to 
4 days. 
For yeast cells to grow they were incubated on YES or MM plates at 30°C for 1 
to 4 days. Plates were also stored at 4°C for a maximum period of 3 weeks.  
Cells were grown until the desired density, measured by spectrophotometry. 
Cell concentration measurements were based on optical density readings at 
600nm (OD600) using a Ultrospec 2000 spectrophotometer (Pharmacia Biotech) 
and adjusted for a 1:10 dilution in water. An OD600 of 0.1 was taken to 
correspond to 2 x 106 cells/ml. 
Liquid cultures were prepared by inoculating colonies from plates. The majority 
of experiments were carried out with cells in mid log phase growth (1 x 106 - 5 x 
106 cells/ml). These cultures were grown in 15ml in 50ml flasks and incubated 
at 30ºC with shaking (200 rpm).  
For plasmid selection, strains containing plasmids were grown on medium 
containing appropriate supplements (adenine, leucine, histidine and uracil). The 
same was done for viability assays where cyclosporine A was added to the 
liquid medium at a final concentration of 0.1 mg/ml, and this was used to 
inoculate cells previously grown to log phase. 
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2.3.3 Transformation of yeast cells 
btn1::ura strain (Table 2.1) was grown in 20ml of MM medium overnight at 30ºC 
to a density of approximately 1 x 107 cells/ml. The cell suspension was 
centrifuged in a Sigma 2-16K centrifuge (SciQuip, UK) at 2000 rpm for 5 
minutes and washed with sterile water. Cell pellet was resuspended in 1ml of 
0.1 M lithium acetate and 100l aliquoted in eppendorf tubes, one for each 
transformation. The adequate amount of DNA and 2µl of herring sperm DNA 
(from 9-12 mg/ml stock) were added to the cells and incubated at room 
temperature for 5 minutes. 280l of PEG solution (50% PEG 4000, 0.1 M 
lithium acetate, 0.01 M Tris.HCl) were added, mixed gently and suspensions 
incubated for 60 minutes at 30ºC. 43µL of DMSO were added and solutions 
heat shocked at 42ºC for 5 minutes.  
In case of cells with a kanamycin-resistance (kanR) marker, cells were 
centrifuged in a Sorvall Pico centrifuge at 5000 rpm for 2 minutes, resuspended 
in 500l of H2O and 250l of suspension plated onto YES plates. Plates were 
incubated for approximately 20 hours at 30ºC, replica plated onto YES plates 
with 100mg/L G418. Replica plates were incubated for 2 to 3 days at 30ºC and 
large colonies restreaked onto fresh YES plates with G418. Colonies were 
checked for homologous recombination by colony PCR and by sequencing with 
the appropriate primers (Table 2.2). 
In case of FOA selection, heat shocked cells were immediately incubated in 
500ml of YES and incubated at 30ºC with shaking (200 rpm) for 2 to 3 days. 
1ml was taken from each suspension, centrifuged and resuspended in 1ml of 
H2O. 100 l were plated onto FOA plates and incubated at 30ºC until colonies 
were visible. Colonies were checked for homologous recombination by colony 
PCR and by sequencing with the appropriate primers (Table 2.2). 
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2.3.4 Labelling vacuoles with FM4-64 and LysoSensor 
For labelling of vacuoles with the FM4-64 dye, cells were grown in MM 
overnight to mid-log phase. 1ml of cells was centrifuged for 5 minutes at 2000 
rpm. Cell pellets were resuspended in 50μl of YES with 1μl of FM4-64 and 
incubated in a 30ºC water bath for 20 minutes. 1ml of YES was added to each 
suspension and these were centrifuged at 2000 rpm for 5 minutes. Cell pellets 
were resuspended in 1ml of YES, 4ml of YES were added and cultures were 
incubated at 30ºC with shaking for 120 minutes. Cells were spun at 2000 rpm 
for 5 minutes and pellets were resuspended in 25μl of MM. 7μl of each sample 
were spotted onto microscope slides to be visualized. 
In order to measure the vacuole pH, vacuoles were labelled with LysoSensor 
dye. Cells were grown overnight to mig-log phase. 1ml of each culture was 
mixed by inversion with 5μl of LysoSensor. Suspensions were incubated in the 
dark at room temperature for 10 minutes. Tubes were spun for 3 minutes at 
2000 rpm, and cells were washed twice with MM. Cell pellets were 
resuspended in 50μl of MM and 5μl were spotted onto microscope slides to be 
visualized. 
 
2.3.5 Calcofluor staining 
For the septation index and cell curving assays, cells were grown overnight in 
MM to mid-log phase. For the cell curving assay, cells were grown for an 
additional 4 hours at 37ºC. Septation index corresponds to the number of cells 
with a clear septum stained with calcofluor (septated cells) divided by the total 
number of cells, in percentage. Septation index is an indication of the amount of 
cells that are halted in the cytokinesis process, and therefore, when this value is 
higher than normal it suggests a delay in the cell cycle. Cell curving is the 
percentage of cells with a curved or bent shape (instead of the normal rod 
shape) in the total number of cells. 5l of each culture were spread onto a 
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microscope slide, 1 l Calcofluor (50 μg/ml) was pipetted onto a coverslip, 
which was then used to cover the cells. Cells were visualized immediately. 
 
2.3.6 Viability assays 
For all the viability assays, cells were grown overnight in MM to mid-log phase. 
Cells were washed in sterile water, transferred to 20ml of YES medium (with or 
without 0.1mg/ml CsA) in a final density of 1 x108 cells/ml and incubated at 37ºC 
for 24 hours. Afterwards, 1ml of each culture was mixed by inversion with 15l 
of propidium iodide (1 mg/ml) and 10l of calcofluor (50 μg/ml). Cells were 
incubated in the dark at room temperature for 10 minutes. Suspensions were 
spun for 5 min at 2000 rpm and washed with 1X PBS. Pellets were 
resuspended in residual PBS and 5l were spotted onto microscope slides, in 
order to be visualized.  
 
2.3.7 Spot assays 
Spot assays were performed in order to evaluate the cell growth rate of yeast 
strains in a range of different conditions. For all the spot assays, cells were 
grown overnight in MM to mid-log phase. Cultures were washed and diluted in 
sterile water to a final density of 1 x 106 cells/ml and four serial dilutions were 
prepared. 10l of each dilution were spotted onto the appropriate plates. Plates 
were incubated at 37ºC for 1 to 5 days. In addition to the plates with chemicals 
used to test sensitivity, strains were also spotted onto plates with 1% DMSO to 
test their sensitivity to DMSO and ensure the sensitivity was due to the 
presence of the chemical and not the carrier (DMSO). 
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2.4 Molecular biology 
2.4.1 Site-directed mutagenesis 
Missense mutations in btn1 in the pREP42GFP-Btn1 plasmid were generated 
using the QuickChange Site-Directed Mutagenesis kit (Stratagene, UK), and 
appropriate primers (Table 2.2). Volumes of reagents were the following: 
10X reaction buffer    5l 
dNTP mix     1l  
Forward primer (100 ng/l)   1.25l 
Reverse primer (100 ng/l)  1.25l 
DNA template    1l  
PfuTurbo DNA polymerase (2.5 U/l) 1l 
ddH2O     40.5l 
   
The reactions were run in a PTC-100 programmable thermal controller machine 
(MJ Research) on the following program: 
1 cycle of  95ºC  30 s   
18 cycles of  95ºC  30 s 
   55ºC  1 min 
   68ºC  15 min 
 
1l of the DpnI restriction enzyme (10 U/l) was added to each amplification 
reaction. The reaction mixtures were spun down for 1 minute and immediately 
incubated at 37ºC for 1 hour, in order to digest the template DNA. Samples 
were stored at 4ºC or -20ºC for longer periods. 
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2.4.2 Polymerase chain reaction (PCR) 
To generate the constructs with the nmt1 promoter, templates were amplified 
using an Expand Long Template PCR system (Roche Applied Science). All the 
reagents that were used in these PCR reactions are listed below: 
10X Expand Long Template Buffer 2  5l 
dNTP mix (10 mM)     1.75l  
Forward primer (50 M)    0.3l  
Reverse primer (50 M)    0.3l  
DNA template (~300ng)    3l 
Expand Long Template enzyme mix (5 U/l) 0.75l 
ddH2O      to 50l 
 
Samples were run in a PTC-100 programmable thermal controller machine on 
the following program: 
1 cycle of  92ºC  2 min   
10 cycles of  92ºC  10 sec 
   60ºC  30 sec  
   68ºC  4 min 
20 cycles of  92ºC  15 sec 
   60ºC  30 sec  
68ºC  4 min + 20 sec for each successive cycle 
1 cycle of  68ºC  7 min 
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The remaining PCR reactions were done using the GoTaq Flexi enzyme 
(Promega) and using the appropriate primers (Table 2.2). Reagents and 
respective volumes for each reaction are listed below: 
5X GoTaq Flexi buffer   5l 
25mM MgCl2     5l  
dNTP mix (10 mM)    1l  
Forward primer (5 M)   1l (or 2 l for colony PCR) 
Reverse primer (5 M)   1l (or 2 l for colony PCR) 
DNA template (~200ng)   1 or 2l 
GoTaq Flexi DNA Polymerase (3 U/l) 0.5l 
ddH2O     to 50l 
 
In colony PCR reactions, a single colony from a plate was resuspended in 20l 
of sterile water and 2l of this suspension used in the PCR reaction. 
Samples were run in a PTC-100 programmable thermal controller machine on 
the following program: 
1 cycle of  95ºC  2 min   
30 cycles of  95ºC  1 min 
   55-65ºC 30 sec  
   72ºC  1 min/kb 
1 cycle of  72ºC  7 min 
 
For colony PCR reactions the PCR program was: 
1 cycle of  95ºC  10 min  
30 cycles of  95ºC  1 min 
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47-51ºC 1 min  
   72ºC  1 min/kb 
1 cycle of  72ºC  5 min 
 
All PCR products were purified using the QIAquick PCR Purification Kit 
(Qiagen), according to the manufacturer’s instructions. DNA was eluted in 50 l 
of H2O. 
 
2.4.3 Cloning 
Digestion 
Purified PCR products (GFP-btn1 with and without mutations) and plasmid 
pSL1180 were digested with restriction enzymes PstI and ApaI (Promega, UK): 
DNA (PCR product/plasmid)  15l 
10X Multicore Buffer (Promega)  5l  
BSA (10 mg/ml)    0.5l  
RNase (5 u/l)    1l 
Restriction enzymes   1l 
ddH2O     to 50l 
Reactions were incubated at 37ºC for approximately 2 hours. Cut products were 
run in a 1% agarose gel to confirm the digestion, and then the DNA was 
extracted with a QIAquick Gel Extraction kit (Qiagen), according to the 
manufacturer’s instructions. 
Ligation 
After being digested with restriction enzymes, products were ligated. 4l of 
insert and 3l of vector were mixed with 2l of 10X T4 DNA ligase buffer 
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(Promega) and 1l of T4 DNA ligase (3u/l; Promega). Reactions were 
incubated at 23ºC for 3 hours and at 4ºC overnight. 
Transformation in Escherichia coli competent cells 
Ligation products were mixed with 100l of thawed competent cells (DH5α from 
Laboratory stock) in chilled eppendorf tubes. Tubes were incubated on ice for 5 
minutes, heat shocked at 42ºC for 2 minutes and chilled on ice for 5 minutes. 
100l of SOC medium was added to the cells and they were incubated at 37ºC 
for 30 minutes with shaking (200 rpm). 200l were plated onto LB plates with 75 
g/ml ampicillin.  
DNA preparation 
Single colonies of transformed Escherichia coli competent cells were inoculated 
in 2 to 5 ml of LB and grown at 37ºC overnight with shaking (200 rpm). 1ml of 
culture was used for plasmid preparation. The preparation was done using a 
Spin Miniprep kit (Qiagen), according to the manufacturer’s instructions. DNA 
was eluted in water.  
Constructs for yeast transformation 
All constructs were confirmed prior to transformation by digestion with different 
enzymes (PstI+ApaI and MluI+AgeI) and sequencing. Once confirmed, 
plasmids were digested with the MluI and AgeI restriction enzymes, cleaned 
with a QIAquick Gel Extraction kit and the eluted DNA was directly used for 
transformation in yeast cells. 
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2.4.4 Sequencing 
To verify constructs, mutations or genes, samples were sent for sequencing to 
Source Bioscience (Nottingham, UK). Samples were supplied as following: 5l 
of 100 ng/l plasmid DNA and 1 ng/l per 100bp. Primers were sent at a 
concentration of 3.2 pmol/l. Sequence data was analysed using the ApE 
software (University of Utah). 
 
2.4.5  Electrophoresis in agarose gels 
All DNA samples were electrophoresed in 1% agarose gels. The agarose gels 
were prepared using agarose, 1X TBE buffer (AppliChem, Germany) and 
0.001% of 10 mg/ml ethidium bromide. A 1kb DNA ladder was used to check 
the size of the bands. Gels were electrophoresed at 110 Volts and 400 
milliAmperes for 40 minutes to 1 hour, with a PowerPac Basic system (BioRad, 
UK). Gels were visualized on a Geneflash UV transilluminator (Syngene, UK). 
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2.4.6 Table of primers 
Table 2.2. Table of primers 
Name Direction Sequence Description 
btn1-P-kan Forward 
CTATTTACAGTTTGTAACAAGTTAA 
CTCGTCTATGAAGTCATCGATAGAA 
GGGCTTTAAAGTGTGCTATTTGCGAA 
ACAACAGCAAATTTGTAGACTAGC – 
GAATTCGAGCTCGTTTAAAC 
Used to create nmt-
GFP-btn1 constructs 
for transformation 
GFP_btn1_orf Reverse 
CAGCGGATAAAATTATCACGTAGAG 
AAGGTTGTTTAACAATCCAAAAATTA 
GGAAGCAACACCCTACTTTCGCATC 
TTTTGTTAACCTCAATTTAATCAT - 
TTTGTATAGTTCATCCATGC 
Used to create nmt-
GFP-btn1 constructs 
for transformation 
btn1_P_check Forward TTTGAACCTGACAACATTACCG 
Used to check nmt-
GFP-btn1 constructs 
kan_check Reverse GTGATGTGAGAACTGTATCCTAGC 
Used to check nmt-
GFP-btn1 constructs 
nmt_check Forward GCTACTGGATGGTTCAGTCAC 
Used to check the 
homologous 
recombination of nmt-
GFP-btn1 constructs 
btn1_ORF_check Reverse AGATGCAAGAAAGAGATTTCGC 
Used to check the 
homologous 
recombination of nmt-
GFP-btn1 constructs, 
and to sequence btn1 
GFP_PstI Forward CCCCTGCAGATGAGTAAAGG 
Used to amplify GFP-
btn1 from the 
pREP42GFPbtn1 
plasmid 
btn1_ApaI Reverse GGTTGGGCCCTCAAGTTAAG 
Used to amplify GFP-
btn1 from the 
pREP42GFPbtn1 
plasmid 
btn1_1kbdel_ApaI Reverse GGTTGGGCCCCTACACAAAAAAG 
Used to amplify GFP-
btn1(1kbΔ) from the 
pREP42GFPbtn1 
plasmid, and to 
sequence btn1 with 
1kb-deletion 
mut_E240K Forward 
CGCAGTTCCTTGTATACTTCTCA 
AAATATACTATCAATATTGGTGTA 
Mutagenesis primer 
to generate the 
E240K mutation in 
btn1 
mut_E240K Reverse 
TACACCAATATTGATAGTATAT 
TTTGAGAAGTATACAAGGAACTGCG 
Mutagenesis primer 
to generate the 
E240K mutation in 
btn1 
mut_G136A Forward 
TGCTGGAGTTCCGCAACAGGCT 
TGGCC 
Mutagenesis primer 
to generate the 
G136A mutation in 
btn1 
mut_G136A Reverse 
GGCCAAGCCTGTTGCGGAAC 
TCCAGCA 
Mutagenesis primer 
to generate the 
G136A mutation in 
btn1 
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btn1 Forward ATGATTAAATTGAGGTTAAC 
Used to sequence 
btn1 
btn1_flanks Forward GTCTACTATCGTATTGCCGG 
Used to check the 
homologous 
recombination of 
GFP-btn1 constructs 
btn1_flanks Reverse GAAACGTCATAGGTTAACTC 
Used to check the 
homologous 
recombination of 
GFP-btn1 constructs 
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2.5 Work with mammalian models 
2.5.1 Mammalian cell culture and assays 
The fibroblast lines that were used were HF527N (control) and H480Pa (patient 
with 1-kb deletion). Fibroblasts were cultured in 1X DMEM with 10% FBS and 
1% PenStrep. The cultures were grown at 37ºC with 5% CO2 in a New 
Brunswick Galaxy 170R incubator (Eppendorf, USA). Cells were split using 
trypsin/EDTA and a final concentration of 3 x 104 cells/ml was used in each well 
of 24-well dishes (Nunc). After 1 to 2 days the compounds were added to the 
fibroblasts (at 5, 10 and 20 M concentrations) and incubated for 24 hours. 
For immunofluorescence, the cells were fixed in 4% PFA in PBS for 20 minutes 
at room temperature. After PFA was removed, cells were washed thrice with 1X 
PBS and 0.1% Triton X-100 in 1X PBS was added for 10 minutes. Cells were 
washed again (as before) and then blocked with 1% BSA (in 0.025% saponin in 
1X PBS) for 30 minutes at 4ºC. Cells were incubated with the primary antibody 
anti cis-Golgi marker protein GM130 (mouse) (BD Transduction LaboratoriesTM, 
UK), at 1:150 in 1%BSA in 0.025% saponin in 1X PBS for 1 hour at room 
temperature; and washed five times in 1x PBS afterwards. The second antibody 
was added to the cells: Alexafluor® 488 anti-mouse (Invitrogen, Life 
Technologies, UK), at 1:700 in 1% BSA in 1X PBS. Cells were washed five 
times as before. Nuclei were stained with Hoechst (diluted 1:10.000 in 1X PBS) 
for 2 minutes. After being washed twice, cells were fixed with 2% PFA (in 1X 
PBS), to prevent dissociation of the secondary antibody. Finally, cells were 
washed 3 times in 1X PBS and placed onto microscope slides with a drop of 
mountant (90% glycerol and 3% N-propyl-galate in 1X PBS) in order to be 
visualized.  
The extent of Golgi complex organization in mammalian cells was analysed 
using the compactness equation: 4π (Σ area)/(Σ perimeter)2. A value of 1.0 
indicates a perfect circle, and as the value approaches 0 it indicates an 
increasingly elongated and less compact object. The Golgi complex labeling 
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image threshold was set at ~45, where all the pixels with a value under 45 are 
excluded from the quantification. Region of interest was defined for each cell 
and the perimeter and area of the Golgi complex was measured using ImageJ. 
 
2.5.2 Zebrafish generation and assays 
All the work done with the juvenile CLN3 disease zebrafish model was done by Dr 
Claire Russell at the Royal Veterinary College of London.  
Zebrafish were housed in a multi-rack aquarium system at 28.5 ± 0.5°C on a 14 
hour light and 10 hours dark cycle to mimic the natural zebrafish environment. 
Following adult breeding, the embryos produced were incubated in the dark at 
28°C, in ‘fish water’, containing aquarium water and methylene blue (0.0002%). To 
generate cln3 morphant embryos, 2ng morpholino (MO) anti-sense 
oligonucleotides against cln3 messenger RNA were pressure-injected into 1-2 cell 
stage wild-type TupLF strain zebrafish embryos using a glass capillary injection 
needle. The sequence of MOs (from Gene Tools) were: cln3 ATG MO 
(CATtgcgactttcacaggagaaatg). 
Between 5 and 10 zebrafish embryos per well of a 24 well plate were arrayed and 
either 1ml of aquarium water, DMSO or test compound added at 12 hours post 
fertilization (hpf).  Compounds were supplied at 100x working strength and diluted 
into fish water. Test compounds and testing concentrations used were: E-64 50µM, 
Alloxazine 55µg/ml and Prochlorperazine dimaleate 62.5µM.  Embryos were 
incubated at 31°C and survival analysis and relative activity (at 36hpf) were 
conducted over the following 4 days. 
In the survival assays, animals were scored as dead (no heartbeat) or alive 
(heartbeat) at daily intervals and dead animals removed.  
In the assay measuring the relative activity, a 24 well plate was mounted on a 
Nikon SMZ1500 stereomicroscope. Videos were made of groups of fish in each 
well of the 24 well plate for 3 minutes using a DMK21AF04 (Imaging Source) 
camera at a frame rate of 30 frames/second (fms) and recorded using Media 
Recorder (Noldus). Each fish was then individually assessed for activity using 
Ethovision XT software (Noldus). This software detects the number of changes in 
pixel intensity, which is attributed to movement.   
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2.6 Microscopy 
2.6.1 Fluorescence microscopy 
All images were visualized using an Axioimager.A1 microscope (Carl Zeiss, UK) 
with x63 1.4 oil objective and a fitted Retiga EXi camera (QImaging, Canada). 
Images were acquired with the Openlab v5.5.2. software (Improvision Ltd).  
 
2.6.2 Confocal microscopy 
Images were acquired on the Leica SPE confocal microscope using a Leica x63 
1.3 oil objective with the Leica Application Suite Advanced Fluorescence 
software. Images were posteriorly analysed using ImageJ. 
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2.7 Drug screen 
For the drug screen, wild-type and btn1Δ strains were grown overnight in MM to 
mid-log phase. Afterwards, they were transferred to YES medium with 0.1mg/ml 
CsA at a final concentration of 5 x 104 cells/ml for the wild-type strain and 1 x 
105 cells/ml for the btn1Δ strain. 50μl of cultures were aliquoted into 384-well 
plates (Nunc) containing the library of pharmacologically active compounds 
(LoPac) 1280 Navigator collection (Sigma-Aldrich), with each compound 
replicated four times. The first column (16 wells) of each plate was aliquoted 
with btn1Δ untreated cells (negative control), and the last column (16 wells) 
aliquoted with wild-type untreated cells (positive control). Plates were incubated 
for 24 hours at 37°C. 10μl of a solution with 40% calcofluor and 60% propidium 
iodide diluted in 1X PBS (1:6 dilution) were added to each well, to label the cells. 
Plates were spun at 2000 rpm for 5 minutes and then imaged in the Opera 
imaging system. Six images per well were acquired, and all images were 
analysed in the CellProfiler software. The screen and analysis were performed 
by Dr Jamie Freeman of the Translational Research Resource Centre in the 
LMCB. 
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2.8 Data analysis and statistics 
All measurements in yeast and mammalian cells were performed using ImageJ 
v1.45s software (NIH, USA).  Preliminary data was analysed in Microsoft Excel 
v14.3.2. and subsequent statistical analysis were performed using Graphpad 
Prism 6.0c software (California, USA). Ordinary one-way ANOVA tests followed 
by Tukey’s multiple comparison post-tests were performed.  
All data shown represents the average value with the standard error of the 
mean (SEM) of at least three independent experiments. For the vacuoles size 
experiments, over 500 vacuoles were measured for each strain in each 
experiment; for the septation, cell curving, vacuole pH and viability assays over 
300 cells were considered in each independent experiment.  
The drug screen analysis was performed by Dr Jamie Freeman in the 
CellProfiler software and part of the mammalian cell data was analysed by 
Davide Marotta using the Fiji imaging software. 
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3 Results 1. Btn1p mutations affect the protein 
function in different manners 
 
The first aims of this project were: 
- to create fission yeast genomic integrants with GFP-tagged Btn1p expressed 
under the control of nmt1 promoters with different strengths, and the control of 
its native promoter to permit uniform endogenous expression; 
- to generate fission yeast genomic integrants with GFP-tagged btn1 containing 
a deletion equivalent to the human 1-kb deletion and equivalents to the human 
missense mutations p.Glu295Lys and p.Gly187Ala; 
-  to assess the relative localisation and expression levels of the different 
strains;  
- to characterise different yeast phenotypes associated with the complete loss 
of btn1 and with the newly generated strains: vacuole size, septation index and 
cell curving.   
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3.1 Generating S. pombe genomic integrants of GFP-tagged 
Btn1p 
In order to study and monitor the endogenous expression of Btn1p in S. pombe¸ 
the N-terminal of the protein was tagged with GFP. Different strains were 
generated, where GFP was under the control of the nmt1 promoter and of the 
btn1 native promoter.  
Three strains with the nmt1 promoter were generated, with three different types 
of this promoter: p3, wild-type strongest promoter (nmt3); p41, medium-strength 
promoter (nmt41); and p81, the weakest promoter (nmt81). The use of these 
promoters allowed the study of different levels of expression of Btn1p and their 
effects.  
Besides having Btn1p tagged with GFP under the control of different nmt1 
promoters, a strain with GFP-tagged Btn1p under the control of btn1 native 
promoter (GFP-btn1) was also created in order to study the endogenous level 
of this protein and look at its cellular location.  
Once the four different strains with GFP-tagged Btn1p (GFP-btn1, nmt3, nmt41 
and nmt81) were obtained, they were further analysed, along with a wild-type 
strain (wt, 972) and a btn1Δ strain (btn1Δ) (first two rows in Table 2.1). 
 
3.1.1 Making the constructs 
For the construction of the nmt1-GFP-tagged proteins, a DNA fragment with the 
GFP cDNA under the control of the nmt1 promoter (with different strengths) was 
created to replace the endogenous chromosomal btn1 promoter by homologous 
recombination. This DNA fragment originated from a plasmid with the kanr gene 
for selection, the nmt1 promoter and GFP (Bahler et al. 1998). By PCR 
amplification, 100bp of the 5’UTR (untranslated region) of btn1 were added 
upstream the kanr gene, and the first 100bp of btn1 open reading frame (ORF) 
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added downstream of GFP. The final purified PCR products were transformed 
into cells of S. pombe wild-type strain 972 (Figure 3.1.1 (A)).  
In order to tag Btn1p with GFP to allow its expression under the native promoter 
of btn1, a different strategy was used. This consisted of, firstly, amplifying GFP-
btn1 from the plasmid pREP42GFP-Btn1 with primers containing two specific 
restriction sites (PstI and ApaI). This product was then digested and ligated into 
a plasmid previously digested with the same enzymes and containing btn1 
flanks (pSL1180-Btn1flanks). Afterwards, the new construct was digested with 
two other specific enzymes (MluI and AgeI) in order to obtain a fragment with 
the btn1 gene, its flanks (both at 5' and 3'UTR) and the GFP gene upstream. 
The final fragment that was obtained was transformed in a btn1::ura4 strain 
(where the ura4 gene is replacing btn1 in the same locus; Table 2.1) and 
integrants were selected with 5-fluoroorotic acid (FOA) (Figure 3.1.1 (B)). FOA 
leads to cell death in the presence of a wild-type active ura3 gene in the yeast 
strain. FOA is converted to a toxic compound, 5-fluorouracil, and this reaction is 
mediated by an enzyme encoded by the ura3 gene. This allows for a negative 
selection against yeast strains carrying the ura3 gene. 
All constructs, including primer positions and restriction sites, are summarised 
in Figure 3.1.1. 
 
3.1.2 Protein expression levels and localisation 
The different strains showed different levels of GFP expression, since 
differences were detected in the intensity of fluorescent signal detected by the 
confocal microscope. The fluorescent signal in the nmt3 strain was quite high 
and clearly visible, showing that btn1 is overexpressed. The nmt41 strain 
showed faint but still visible fluorescence. The nmt81-bnt1 strain did not 
express GFP at sufficient levels for any fluorescence to be detected. The GFP-
btn1 strain showed a weak fluorescent signal, which was expected since native 
and endogenous levels of Btn1p are known to be very low (Codlin & Mole 2009). 
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Therefore, only nmt3-btn1 and GFP-btn1 strains were used for localisation 
experiments. 
The GFP tag at the N-terminal of the protein allowed for analysis of the 
localisation and trafficking of Btn1p. It was expected that, just like the 
ectopically expressed GFP-Btn1p, all the tagged integrated strains localise in 
the Golgi and are capable of trafficking to the vacuole (Codlin & Mole 2009). In 
fact, in both strains (nmt3 and GFP-btn1), Btn1p co-localised mostly with a 
vacuolar membrane marker, FM4-64. According to the images, Btn1p seems to 
localise in punctate structures as well, probably in the Golgi (Figure 3.1.2). In 
order to confirm this, other markers for these cell organelles have to be used in 
the future.  
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Figure 3.1.1.  Constructing different GFP-tagged Btn1p strains 
(A) Construction of nmt1-GFP-btn1 strains. Arrows within the boxes show directions of 
transcription; White boxes: kanMX6 module containing the promoter and terminator sequences 
of the Ashbya gossypii translation elongation factor 1α gene together with the kan
r
 gene from E. 
coli; S. pombe nmt1 promoter, and the GFP tag from the jellyfish Aequorea victoria. Grey 
boxes: sequences from btn1 gene, including its 5’UTR. The size of the boxes is not proportional 
to their real size. Forward primer (F primer) has 100bp of 5’UTR of btn1, including part of its 
promoter, and 20bp of the kan
r 
gene and its TEF terminator sequence. Reverse primer (R 
primer) has the first 100bp of the btn1 ORF and 20bp of GFP. Construct was integrated into the 
yeast genome by homologous recombination (HR), after being transformed into the cells. 
(B) Construction of GFP-tagged Btn1p under the control of its native promoter. GFP-btn1 
fragment was amplified from the pREP42GFP-Btn1 plasmid using primers containing two 
restriction sites, PstI and ApaI. Both primers and sites are indicated in the diagram. Bold arrows 
represent ligation between the GFP-btn1 fragment and the pSL1180 plasmid containing btn1 
flanks separated by multiple restriction sites including PstI and ApaI. White arrow represents 
digestion of pSl1180 plasmid (containing already inserted GFP-btn1) with MluI and AgeI 
restriction enzymes, in order to create the final fragment (right side panel) that was transformed 
into btn1::ura4 cells. After transformation, the ura4 gene was replaced with GFP-btn1 by HR. 
5’F and 3’F in the final fragment represent the 5’ and 3’ btn1 flanks, respectively. 
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Figure 3.1.2.  Localisation of GFP-Btn1p 
Strains with GFP-tagged Btn1p. Images obtained by confocal microscopy showing fluorescent 
signal from Btn1p in green. Strain with GFP-btn1 under the control of the nmt1 p3 promoter 
(nmt3-btn1) (upper left side panel) and strain with GFP-tagged Btn1p where Btn1p is expressed 
at its normal native levels (GFP-btn1) (upper right side panel). The image on the right panel was 
manipulated in order to increase the visible GFP signal that was originally very weak. Btn1p co-
localises with vacuolar membrane marker, FM4-64, but not totally (lower panel). Cells labelled 
with FM4-64 (red), expressing GFP from Btn1p (green) and co-localisation of GFP signal with 
labelled vacuoles. Scale bars – 4.38µm.  
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3.2 Generating S. pombe genomic btn1 mutants  
Three different strains with integrated GFP-tagged Btn1p containing three 
different mutations were generated.  
The first strain includes the deletion equivalent to the 1-kb deletion in CLN3 
(1kb∆ strain). More specifically, the equivalent to the transcript containing exons 
1-6 spliced to exon 9, which, if expressed, would encode the first 153 amino 
acids of CLN3 (or 102 amino acids in S. pombe) followed by a frame shift, 28 
novel amino acids and a stop codon (102fsX5). This strain was designated as 
1kbΔ and represents the most common CLN3 deletion present in juvenile NCL 
patients. 
Moreover, two other strains with genomic btn1 containing two missense 
mutations specific to juvenile CLN3 disease were generated: one with the 
p.E240K mutation (E240K strain), equivalent to the human p.Glu295Lys 
mutation in CLN3, and the other containing the p.G136A mutation (G136A 
strain), equivalent to the p.Gly187Ala mutation. The first mutation is associated 
with the mildest phenotype identified in juvenile NCL, and the second 
resembles the complete deleted strain btn1∆ in terms of phenotype (Haines et 
al. 2009). 
 
3.2.1 Generating the mutants 
To construct these three integrated GFP-tagged mutants, a similar approach 
used to create the GFP-btn1 strain was used (Figure 3.1.1 (B)).  
The initial plasmids used as templates for the first PCR reaction were 
pREP42GFP-Btn1 plasmids, with btn1 containing the desired mutations, such 
as the 1-kb deletion, the p.E240K and the p.G136A mutations. These mutations 
had been inserted into the btn1 gene using the QuickChange Site-Directed 
Mutagenesis approach. The primers used to amplify the mutated btn1 
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contained two specific restriction sites to facilitate the cloning into a plasmid 
containing btn1 flanks (pSL1180-Btn1flanks). Afterwards, this plasmid was 
digested with two other specific enzymes in order to obtain a fragment with the 
mutated btn1 gene, its flanks (both 5' and 3'UTR) and GFP upstream. The final 
fragment that was obtained was transformed in a btn1::ura4 strain (Table 2.1) 
and integrants were selected with FOA.  
 
3.2.2 Localisation and expression levels of integrated mutants 
One of the goals of tagging Btn1p in these three different mutant strains is to 
look at the localisation of these mutants in the cell and see how their levels of 
expression differ from wild-type Btn1p. Although it has been previously reported 
that the mutant protein with the 1-kb deletion and the p.G136A mutation are 
localised in the endoplasmic reticulum and/or the Golgi, and the one containing 
p.E240K in prevacuolar compartments (Haines et al. 2009), it was not possible 
to confirm this with certainty since no co-staining with subcellular markers was 
done. However, according to the GFP signal present in the cells, it is clear that 
there are differences between the mutant strains and the wild-type tagged 
strains mentioned in the sections above, more specifically in their expression 
levels. The strain with the p.G136A mutation is the one showing the less 
intense GFP signal, whereas the p.E240K mutation shows similar fluorescence 
intensity to wild-type Btn1p (Figure 3.2.1). This is expected in regards to the 
effects that the equivalent human mutations have in the juvenile NCL patients, 
where p.Glu295Lys underlies the mildest form of the disease. In summary, 
different mutations cause differences in the levels of GFP expression, based in 
different intensities of fluorescent signal detected by the confocal microscope. 
In order to confirm the exact localisation, other markers for cell organelles have 
to be used in the future. And also to confirm and quantify the differences in 
expression levels, a Western Blot assay has to be performed, since 
measurement based on the GFP microscope signal is merely qualitative and 
relative. 
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Figure 3.2.1.  Localisation of Btn1p integrated mutants 
Yeast strains with wild-type GFP-tagged Btn1p (upper left panel) and containing the 1-kb 
deletion (upper right panel), the G136A mutation (lower left panel) and the E240K mutation 
(lower right panel). Scale bars – 4.4μm  (GFP-btn1), 7μm (GFP-1kb∆) and 10 μm (GFP-E240K 
and G136A). 
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3.3 Characterising phenotypes of integrated Btn1p mutants 
It is known that cells deleted for btn1 exhibit many phenotypes, and that some 
disease mutant Btn1p proteins exhibit activity that restores one or more of these 
phenotypes, because the mutation does not completely abolish Btn1p function. 
Therefore, the newly created integrated mutant strains were investigated and 
characterised and the effect of the endogenously expressed mutant proteins 
analysed on the different phenotypes. Three phenotypes were chosen to be 
analysed first, since these were previously studied in btn1Δ cells with 
ectopically expressed mutant proteins (Haines et al. 2009).  Two of these 
phenotypes are present at the permissive growth temperature (30ºC), and the 
other becomes apparent at a high temperature of 37ºC: an increase in the 
vacuoles size, a delay in cytokinesis (illustrated by an increase in the number of 
septated cells) and curving of cells after 4 hours at 37ºC. All three of the 
phenotypes can be fully rescued by ectopic expression of GFP-Btn1p from the 
pREP42GFP-Btn1 plasmid (Figures 3.3.1, 3.3.2 and 3.3.3) but not by 
expression of the empty pREP42 vector (data not shown). 
Besides looking at different phenotypes in the mutant strains, the GFP-tagged 
strains were also analysed, to verify the effect of the tag protein and the Btn1p 
expression level in the phenotypes. Analysed strains included: the 972 wild-type 
(wt), the tagged strains where GFP is under the control of the strong nmt1 
promoter p3 (nmt3) and the medium promoter nmt1 p41 (nmt41), the tagged 
strain with GFP under the control of the native promoter of btn1 (GFP-btn1), the 
GFP-1kb∆ strain (1kb∆), the mutant tagged strains GFP-E240K (E240K) and 
GFP-G136A (G136A), and finally the btn1-deleted (btn1∆). 
 
3.3.1 Vacuole size 
The average vacuole size of different mutant and tagged wild-type strains was 
measured and compared to wild-type untagged cells and btn1 cells. Vacuoles 
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were measured in five independent experiments, where at least 500 vacuoles 
were measured in each one. 
Cells deleted for btn1 have significantly larger vacuoles than wild-type cells, and 
ectopic expression of Btn1p significantly reduces the vacuole size to a similar 
size to those of wild-type cells. In this case, the mean vacuole size of the 
G136A strain, which models a disease-causing missense mutation that had 
previously been shown as not being able to rescue vacuole size (Haines et al. 
2009), was included as an additional negative control, similar to btn1. 
Expression of any of the other mutants (1kbΔ and E240K) was sufficient to 
significantly rescue the vacuole size defect of btn1 cells as effectively as 
Btn1p, with the mean vacuole diameter being around 0.9 m for these mutants, 
compared to 1.02 m for btn1 cells or 1 m for G136A (Figure 3.3.1). This 
suggests that the 1-kb deletion and the p.E240K mutation of btn1 (and CLN3), 
are not complete null mutations, since expression of protein products modelling 
these mutations causes vacuole size to decrease in a significant manner, 
suggesting that they retain significant function in S. pombe, as documented 
before (Haines et al. 2009). This result has been confirmed in mammalian cell 
studies, at least for the 1-kb deletion, using expression of mammalian CLN3 
constructs similar to those described here (Kitzmuller et al. 2008).  
As expected, wild-type strains (wt, nmt3, nmt41, GFP-btn1) show the smaller 
vacuoles, with sizes ranging from 0,85 to 0,9 µm. Although slight variations are 
observed between the four wild-type strains, these differences in the vacuole 
size are not significant. (Figure 3.3.1).  
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Figure 3.3.1. Vacuole size of different strains 
The btn1 strain has larger vacuoles than wild-type strain. Images show vacuoles labeled with 
FM4-64 of wt (left) and btn1 (right) strains. Scale bars - 10µm. Graph shows the mean (±SEM) 
of the vacuoles diameter (in μm) in different strains from five independent experiments, where 
at least 500 vacuoles were measured in each one. Statistical significances between each strain 
were determined using a one-way ANOVA with a Tukey’s multiple comparison post-test. 
Statistical significances between wild-type and btn1 and G136A are represented in the graph 
above the bars (****p= <0.0001). Strains: wt – wild-type; nmt3 – GFP-btn1 under the control of 
the nmt1 p3 promoter; nmt41 - GFP-btn1 under the control of the nmt1 p41 promoter; GFPbtn1 
– GFP-tagged Btn1p; btn1d – btn1 strain; 1kbD – btn1 with 1-kb deletion; E240K – btn1 with 
the E240K mutation; G136A – btn1 with the G136A mutation; btn1D+btn1 – btn1 strain 
transformed with the pREP42GFPbtn1 plasmid. 
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3.3.2 Septation index 
Septation index (the percentage of septated cells in the total number of cells) of 
different strains was calculated and the obtained values from five independent 
experiments are shown in Figure 3.3.2. At least 300 cells were counted in each 
experiment. Septation index is an indication of the amount of cells that are 
halted in the cytokinesis process, and therefore, when this value is higher than 
normal it suggests a delay in the cell cycle 
Wild-type strains, as well as the mutant E240K strain, show significantly less 
septated cells than the G136A and btn1∆ strains. The wild-type strains show 
the same pattern as seen in the vacuoles size phenotype, where the nmt3 and 
the nmt41 strains have a slightly lower septation index (7% and 8.36%) than the 
wt strain (11.87%) and the GFP-btn1 (11.19%) is the one with the highest value 
from the four wild-type strains. In fact, there is a significant difference between 
the wild-type and the nmt3 strains. Once again this suggests that the level of 
expression of Btn1p influences the manifestation of the phenotypes associated 
with its deletion.  
The E240K strain has a septation index value that is very similar to the wt strain 
(11.27%), and the 1kb∆ strain showed a small but significant reduction (p=<0.1) 
in the septation index compared to btn1 cells (15.3%), suggesting once again 
that these mutant proteins retain significant function. The other two strains, 
G136A and btn1, showed a value significantly higher than the other six strains 
(23.28% and 20.26% respectively). Ectopic expression of Btn1p in the btn1 
strain significantly reduces the septation index to a similar value to wild-type 
strain (11.74%). 
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Figure 3.3.2. Septation index of different strains 
btn1 strain has a higher septation index than wild-type strain. Images show yeast cells stained 
with calcofluor, delineating cell walls and septa: wt (left) and btn1 (right) strains. Scale bars - 
10µm. Graph shows the mean (±SEM) septation index (percentage of septated cells in total 
number of cells) of different strains from five independent experiments, where at least 300 cells 
were counted in each one. Statistical significances between each strain were determined using 
a one-way ANOVA with a Tukey’s multiple comparison post-test. Statistical significances 
between wild-type and btn1 and G136A are represented in the graph above the bars 
(*p=<0.1***p=<0.001****p=<0.0001). Strains: wt – wild-type; nmt3 – GFP-btn1 under the control 
of the nmt1 p3 promoter; nmt41 - GFP-btn1 under the control of the nmt1 p41 promoter; 
GFPbtn1 – GFP-tagged Btn1p; btn1D – btn1 strain; 1kbD  – btn1 with 1-kb deletion; E240K – 
btn1 with the E240K mutation; G136A – btn1 with the G136A mutation; btn1D+btn1 – btn1 
strain transformed with the pREP42GFPbtn1 plasmid. 
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3.3.3 Cell curving 
The number of curved cells (cells that lost their normal rod shape and became 
curved or bent) was calculated for eight different strains, and percentage of 
curved cells (in total number of cells) obtained from five independent 
experiments are shown in Figure 3.3.3. At least 300 cells were counted in each 
experiment. For this phenotype, the nmt41 strain was not included.  
1kb∆, G136A and btn1∆ strains show significantly more curved cells than the 
wild-type strains. The wild-type strains show the same pattern as mentioned 
above (sections 3.3.1 and 3.3.2), where the nmt3 strain shows slightly less 
curved cells (9.34%) than the wt strain (10.53%). However, in this case, the 
GFP-btn1 strain showed less curved cells than the other two (8.95%). 
Differences between these wild-type strains are not statistically significant. 
The E240K strain has a similar fraction of curved cells to the wt strain (9.02%) 
and significantly lower than the btn1Δ strain, suggesting once again that this 
mutant protein retains significant function. Other values of strains with higher 
percentage of curved cells are: 19.84% for the 1kbΔ strain, 23.99% for the 
G136A strain and 22.45% for the btn1Δ strain, the highest value, as expected. 
These values are significantly different from the three wild-type and the E240K 
strains. Ectopic expression of Btn1p in the btn1 strain significantly reduces the 
number of curved cells to a similar value than wild-type strain (10.58%). 
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Figure 3.3.3. Cell curving of different strains 
The btn1 strain shows more curved cells than wild-type strain. Images show yeast cells 
stained with calcofluor, after growth at 37°C for 4 hours: wild-type (left panel), btn1 (middle 
panel) and the 1kb (right panel) strains. Arrows indicate curved cells. Scale bars – 10µm. 
Graph shows the mean (±SEM) cell curving percentage (percentage of curved cells in total 
number of cells) of different strains from five independent experiments, where at least 300 cells 
were counted in each one. Statistical significances between each strain were determined using 
a one-way ANOVA with a Tukey’s multiple comparison post-test. Statistical significances 
between wild-type and btn1, 1kb and G136A are represented in the graph above the bars 
(****p= <0.0001). Strains: wt – wild-type; nmt3 – GFP-btn1 under the control of the nmt1 p3 
promoter; nmt41 - GFP-btn1 under the control of the nmt1 p41 promoter; GFPbtn1 – GFP-
tagged Btn1p; btn1D – btn1 strain; 1kbD – btn1 with 1-kb deletion; E240K – btn1 with the 
E240K mutation; G136A – btn1 with the G136A mutation; btn1D+btn1 – btn1 strain 
transformed with the pREP42GFPbtn1 plasmid.  
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3.4 Summary 
Overexpression of btn1 (when under the control of the nmt1 p3 promoter) 
overcompensates phenotypes seen in btn1-deleted cells. Values recorded for 
the nmt3-GFP-btn1 strain were lower than the wild-type 972 strain values in all 
the phenotypes that were analysed: vacuole size, septation index and cell 
curving. This nmt3 strain also has smaller vacuoles and significantly less 
septated cells than the strain where Btn1p is tagged with GFP under the control 
of its native promoter.  
It had previously been demonstrated that the most common mutation of CLN3, 
a large intragenic deletion of about 1-kb is not a null mutation that completely 
abolishes CLN3 function, since the mutant protein retains some function 
(Kitzmuller et al. 2008; Haines et al. 2009). This observation was corroborated 
in this study, since the strain containing Btn1p102fsX5 (which models a transcript 
expressed in cells from patients homozygous for the 1-kb deletion) showed 
significant rescue of two phenotypes (increased vacuole size and septation 
index) almost as effectively as the full-length protein.  
As for the p.E240K mutation, the mutant Btn1 protein is able to rescue all three 
phenotypes examined in this chapter, showing that this mutation (which is 
equivalent to the human mutation that underlies a markedly protracted form of 
juvenile NCL) does not affect the function of Btn1p as much as the 1-kb deletion. 
Understanding why this is the only mutation capable of rescuing the cell curving 
phenotype and studying its molecular basis may reveal a novel target for 
therapies to delay onset of symptoms in juvenile CLN3 disease.  
On the other hand, the p.G136A mutation did not rescue any of the phenotypes, 
indicating that it affects the protein function to a greater extent than the other 
two mutations. This may be a null mutation that leads to a significant reduction 
in the protein levels. 
All the three mutations are sufficient to change the levels of expression of Btn1p 
and possibly its localisation, according to the GFP fluorescent signal that was 
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observed. All showed a different signal pattern when visualized under the 
microscope. To further clarify the localisation of the different mutant proteins, 
other organelle markers have to be used. 
Taken together these results show that different integrated mutations affect 
Btn1p function differently leading to diverse phenotypes. 
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4 Results 2. Drug Screen 
 
The aims of this part of the project were: 
- to explore different btn1∆ phenotypes in order to identify a robust and specific 
phenotype suitable for a high-throughput drug screen: sensitivity to chemicals 
such as ANP, chloroquine and cyclosporine A and to high temperature, and 
increased vacuole pH; 
- to optimise the conditions for the performance of the drug screen; 
- to perform the screen based on a library with 1280 FDA-approved small 
compounds in the Translational Research Resource Centre at the LMCB. 
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4.1 Exploring different phenotypes as basis of a screen 
In order to find a robust and striking phenotype that is easily identified when 
rescued and significantly different between wild-type and btn1-deleted strains, 
several conditions and characteristics were tested. These included sensitivity to 
certain chemicals such as ANP, chloroquine and cyclosporine A (CsA); growth 
at higher temperature (37°C) and differences in vacuole pH. The majority of 
these phenotypes were not adequate for the desired purposes. However, 
growth in the presence of cyclosporine A at 37°C was eventually selected as 
the basis for the drug screen. 
 
4.1.1 Sensitivity to ANP and chloroquine 
The first phenotype to be analysed was growth in the presence of ANP, a 
chemical that was previously reported to differentially affect the BTN1Δ strain in 
S. cerevisiae (Pearce & Sherman 1998). In budding yeast, this BTN1Δ strain 
shows resistance to ANP but the average vacuolar pH is more acidic than wild-
type cells, contrary to what is seen in fission yeast. Since the resistance to this 
chemical is pH-dependent, I hypothesized that btn1Δ S. pombe strain could be 
more sensitive to ANP than wild-type cells. Therefore, a spot assay was 
performed in MM plates containing ANP at two different concentrations (0.75 
mM and 1 mM) to determine if there was a difference in the growth of wild-type 
and btn1Δ S. pombe strains. This experiment was replicated three independent 
times with three similar plates in each. At both concentrations, there was no 
striking difference between the patterns of growth of the two strains (Figure 
4.1.1). Therefore, the loss of btn1 does not confer resistance or sensitivity to 
this chemical, and this phenotype cannot be used for a screen. Cells were also 
spotted onto MM plates without any added substance as a control (data not 
shown). 
Other chemical, chloroquine, was added to the medium to test if the 
combination of the two chemicals could reveal a difference between wild-type 
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and btn1Δ. In a study with budding yeast, chloroquine was shown to reverse the 
resistance of the BTN1Δ strain to ANP, by elevating the vacuole pH (Pearce et 
al. 1999a), and therefore this combination (ANP and chloroquine) was chosen 
to be tested in S. pombe to verify if there was sensitivity in the strain lacking 
btn1. The addition of 0.1 mM of chloroquine to the medium didn’t change the 
pattern of growth of the two strains in a significant manner (Figure 4.1.1).  
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Figure 4.1.1. Spot assays of wild-type and btn1Δ strains in 
plates with ANP and chloroquine 
btn1Δ strain is not sensitive to ANP and/or chloroquine. Wild-type and btn1Δ cells were serially 
diluted from a log-phase culture (1x10
6
 cells/ml) and spotted onto Minimal Medium (MM) plates 
containing either 0,75mM (upper left panel) or 1mM (upper right panel) of ANP; or 1mM 
ANP+0.1mM chloroquine (lower panel). Plates were then incubated at 30°C for 6-7 days to 
determine the growth in the presence of these chemicals. This assay was replicated thrice. wt – 
wild-type strain; btn1Δ – btn1-deleted strain. 
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4.1.2 Growth at high temperature (37°C) 
Growth in rich medium at a higher temperature than the permissive one, 37°C, 
was analysed at two different points, after 24 and after 48 hours. Cells were 
stained with the cell impermeant nucleotide stain propidium iodide to mark dead 
cells and calcofluor white to mark the total cell population. The viability 
(percentage of live cells in total number of cells) was measured for four strains: 
wild-type, btn1Δ, E240K and 1kbΔ. At least 300 cells were counted in three 
independent experiments. Besides this experiment, a spot assay in YES plates 
incubated at 37°C was done, with the same four strains (not shown). 
The high temperature of 37°C affects the growth of mutant and btn1-deleted 
strains but does not cause a strong complete inhibition of growth in these 
strains, which would be necessary for a rescue screen. For instance, although 
there was a significant difference between the wild-type and the btn1Δ strains, 
the percentage of dead cells with no btn1 was not high enough to be able to 
readily identify a significant rescue by any drug or compound (around 22.1% 
viability after 48 hours). Moreover, the viability of wild-type cells after 48 hours 
was not high enough (52.31%). Neither one of the mutant strains (1kbΔ and 
E240K) showed a significant difference from the wild-type strain (59.22% and 
47.83% after 48 hours, respectively) (Figure 4.1.2). 
Furthermore, liquid cultures, after growth for 48 hours at 37°C, were plated onto 
YES plates and incubated at 37°C again, to examine the extent of cell death. 
However, colonies were able to grow in the plates, and therefore, once again, it 
was proven that this phenotype is not adequate for developing a drug screen.  
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Figure 4.1.2. Growth of different strains at 37°C 
Cell viability of wt, E240K, 1kbΔ and btn1Δ strains upon growth in YES medium at a high 
temperature of 37°C over two periods of 24 and 48 hours (after the temperature shift). The 
graph shows the survival curve of different strains at three time points, after cultures were 
shifted from 30 to 37°C: 0, 24 and 48 hours. Data shown is a mean (±SEM) of 3 independent 
experiments. Survival is the percentage (%) of live cells in total number of cells. Statistical 
significances between each strain were determined using a one-way ANOVA with a Tukey’s 
multiple comparison post-test. Statistical significances between wild-type and btn1Δ are 
represented in the graph (***p= <0.001). wt – wild-type; btn1D – btn1 strain; 1kbD – btn1 with 
1-kb deletion; E240K – btn1 with the E240K mutation. 
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4.1.3 Vacuole pH 
It was previously shown that cells deleted for btn1 have larger and less acidic 
vacuoles than wild-type cells (Gachet et al. 2005). Therefore, these strains, 
along with 1kbΔ and E240K, were labelled with LysoSensor to compare vacuole 
pH, where the intensity of fluorescence obtained correlates with vacuole pH – 
the more intense the fluorescence, the lower the pH. Intensity was measured in 
units of corrected total cell fluorescence (CTCF). At least 300 cells were 
counted in three independent experiments. As expected, wild-type cells showed 
a significantly higher fluorescence than btn1Δ cells, corresponding to more 
acidic vacuoles. 1kbΔ cells showed an intermediate value of fluorescence, with 
a vacuole pH value between wild-type and btn1Δ, but not significantly different 
from any of them (Figure 4.1.3). 
Although this phenotype could be used for a drug screen, since there is a 
detectable and significant difference between cells with and without btn1, after 
further testing, it was shown that the intensity of fluorescence from the 
LysoSensor was not high enough to be differentially detected and measured in 
the Opera Software, and therefore, this phenotype was considered as not 
suitable for screening with this robot. 
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Figure 4.1.3. Vacuole pH of different strains 
btn1 strain have less acidic vacuoles than wild-type strain. The graph shows the mean (±SEM) 
corrected total cell fluorescence (CTCF) intensity of vacuoles of wild-type (wt), 1kbΔ and btn1Δ 
strains. Vacuoles were labelled with LysoSensor dye: the intensity of fluorescence inversely 
correlates with vacuole pH - the more intense the fluorescence, the lower the pH.  Data shown 
was collected from 3 independent experiments. Statistical significances between each strain 
were determined using a one-way ANOVA with a Tukey’s multiple comparison post-test. 
Statistical significances between wild-type and btn1Δ are represented in the graph above the 
btn1D bar (*p= <0.1). wt – wild-type; 1kbD – btn1 with 1-kb deletion; btn1D - btn1Δ strain. 
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4.1.4 Sensitivity to cyclosporine A at 37°C 
It was found that the btn1Δ strain is sensitive to cyclosporine A (CsA), an 
inhibitor of calcineurin. The link between Btn1p and calcineurin and/or CsA will 
be explored in the Discussion Chapter. Furthermore, in order to exacerbate the 
phenotype, strains were grown at 37°C. There was a significant difference 
between viability of wild-type and btn1Δ strains when grown in these conditions. 
In the presence of cyclosporine A (0.1 mg/ml) at a high temperature of 37°C, 
btn1∆ cells were not able to grow; the growth was completely inhibited, both in 
a spot assay (Figure 4.1.4 A) and when 106 cells were plated in plates with CsA 
(not shown). Since the presence of this chemical was shown to greatly affect 
the growth of btn1Δ strain, growth of all the integrated mutant strains were also 
analysed in these conditions: 1kbΔ, E240K and G136A. None of these strains 
showed sensitivity to the chemical, even at a higher concentration of 0.15mg/ml  
(Figure 4.1.4).  
Viability of liquid cultures in the presence of CsA and at 37°C, after 24 hours of 
growth, was also measured for all the five strains, following the same approach 
that was used for viability at 37°C with propidium iodide and calcofluor staining 
(section 4.1.2). At least 300 cells were counted in three independent 
experiments. A significant difference was seen between the number of wild-type 
and btn1Δ dead cells (viabilities of 94.07% and 5.68%, respectively). Regarding 
the mutant strains, the G136A strain is the only one showing sensitivity to CsA, 
in liquid culture (11.79%); E240K and 1kbΔ showed similar viability values to 
wild-type: 81.71% and 84.86%, respectively  (Figure 4.1.4). Thus, once again, 
partial function of Btn1p was able to be distinguished from complete lack of 
function. 
Therefore, this phenotype was selected to be the basis for a high-throughput 
screen using the btn1∆ strain. However, it was not suitable for mutation-specific 
screening. 
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Figure 4.1.4. Sensitivity of different strains to cyclosporine A at 
37°C 
btn1Δ is sensitive to cyclosporine A (CsA). Spot assays of different strains in YES plates with 
0.1 mg/ml of CsA were done by serially diluting cells from a log-phase culture (1x10
6
 cells/ml) 
and spotted onto YES plates containing 0.1 mg/ml of CsA. Plates were then incubated at 37°C 
for 3-4 days to determine growth at 37°C in the presence of CsA. Cells were also spotted onto 
YES plates lacking CsA as a control (data not shown). The graph represents the cell viability of 
wt, E240K, 1kb, G136A and btn1Δ strains upon growth in YES medium with CsA (0.1mg/ml) at 
a high temperature of 37°C over 24 hours (after the temperature shift). The graph shows the 
survival curve of different strains at two time points, after cultures were shifted from 30 to 37°C: 
0 and 24 hours. Data shown is a mean (±SEM) of 3 independent experiments. Viability is the 
percentage (%) of live cells in total number of cells. Statistical significances between each strain 
were determined using a one-way ANOVA with a Tukey’s multiple comparison post-test. 
Statistical significances between wild-type and btn1 and G136A are represented in the graph 
(****p= <0.0001). wt – wild-type; btn1 – btn1-deleted strain; 1kbΔ – btn1 with 1-kb deletion; 
E240K – btn1 with the E240K mutation; G136A - btn1 with the G136A mutation. 
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4.2 Drug screen 
After choosing the ideal phenotype to be used as basis of the screen, screening 
conditions were optimized. The developed high-throughput screen used a small 
compound library (LoPac collection), all at a concentration of 10μM, kindly 
provided by Dr. Robin Ketteler, and executed by the Opera® system. This 
screen was optimized and completed in collaboration with Dr Jamie Freeman. 
All the hits from the screen were validated in further experiments.  
 
4.2.1 Optimisation of the screen 
The high-throughput drug screen was executed by the Opera® High Content 
Screening System, a confocal microplate imaging robot. This system allows for 
the acquisition of several images in a rapid manner. These images are 
posteriorly analysed with the CellProfiler software, where the selected 
phenotype can be quantitatively measured in an automatic way. The analysis 
was based in the amount of fluorescence seen in the images from wild-type and 
btn1Δ untreated strains, and btn1Δ after being treated with the LoPac 
compounds. The detected fluorescence was from propidium iodide, which 
labels dead cells. Positive hits were compounds that were able to rescue cell 
death, characteristic of the btn1Δ strain in the presence of CsA at 37°C, and 
therefore showed less fluorescence than the untreated btn1Δ strain.  
Several conditions were tested before images with good quality and accurate 
amount of fluorescence were obtained: initial cell density, different manners of 
plating and amount of calcofluor and propidium iodide used to stain the cells, 
amongst others.  
All 1280 compounds were tested four times, and two controls, positive and 
negative, were included in each plate: wild-type and btn1Δ cells without any 
compound. 
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4.2.2 Results of the screen 
For each of the 384 wells in each plate, six images were acquired in order to 
cover a great part of the area. This means that for each compound that was 
tested, twenty-four images were acquired, since each compound was replicated 
in four wells. All images were analysed by Dr. Jamie Freeman using the 
CellProfiler software. A value corresponding to the amount of fluorescence in 
the whole area was given to each image, and an average of the different values 
was calculated for each compound. Values for the negative controls (cells with 
no btn1 and no added compound) and positive controls (wild-type cells with no 
added compound) were also calculated and compared to those of the samples 
(btn1Δ cells with compounds). The average value for the negative controls was 
0.723, and therefore only compounds giving numbers less than this value were 
considered further.  
Images corresponding to positive hits were all analysed individually in order to 
eliminate false positive results where, for instance, no cells were seen in the 
image.  
After the analysis, the six stronger hits were chosen to be validated in further 
experiments. These were atenolol, alloxazine, L-trans-Epoxysuccinyl-
leucylamido(4-guanidino)butane (E-64), prochlorperazine dimaleate, etoposide 
and daphnetin. Examples of screen images corresponding to controls (wild-type 
and btn1Δ untreated cells) and two positive hits are displayed in Figure 4.2.1. 
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Figure 4.2.1. Drug screen: negative and positive controls, and 
two positive hits  
Sample images obtained in the drug screen. Cells in log-phase were grown in YES medium with 
CsA (0.1mg/ml) and a randomly assigned compound of the LoPac collection (10μM) at a high 
temperature of 37°C over 24 hours. Cells were stained using the cell impermeant nucleotide 
stain propidium iodide to mark dead cells (red/pink) and calcofluor white to mark the total cell 
population (blue). Images correspond to: btn1∆ untreated cells with no added compound 
(negative control) (upper left side); wild-type untreated cells with no added compound (positive 
control) (upper right side); and two positive hits from the screen in the lower panel (btn1∆ cells 
treated with two compounds that were able to rescue the low viability seen in the presence of 
CsA). In smaller squares zoomed images of the respective larger pictures (positive and 
negative controls) are shown. 
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4.3 Summary 
The first step towards the development of the drug screen was to find a robust 
and striking phenotype that is easily identified when rescued and significantly 
different between strains with and without btn1. The ideal is a phenotype based 
on a type of assay that will assess something as basic as survival/death of the 
strains, where cells with defective or no Btn1p are unable to grow or survive as 
well as wild-type cells. These kind of selective screens are not yet possible to 
be performed in mammalian cells, since no robust adequate phenotype has 
been reported to date. On the other hand, the fission yeast model is ideal to 
perform this type of screen, since multiple phenotypes (caused by the loss of 
btn1 or associated with the 1-kb deletion mutant) have already been identified.  
Four different phenotypes were analysed, and they were chosen for different 
reasons. Firstly, the growth of btn1Δ in the presence of ANP and chloroquine 
was investigated. It was previously reported that S. cerevisiae strains lacking 
BTN1 are more resistant to ANP, in a pH-dependent manner (Pearce & 
Sherman 1998). Since in S. cerevisiae BTN1Δ strain the vacuole pH is more 
acidic, but in S. pombe this pH is higher than normal, it was thought that fission 
yeast strains without btn1 could be more sensitive to ANP.  Moreover, in other 
study in budding yeast, chloroquine was shown to reverse the resistance to 
ANP, elevating the vacuole pH (Pearce et al. 1999a), and therefore this 
combination (ANP and chloroquine) was tested in S. pombe to verify if there 
was an exacerbation in the sensitivity of strains without btn1 to these 
compounds. However, there was no striking difference between the pattern of 
growth of wild-type and btn1Δ strains, neither in the presence of ANP nor in the 
presence of ANP and chloroquine.  
The next phenotype to be analysed was the growth of strains at a high 
temperature of 37°C. In a study by Codlin and others (Codlin et al. 2008b) it 
was reported that Btn1p is essential for growth at 37°C, since its absence 
ultimately results in cell lysis. In fact, in this study, the high temperature was 
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shown to severely affect the growth of btn1Δ strain; however this was not a 
complete inhibition of growth, which would be desirable for a rescue screen. 
It was previously shown that cells deleted for btn1 have a higher vacuole pH 
than wild-type cells (Gachet et al. 2005), and therefore this was measured in 
these two types of strains (wild-type and btn1Δ). A significant difference was 
seen between these two strains, and therefore this phenotype was initially 
selected for the drug screen. However, after further testing by Dr Jamie 
Freeman, it was shown that the fluorescence intensity from the Lysosensor 
used to measure vacuole pH was difficult to measure in the Opera Software, 
and therefore, this phenotype was abandoned. 
Finally, work done by Dr Michael Bond (unpublished data) showed that the TOR 
complex 2 (TORC2) pathway is related to the function of Btn1p, and it was 
known that the calcineurin phosphatase is consistently active in yeast mutants 
defective for TORC2 (Mulet et al. 2006). Therefore, an inhibitor of calcineurin, 
cyclosporine A, was tested to verify its effect on the growth of btn1Δ strain at a 
concentration of 0.1mg/ml and at 37°C. btn1Δ cells are sensitive to growth in 
these conditions. Therefore, this phenotype was selected as basis of the drug 
screen. 
The developed high-throughput screen was performed using a library (LoPac 
collection) with 1280 FDA-approved compounds. The screen was optimized 
and completed in collaboration with Dr Jamie Freeman. This screen was 
performed in the Opera system, a high-throughput microscope suitable for this 
type of screening campaigns. 
After acquiring all the images from the screen, these were primarily analysed by 
Dr. Jamie Freeman using the Cell Profiler software. Afterwards, images from 
the positive hits were manual and individually analysed in order to eliminate 
false positive results. 
The six stronger hits were selected for further experiments of validation: 
atenolol, a selective β1 adrenoreceptor antagonist (β-blocker), used mainly in 
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treatment of cardiovascular diseases; alloxazine, an adenosine A2B receptor 
antagonist; E-64, an inhibitor of a range of cysteine peptidases; 
prochlorperazine dimaleate, a D2 dopamine receptor antagonist; etoposide, a 
topoisomerase inhibitor, used as an anticancer drug; and daphnetin, an inhibitor 
of several protein kinases, with antioxidant and immunosuppressant properties. 
Although some of these compounds do not have apparent targets in yeast, 
these were further explored in this model, since they could be acting in a 
different pathway than in humans. More details about these hits will be 
discussed in the following chapters.  
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5 Results 3. Compounds identified in drug screen are 
able to rescue other phenotypes arising from loss of 
btn1 in fission yeast 
 
The aims of this part of the project were: 
- to validate the six strongest positive hits obtained in the drug screen, by 
manually retesting these in the same conditions as the screen; 
- to test three hit compounds on their ability to rescue other phenotypes in 
btn1Δ cells: increased vacuole size, higher septation index and cell curving, and 
sensitivity to high temperature; 
- to test the same compounds for their ability to rescue compactness of the 
Golgi apparatus in fibroblasts from juvenile CLN3 disease patients;   
- to test the same compounds in a zebrafish juvenile NCL model to verify their 
ability to rescue other phenotypes associated with mutated cln3: increased 
relative activity of the fish and low survival rate.  
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5.1 Validating hits from the drug screen 
In order to validate the results obtained in the drug screen, the six strongest 
hits, that showed the most significant rescue of sensitivity to cyclosporine A in 
btn1Δ cells, were selected: atenolol, alloxazine, E-64, prochlorperazine 
dimaleate, etoposide and daphnetin. These compounds were added to both 
wild-type and btn1Δ strains and they were grown in the same exact conditions 
as the drug screen (Results 2.1.2), but in a larger volume. Strains were grown 
at 37°C in the presence of CsA (0.1mg/ml) and the respective compound 
(10μM) for 24 hours. Strains were also treated with the compounds’ carrier, 
DMSO, as a control. Images were taken and analysed manually. At least 300 
cells were counted in three independent experiments. 
Alloxazine was the first compound to be analysed: its presence significantly 
rescued the lower viability of the btn1Δ strain (49.25% instead of 3.36% in the 
untreated btn1Δ strain) and didn’t significantly alter the viability of the wild-type 
strain (88.93% with alloxazine, compared to 92.22% for untreated wt). Similar 
results were obtained for E-64 and prochlorperazine dimaleate. Both of these 
compounds slightly (but not significantly) decreased the viability of the wild-type 
strain (81.24% for E-64 and 84.32% for prochlorperazine) and significantly 
increased the viability of the btn1Δ strain, especially E-64, validating their ability 
to rescue the sensitivity to CsA (73.85% and 63.18%, respectively for E-64 and 
prochlorperazine) (Figure 5.1.1). Therefore, these three compounds (alloxazine, 
E-64 and prochlorperazine dimaleate) were all selected for further experiments, 
to verify their ability to rescue other phenotypes associated with the loss of 
btn1. 
Only compounds that rescued viability to values above 50% without affecting 
the wild-type strain were chosen for further studies. Therefore, the other three 
compounds, atenolol, etoposide and daphnetin were excluded. Atenolol was 
able to slightly rescue the CsA sensitivity of the btn1Δ strain (16.29% instead of 
3.36%). However, the rescue was not statistically significant and therefore 
atenolol was not further tested. On the other hand, the addition of etoposide 
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significantly rescued the growth of the btn1Δ, but also affected the wild-type 
strain (61.73% instead of 92.22%) and therefore it was not used in further 
experiments. A similar effect was observed with daphnetin, where the viability of 
wild-type significantly decreased after treatment (41.24%) (Figure 5.1.1). Due to 
time restrictions, only the three compounds that led to the strongest rescues 
were further explored in this project. However, the other three compounds 
should be considered in the future. 
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Figure 5.1.1. Validation of six strongest hits from the drug 
screen in wild-type and btn1Δ strains 
Alloxazine, E-64 and prochlorperazine dimaleate are able to significantly rescue sensitivity of 
btn1Δ strain to cyclosporine A (CsA). Cell viability of wild-type and btn1Δ strains upon growth in 
YES medium with CsA (0.1mg/ml) and six compounds (10μM) at a high temperature of 37°C 
after 24 hours. Graphs show the viability (percentage % of live cells in total number of cells) of 
wild-type (upper graph) and btn1Δ strains (lower graph) after treatment with different 
compounds: alloxazine, atenolol, etoposide, E-64, daphnetin and prochlorperazine dimaleate 
(proc dimaleate). Strains were also treated with the compounds’ carrier, DMSO, as a control. 
Data shown is a mean (±SEM) of 3 independent experiments. Statistical significances between 
each treatment were determined using a one-way ANOVA with a Tukey’s multiple comparison 
post-test. Statistical significances between wild-type and btn1Δ and all the six compounds are 
represented in the graph above the compounds’ bars (*p= <0.1; **p= <0.01; ****p= <0.0001). In 
the upper graph significances were calculated against the wild-type strain (wt), and in the lower 
graph against the btn1Δ strain (btn1D), both treated with DMSO. 
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5.2 Testing compounds’ ability to rescue other btn1Δ 
phenotypes 
The three compounds that were positively selected in the drug screen and 
subsequently validated (alloxazine, E-64 and prochlorperazine dimaleate) were 
used in further experiments to verify their ability to rescue other phenotypes 
associated with the loss of btn1: enlarged vacuoles, higher septation index, 
increased cell curving and sensitivity growth at high temperature.  
 
5.2.1 Vacuole size 
The first phenotype to be analysed was vacuole size, which was shown to be 
significantly larger in btn1Δ cells (Results 1.3.1). Wild-type and btn1Δ strains 
were grown in the presence of the three validated compounds prior to labelling 
the vacuoles: alloxazine, E-64 and prochlorperazine dimaleate. At least 500 
vacuoles for each compound were measured in three independent experiments. 
Strains were also treated with DMSO as a control. After measuring the average 
vacuole diameter, it was found that all three compounds were able to 
significantly rescue this phenotype. The average vacuole diameter is smaller in 
the presence of the compounds than in untreated btn1Δ cells, a similar size of 
vacuoles in wild-type cells: an average size of 0.87 μm for alloxazine, 0.9 μm for 
E-64 and prochlorperazine dimaleate, when compared to 0.87 μm in the wild-
type strain and 1.02 μm in the btn1Δ strain (Figure 5.2.1). None of the 
compounds significantly affected the size of wild-type vacuoles (data not 
shown). 
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Figure 5.2.1. Effects of alloxazine, E-64 and prochlorperazine 
dimaleate on the vacuole size of btn1Δ strain 
Alloxazine, E-64 and prochlorperazine dimaleate are able to significantly rescue enlarged 
vacuoles of btn1Δ strain. The graph shows the mean (±SEM) of the vacuoles diameter (in μm) 
in the btn1Δ strain treated with DMSO (control) and different compounds (10μM): alloxazine, E-
64 and prochlorperazine dimaleate (proc). The average vacuole diameter of the wild-type strain 
is represented by a grid line in the graph (wt). Data was collected in three independent 
experiments. Statistical significances between each treatment were determined using a one-
way ANOVA with a Tukey’s multiple comparison post-test. Statistical significances between 
btn1Δ treated with DMSO and with the three compounds are represented in the graph above 
the compounds’ bars (****p= <0.0001).  
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5.2.2 Septation index 
Wild-type and btn1Δ strains were grown in the presence of alloxazine, E-64 and 
prochlorperazine dimaleate and then imaged to calculate the respective 
septation index. Strains were also treated with DMSO as a control. At least 300 
cells were counted for each compound in three independent experiments. All 
three compounds were able to significantly rescue this phenotype, decreasing 
the number of septated cells to similar values to wild-type, or even slightly 
lower: 7.135% for alloxazine, 9.09% for E-64 and 12.87% for prochlorperazine 
dimaleate, when compared to 11.43% for wild-type strain and 20.67% for btn1Δ 
strain (Figure 5.2.2). None of the compounds significantly affected the number 
of septated cells in the wild-type strain or caused multiseptated cells (data not 
shown). 
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Figure 5.2.2. Effects of alloxazine, E-64 and prochlorperazine 
dimaleate on the septation index of btn1Δ strain 
Alloxazine, E-64 and prochlorperazine dimaleate are able to significantly rescue the elevated 
septation index of btn1Δ strain. The graph shows the mean (±SEM) of septation index in the 
btn1Δ strain treated with DMSO (control) and different compounds (10μM): alloxazine, E-64 and 
prochlorperazine dimaleate (proc). The average septation index of the wild-type strain is 
represented by a grid line in the graph (wt). Septation index is the percentage of septated cells 
in total number of cells. Data was collected in three independent experiments. Statistical 
significances between each treatment were determined using a one-way ANOVA with a Tukey’s 
multiple comparison post-test. Statistical significances between btn1Δ treated with DMSO and 
with he three compounds are represented in the graph above the compounds’ bars (***p= 
<0.001; ****p= <0.0001).  
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5.2.3 Cell curving 
Wild-type and btn1Δ strains were treated with the same three compounds as 
before, in order to determine any effect on the cell curving phenotype. Strains 
were also treated with DMSO as a control. At least 300 cells were counted for 
each compound in three independent experiments. All three compounds were 
able to significantly rescue the curved morphology of cells, decreasing the 
number of curved cells to similar or lower values than wild-type: 9.82% for 
alloxazine, 8.55% for E-64 and 9.99% for prochlorperazine dimaleate, when 
compared to 11.47% for the wild-type strain and 22.4% for the btn1Δ strain 
(Figure 5.2.3). Furthermore, and since the 1kbΔ also showed a significantly 
higher number of curved cells strain similar to btn1Δ strain (19.84%) (Results 
1.3.3), this strain was also treated with the same compounds. All three 
compounds were able to rescue the phenotype in this strain, in a significant 
manner, to values lower than the wild-type strain: 8.98%, 8.88% and 9.21% for 
alloxazine, E-64 and prochlorperazine dimaleate, respectively (Figure 5.2.3). 
None of the compounds significantly affected the number of curved cells in the 
wild-type strain (data not shown). 
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Figure 5.2.3. Effects of alloxazine, E-64 and prochlorperazine 
dimaleate on the cell curving of btn1Δ and 1kbΔ strains 
Alloxazine, E-64 and prochlorperazine dimaleate are able to significantly rescue the elevated 
cell curving percentage of btn1Δ and 1kbΔ strains. Graphs show the mean (±SEM) of cell 
curving percentage in the btn1Δ (upper graph) and 1kbΔ (lower graph) strains treated with 
DMSO (controls) and different compounds (10μM): alloxazine, E-64 and prochlorperazine 
dimaleate (proc). The average  cell curving of the wild-type strain is represented by a grid line in 
both graphs (wt). Cell curving is the percentage of curved cells in total number of cells. Data 
was collected in three independent experiments. Statistical significances between each 
treatment were determined using a one-way ANOVA with a Tukey’s multiple comparison post-
test. Statistical significances between btn1Δ and 1kbΔ treated with DMSO and with the three 
compounds are represented in the graph above the compounds’ bars (****p= <0.0001). DMSO 
– btn1Δ strain with DMSO and no compound; 1kbD – 1kbΔ strain with DMSO and no compound. 
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5.2.4 Growth at high temperature 
The last phenotype that was analysed was the sensitivity of btn1Δ strain to 
growth at a high temperature of 37°C. Wild-type and btn1Δ strains were grown 
in the presence of alloxazine, E-64 and prochlorperazine dimaleate for 48 hours 
at 37°C and their viability was measured after 24 and 48 hours. Strains were 
also treated with DMSO as a control. At least 300 cells were counted for each 
compound in three independent experiments. None of the compounds 
significantly affected the viability of wild-type cells. Regarding the btn1Δ strain, 
the effect varied. Only alloxazine was able to significantly rescue the sensitivity 
of btn1Δ strain to high temperature after 24 and 48 hours (91.48% after 24 
hours and 58.51% after 48 hours, compared to 54.47% and 22.09% in btn1Δ 
strain). E-64 and prochlorperazine were not able to rescue this phenotype 
(27.78% and 34.34% after 48 hours, for E-64 and prochlorperazine, 
respectively) (Figure 5.2.4). 
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Figure 5.2.4. Effects of alloxazine, E-64 and prochlorperazine 
dimaleate on the growth of btn1Δ strain at 37°C 
Alloxazine is able to significantly rescue the sensitivity of btn1Δ strain to growth at 37°C. Cell 
viability of btn1Δ strain upon growth in YES medium at a high temperature of 37°C over two 
periods of 24 and 48 hours (after the temperature shift), and treated with DMSO (control) and 
three different compounds (10μm): alloxazine, E-64 and prochlorperazine dimaleate (proc). 
Data from wild-type (wt) strain treated with DMSO is also included in the graph. Graph shows 
the survival curve of different strains at three time points, after cultures were shifted from 30 to 
37°C: 0, 24 and 48 hours. Data shown is a mean (±SEM) of 3 independent experiments. 
Viability is the percentage (%) of live cells in total number of cells. Statistical significances 
between each strain were determined using a one-way ANOVA with a Tukey’s multiple 
comparison post-test. Statistical significances between btn1Δ treated with DMSO and alloxazine, 
and wild-type are represented in the graph (***p=<0.001****p= <0.0001). Treatment with the 
other two compounds was not statistically significant.   
 
 
Chapter 5 Results 3 
 
 130 
5.2.5 Spot assays 
In order to reinforce the previous results that showed the ability of three 
compounds (alloxazine, E-64 and prochlorperazine dimaleate) to rescue the 
sensitivity to a temperature of growth of 37°C and the presence of cyclosporine 
A, wild-type and btn1Δ strains were spotted onto YES plates with and without 
cyclosporine A, and with the respective compound, and incubated at 37°C. The 
assay was repeated in three independent experiments with three replicas of 
each plate with the different compounds. Alloxazine was also able to rescue the 
growth of btn1Δ strain in both conditions, but more significantly in plates without 
CsA. On the other hand, E-64 and prochlorperazine dimaleate were able to 
completely rescue the growth of btn1Δ strain in the presence of CsA (0.1mg/ml), 
but not in plates without CsA (Figure 5.2.5). Cells were also spotted onto YES 
plates with DMSO (with or without CsA) without any added compound as a 
control. 
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Figure 5.2.5. Effects of alloxazine, E-64 and prochlorperazine 
dimaleate on the growth of wild-type and btn1Δ strains in 
YES plates with cyclosporine A at 37°C 
Alloxazine is able to recover growth of btn1Δ cells at 37°C in YES plates with and without 
cyclosporine A (CsA), whereas E-64 and prochlorperazine dimaleate are only able to recover 
growth in plates with CsA. Wild-type and btn1Δ cells were serially diluted from a log-phase 
culture (1x10
6
 cells/ml) and spotted onto YES plates containing or lacking 0.1mg/ml of 
cyclosporine A (right and left panel, respectively), and containing 10μM of alloxazine, E-64 and 
prochlorperazine dimaleate (upper, middle and lower panel respectively). Plates were then 
incubated at 37°C for 3-4 days to determine growth at high temperature in the presence (or 
absence) of CsA and three compounds.  
 
 
Chapter 5 Results 3 
 
 132 
5.3 Testing compounds in other disease models 
The three compounds (alloxazine, E-64 and prochlorperazine dimaleate) 
selected from the drug screen and proved to be able to rescue other 
phenotypes associated with the loss of btn1 in fission yeast, were tested in 
other mammalian models of juvenile CLN3 disease. The ability of these 
compounds to rescue other phenotypes in patient fibroblasts and in a vertebrate 
disease model (zebrafish) was tested. In fibroblasts, compactness of the Golgi 
apparatus was assessed, since this organelle was shown to be less compact in 
patient cells when compared with healthy control cells (Davide Marotta, 
unpublished data). In the zebrafish model, relative activity and survival of the 
fish were assessed. This work was done in collaboration with Davide Marotta 
(fibroblasts) and with Dr Claire Russell from the Royal Veterinary College 
(zebrafish). 
 
5.3.1 Compactness of Golgi apparatus in patient fibroblasts 
Healthy control and patient fibroblasts (homozygous for the 1-kb deletion in 
CLN3) were incubated with different concentrations of alloxazine, E-64 and 
prochlorperazine dimaleate (5, 10 and 20µM) for 24 hours. Afterwards, cells 
were prepared for immunofluorescence and imaged. Compactness of the Golgi 
apparatus (numerical quantity that shows the degree to which the Golgi is 
compact when compared to a perfect circle, which has a value of 1.0) was 
measured for all fibroblasts, with and without compound. These measurements 
were performed in three independent experiments. Previous work done by 
Davide Marotta showed that in patient fibroblasts the Golgi apparatus is less 
compact than in healthy fibroblasts, suggesting that it may be less organised 
(unpublished data). This difference in Golgi compactness between patient and 
healthy control untreated fibroblasts was observed again in this study: 0.08 in 
control and 0.02 in patient cells (figure 5.3.1). After incubation with the three 
compounds at three different concentrations (5, 10 and 20µM), all except 
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alloxazine significantly rescue the low compactness of the Golgi apparatus in 
fibroblasts from patients with the 1-kb deletion. E-64 restores the compactness 
value to 0.08 at 5 and 10µM and to 0.1 at the higher concentration of 20µM. 
Prochlorperazine dimaleate also restores the value to 0.09 and 0.08 at 5 and 
10µM respectively. At a higher concentration (20µM), it appears to be lethal to 
the cells, since no fibroblasts were seen in any of the three experiments (Figure 
5.3.1). With the exception of prochlorperazine dimaleate at 20µM, none of the 
compounds affected the Golgi compactness of healthy control fibroblasts, at 
any concentration. 
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Figure 5.3.1. Effects of alloxazine, E-64 and prochlorperazine 
dimaleate on the compactness of the Golgi apparatus in 
the juvenile CLN3 disease patient fibroblasts 
E-64 and prochlorperazine dimaleate are able to significantly rescue compactness of the Golgi 
apparatus seen in fibroblasts from juvenile NCL patients. Images showing healthy control 
fibroblasts (left panel) and patient fibroblasts untreated (middle panel) and treated with E-64 (20 
μM) (right panel). Nuclei were stained with Hoechst (blue) and the green fluorescence 
corresponds to GM130 Golgi marker protein. More compact Golgi can be seen in the left and 
right panels when compared to the middle panel, which shows more distended Golgi staining. 
Graphs show the mean (±SEM) of Golgi apparatus’ compactness in control healthy fibroblasts 
and juvenile NCL patient fibroblasts: untreated (0μM) or treated with 5, 10 or 20μM of alloxazine, 
E-64 and prochlorperazine dimaleate. There is no value correspondent to the treatment with 
20μM of prochlorperazine dimaleate because at this concentration this compound is lethal to 
the fibroblasts. Compactness is a numerical quantity that shows the degree to which the Golgi is 
compact when compared to a perfect circle, which has a value of 1.0. Data was collected in 3 
independent experiments. Statistical significances between each treatment were determined 
using a one-way ANOVA with a Tukey’s multiple comparison post-test. Statistical significances 
between control fibroblasts and patient fibroblasts treated with compounds at different 
concentrations in relation to untreated patient fibroblasts are represented in the graphs above 
the bars (****p= <0.0001).  
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5.3.2 Zebrafish model 
Dr Claire Russell at the Royal Veterinary College of London investigated the 
ability of the three compounds (alloxazine, E-64 and prochlorperazine 
dimaleate) to rescue two phenotypes in a zebrafish model of the juvenile CLN3 
disease. Compounds were added to fish 12 hours post fertilization. Both 
phenotypes were analysed in three independent experiments. 
The first phenotype to be analysed was the relative activity of the fish recorded 
for 3 minutes. This activity consists of a tail flicking movement, which was 
previously shown to be more frequently seen in fish with Cln3 morpholino (Cln3 
MO) (Claire Russell and Kim Wager, personal communication). Relative activity 
was measured in number of pixels that change in time during the recorded time 
(3 minutes). All three compounds are able to significantly rescue this phenotype, 
decreasing the relative activity of the Cln3 MO fish to values close to wild-type 
fish treated only with DMSO: 75.27 for E-64, 110 for alloxazine and 200.56 for 
prochlorperazine dimaleate, compared to 116.13 for wild-type fish and 1281.74 
for Cln3 morpholino fish, both treated with DMSO (Figure 5.3.2). However, 
prochlorperazine dimaleate also affects the tail flicking of the wild-type zebrafish, 
increasing the value to 466.47 (data not shown). None of the other compounds 
have any effect on wild-type fish (data not shown). 
The other phenotype that was analysed was the fish survival, which is reduced 
in the zebrafish model of the juvenile CLN3 disease: Cln3 morpholino treated 
with only DMSO normally die after 3 days. E-64 gives a partial rescue of this 
phenotype, increasing the survival rate to approximately 50% at 125 hpf, 
compared to almost 0% survival in the Cln3 morpholino fish treated with only 
DMSO at this time point. None of the other compounds was able to significantly 
affect the survival ratio of the morpholino fish. 
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Figure 5.3.2. Effects of alloxazine, E-64 and prochlorperazine 
dimaleate on the relative activity and survival of a zebrafish 
model of the juvenile CLN3 disease 
Alloxazine, E-64 and prochlorperazine dimaleate are able to rescue relative activity of a 
zebrafish model of juvenile CLN3 disease. E-64 is also able to rescue fish survival in this model 
The upper graph shows the mean (±SEM) of relative activity in zebrafish: control, Cln3 
morpholino fish treated with DMSO (DMSO) and treated with alloxazine, E-64 and 
prochlorperazine dimaleate (proc). The relative activity was measured in number of pixels that 
change in time during three minutes. The lower graph shows fish survival in zebrafish: control 
(wild-type treated with DMSO), Cln3 morpholino fish treated with DMSO (DMSO) and treated 
with alloxazine, E-64 and prochlorperazine dimaleate (proc). Data was collected by Dr. Claire 
Russell in three independent experiments. Statistical significances between each treatment 
were determined using a one-way ANOVA with a Tukey’s multiple comparison post-test. 
Statistical significances between morpholino fish and control fish and treatment with compounds 
are represented in the graphs (*p= <0.1). hpf - hours post fertilization. 
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5.4 Summary 
After obtaining the results from the drug screen described in the Results 
Chapter 2 (Chapter 4.2.2), six stronger hits were validated by manually 
repeating the same assay of the automated screen. Three of the compounds, 
alloxazine, E-64 and prochlorperazine dimaleate showed again a significant 
rescue of the cyclosporine A sensitivity, more specifically E-64, which increased 
the viability of the btn1Δ strain to approximately 74%. These compounds were 
chosen for further validation studies, where they were tested for their ability to 
rescue four other phenotypes in btn1Δ cells. 
The first phenotype that was tested was vacuole size, which is larger in the 
btn1Δ strain (Chapter 3.3.1). All compounds (alloxazine, E-64 and 
prochlorperazine dimaleate) were able to significantly rescue this phenotype to 
values similar to those seen in wild-type strain, although alloxazine was the 
drug that led to a better rescue. A similar rescue pattern was seen in other 
phenotype that was analysed, higher septation index, with all compounds 
showing ability to rescue the number of septated cells, especially alloxazine, 
which decreased this number to a value even lower than that seen in the wild-
type strain. All three compounds were also able to rescue the cell curving 
phenotype seen after 4 hours at 37°C, but in this case the compound 
responsible for the strongest rescue was E-64. All compounds were able to 
decrease the number of curved cells in the btn1Δ strain and in the strain 
containing the 1-kb deletion, to values lower than those seen in the wild-type 
strain. On the other hand, sensitivity of btn1Δ strain to growth at high 
temperature, 37°C, after 24 and 48 hours (and in spot assays) was only 
rescued by alloxazine. Treatments with E-64 and prochlorperazine dimaleate 
were not sufficient to give a significant rescue of the btn1Δ low viability in these 
conditions. Additionally, all compounds were able to rescue colony growth in 
spot assays at 37°C in the presence of cyclosporine A. 
Finally, compounds were tested in two different mammalian models: patient 
fibroblasts containing the 1-kb deletion, and a zebrafish model of juvenile CLN3 
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disease. In the first model, the investigated phenotype was compactness of the 
Golgi apparatus, which is reduced in patient fibroblasts when compared to 
healthy control cells. E-64 and prochlorperazine dimaleate were both able to 
rescue this phenotype at different concentrations, but not alloxazine. At a high 
concentration of 20µM, prochlorperazine dimaleate induces cell death, which 
suggests that at higher concentrations this compound is toxic. Work done in the 
zebrafish model showed that all compounds are able to significantly rescue the 
fish relative activity, which is normally increased in this model. Furthermore, E-
64 was shown to rescue another phenotype, fish survival, which is normally 
compromised in the CLN3 disease model.  
Altogether these preliminary results are very encouraging, with respect to the 
development of a potential therapy for juvenile CLN3 disease using any of the 
three compounds that were studied; however, future work is needed to further 
clarify their mechanism of action in yeast.  
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6 Results 4. Characterisation of other lysosomal 
storage disorder yeast strains 
 
The aims of the last part of the project were: 
- to characterise phenotypes that were previously associated with btn1Δ in 
three different fission yeast strains that model other lysosomal storage 
disorders (LSDs): Chédiak Higashi Syndrome (lvs1Δ), Niemann-Pick disease 
type C2 (npc2Δ) and CLN10 disease (sxa1Δ); 
- to test the three hit compounds that were shown to efficiently rescue 
phenotypes in the btn1Δ strain for their ability to rescue the newly described 
phenotypes in the three LSD yeast models. 
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6.1 Characterising phenotypes of other lysosomal storage 
disorders yeast strains 
It was shown in the previous chapters (Results Chapters 2 and 3) that the 
fission yeast model of juvenile CLN3 disease exhibits different phenotypes that 
can be rescued by three compounds, which were identified in a drug screen. 
Bearing in mind that the juvenile CLN3 disease is a lysosomal storage disorder, 
other disorders with the same classification that can be modelled in yeast were 
chosen for further investigation. All of these diseases have fission yeast models 
where the orthologue of the responsible human gene is deleted:  lvs1Δ strain 
(Chédiak Higashi Syndrome), npc2Δ strain (Niemann-Pick disease type C2) 
and sxa1Δ (CLN10 disease). These mutant strains were characterised in terms 
of phenotypes that are associated with the btn1Δ strain. The five chosen 
phenotypes were: size of the vacuoles, cytokinesis defects (illustrated by the 
septation index), number of curved cells after 4 hours of growth at 37ºC, viability 
at 37ºC and sensitivity to cyclosporine A.  
 
6.1.1 Vacuole size 
The first phenotype to be analysed was the diameter of vacuoles in the cells. 
Therefore, lvs1Δ, npc2Δ and sxa1Δ strains were labelled with FM4-64 and 
vacuoles were measured, in the same manner as for the btn1 mutant strains 
(Chapter 3.3.1). All three strains show significantly larger vacuoles when 
compared to the wild-type strain, specially the lvs1Δ strain, whose average 
vacuole diameter is 1.62 μm. The other two strains, npc2Δ and sxa1Δ, show a 
smaller but still large size when compared to wild-type: 1.06 and 1.08 μm, 
respectively. These values are all significantly higher than the wild-type strain, 
which shows average size of 0.86 μm (Figure 6.1.1). 
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Figure 6.1.1. Vacuole size of different lysosomal storage 
disorders yeast strains 
Yeast models of lysosomal storage disorders lvs1Δ, npc2Δ and sxa1Δ show large vacuoles. 
Images show vacuoles labeled with FM4-64 of wild-type, lvs1Δ, npc2Δ and sxa1Δ strains. Scale 
bars - 10µm (wild-type and lvs1Δ) and 5µm (npc2Δ and sxa1Δ). Graph shows the mean (±SEM) 
of the vacuoles diameter (in μm) in different strains from three independent experiments. 
Statistical significance between each strain was determined using a one-way ANOVA with a 
Tukey’s multiple comparison post-test. Statistical significances between wild-type and lvs1Δ, 
npc2Δ and sxa1Δ strains are represented in the graph above the bars (*p= <0.1; ****p= 
<0.0001). wt – wild-type; lvs1D – Chédiak-Higashi syndrome yeast model: lvs1Δ strain; npc2D – 
Niemann-Pick type C2 yeast model: npc2Δ strain; sxa1D – congenital CLN10 disease yeast 
model: sxa1Δ strain. 
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6.1.2 Septation index 
Wild-type, lvs1Δ, npc2Δ and sxa1Δ strains were grown in normal conditions and 
then imaged to calculate the respective septation index. At least 300 cells were 
counted in three independent experiments. The three LSDs strains (lvs1Δ, 
npc2Δ and sxa1Δ) show significantly more septated cells than the wild-type 
strain, similar to what was observed in the btn1Δ strain (Chapter 3.3.2): 20.11% 
for lvs1Δ, 24.11% for npc2Δ and 18.76% for sxa1Δ, when compared to 12.68% 
for the wild-type strain (Figure 6.1.2). 
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Figure 6.1.2. Septation index of different lysosomal storage 
disorders yeast strains 
Yeast models of lysosomal storage disorders lvs1Δ, npc2Δ and sxa1Δ have a high septation 
index. Images show yeast cells stained with calcofluor delineating cell walls and septa: wild-type, 
lvs1Δ, npc2Δ and sxa1Δ strains. Scale bars - 10µm. Graph shows the mean (±SEM) septation 
index (percentage of septated cells in total number of cells) of different strains from three 
independent experiments. Statistical significances between each strain were determined using 
a one-way ANOVA with a Tukey’s multiple comparison post-test. Statistical significances 
between wild-type and lvs1Δ, npc2Δ and sxa1Δ strains are represented in the graph above the 
bars (*p= <0.1; **p= <0.01 ***p= <0.001). wt – wild-type; lvs1D – Chédiak-Higashi syndrome 
yeast model: lvs1Δ strain; npc2D – Niemann-Pick type C2 yeast model: npc2Δ strain; sxa1D – 
congenital CLN10 disease yeast model: sxa1Δ strain. 
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6.1.3 Cell curving 
Yeast strains were analysed after growth at a high temperature of 37°C for 4 
hours. The high temperature was shown to affect the morphology of the btn1Δ 
strain, represented by an increased number of curved cells when compared to 
the wild-type strain (Chapter 3.3.3). This phenotype was analysed for the LSD 
strains lvs1Δ, npc2Δ and sxa1Δ. At least 300 cells were counted in three 
independent experiments. In contrast to the previously described phenotypes, 
there is no significant difference between the wild-type and the LSD strains, 
where the percentage of curved cells with no lvs1, npc2 and sxa1 genes is not 
significantly different from wild-type cells (11.47%): 15.48%, 14.44% and 
14.26% respectively (Figure 6.1.3). This suggests that this phenotype might be 
specific for the btn1Δ strain. 
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Figure 6.1.3. Cell curving of different lysosomal storage 
disorders yeast strains 
Images show yeast cells stained with calcofluor (delineating cell walls and septa), after growth 
at 37°C for 4 hours: wild-type, lvs1Δ, npc2Δ and sxa1Δ strains. Scale bars – 10µm. Graph 
shows the mean (±SEM) cell curving percentage (percentage of curved cells in total number of 
cells) of different strains from three independent experiments. Statistical significances between 
each strain were determined using a one-way ANOVA with a Tukey’s multiple comparison post-
test. None of the strains (lvs1Δ, npc2Δ and sxa1Δ) showed a percentage of curved cells 
significantly different from the wild-type strain. wt – wild-type; lvs1D – Chédiak-Higashi 
syndrome yeast model: lvs1Δ strain; npc2D – Niemann-Pick type C2 yeast model: npc2Δ strain; 
sxa1D – congenital CLN10 disease yeast model: sxa1Δ strain. 
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6.1.4 Growth at high temperature 
The viability of the three LSD strains after growth at 37°C was calculated 
(percentage of live cells in the total number of cells), and the mean of three 
independent experiments was considered. lvs1Δ, npc2Δ and sxa1Δ show 
similar viability values to the wild-type strain. After 24 hours the viability values 
were the following: 88.3% for the wild-type strain, 76.74%, 79.11% and 85.43% 
for lvs1Δ, npc2Δ and sxa1Δ strains respectively. After 48 hours, the values 
were: 49.74% for the wild-type strain, 53.47% for lvs1Δ, 59.94% for npc2Δ and 
43.04%, for sxa1Δ (Figure 6.1.4). None of the LSD strains show sensitivity to 
growth at high temperature, in contrast to what was seen in the btn1 strain 
(Chapter 4.1.2). 
Additionally, a spot assay experiment in YES plates incubated at 37°C was 
performed for the same LSD strains. As expected, and according to the liquid 
culture viability assay, all colonies were able to grow in the plates, corroborating 
the fact that these strains are not sensitive to growth at 37°C (Figure 6.1.4). 
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Figure 6.1.4. Growth at 37°C of different lysosomal storage 
disorders yeast strains 
Spot assays of different strains grown at 37°C in YES plates. Cells were serially diluted from a 
log-phase culture (1x10
6
 cells/ml) and spotted onto YES plates. Plates were then incubated at 
37°C for 3-4 days to determine growth at high temperature. The graph represents cell viability of 
wt, lvs1Δ, npc2Δ and sxa1Δ strains upon growth in YES medium at a high temperature of 37°C 
over 24 hours. The graph shows the survival curve of different strains at three time points, after 
cultures were shifted from 30 to 37°C: 0, 24 and 48 hours. Data shown is a mean (±SEM) of 
three independent experiments. Viability is the percentage (%) of live cells in total number of 
cells. Statistical significances between each strain were determined using a one-way ANOVA 
with a Tukey’s multiple comparison post-test. None of the strains (lvs1Δ, npc2Δ and sxa1Δ) 
show sensitivity to growth at 37°C. wt – wild-type; lvs1D – Chédiak-Higashi syndrome yeast 
model: lvs1Δ strain; npc2D – Niemann-Pick type C2 yeast model: npc2Δ strain; sxa1D – 
congenital CLN10 disease yeast model: sxa1Δ strain. 
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6.1.5 Sensitivity to cyclosporine A 
The last phenotype to be analysed was the sensitivity to cyclosporine A (CsA) 
at 37°C, which was observed in btn1Δ cells (Chapter 4.1.4). Wild-type and LSD 
strains (lvs1Δ, npc2Δ and sxa1Δ) were grown in liquid medium with 0.1mg/ml of 
cyclosporine A and at 37°C for 24 hours prior to the analysis. At least 300 cells 
were counted in three independent experiments. After measuring the number of 
live and total cells in all strains, it was shown that all three LSDs strains are 
slightly but not significantly sensitive to the presence of CsA. The viability 
percentages for these strains is slightly less (but not significantly) than wild-type 
strain, in the presence of the compound: 63.88% for lvs1Δ, 69.07% for npc2Δ 
and 74.28% for sxa1Δ, when compared to 95.25% for the wild-type (Figure 
6.1.5). Concluding, none of the LSD strains show a significant sensitivity to CsA.  
A similar result was seen when the LSD strains were spotted onto YES plates 
with 0.1mg/ml of cyclosporine A: all colonies were able to grow.  
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Figure 6.1.5. Growth of different lysosomal storage disorders 
yeast strains in the presence of cyclosporine A 
lvs1Δ, npc2Δ and sxa1Δ strains are not sensitive to CsA. Spot assays of different strains in YES 
plates containing 0.1mg/ml of cyclosporine A (CsA) are shown in the upper panel. Cells were 
serially diluted from a log-phase culture (1x10
6
 cells/ml) and spotted onto YES plates containing 
0.1 mM of cyclosporine A (CsA). Plates were then incubated at 37°C for 3-4 days to determine 
growth at high temperature in the presence of CsA. The graph shows the cell viability of wt, 
lvs1Δ, npc2Δ and sxa1Δ strains upon growth in YES medium with CsA (0.1mg/ml) at a high 
temperature of 37°C over 24 hours (after the temperature shift), more specifically the survival 
curve of these different strains at two time points, after cultures were shifted from 30 to 37°C: 0 
and 24 hours. Data shown is a mean (±SEM) of three independent experiments. Viability is the 
percentage of live cells (%) in total number of cells. Statistical significances between each strain 
were determined using a one-way ANOVA with a Tukey’s multiple comparison post-test. None 
of the strains (lvs1Δ, npc2Δ and sxa1Δ) showed sensitivity to CsA. wt – wild-type; lvs1D – 
Chédiak-Higashi syndrome yeast model: lvs1Δ strain; npc2D – Niemann-Pick type C2 yeast 
model: npc2Δ strain; sxa1D – congenital CLN10 disease yeast model: sxa1Δ strain. 
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6.2 Testing compounds in other lysosomal storage disorders 
yeast strains 
In the drug screen performed with the btn1Δ strain, three compounds were 
positively selected and subsequently validated in their ability to rescue several 
phenotypes in btn1Δ cells: alloxazine, E-64 and prochlorperazine dimaleate 
(Results Chapters 2 and 3). Since the yeast strains modelling the lysosomal 
storage disorders (Chédiak Higashi Syndrome, Niemann-Pick disease type C2 
and congenital CLN10 disease) share at least two common phenotypes with the 
strain modelling juvenile CLN3 disease, the same compounds were tested for 
their ability to rescue the two phenotypes in these other strains: enlarged 
vacuoles and high septation index. The three compounds are, in fact, able to 
rescue the enlarged vacuoles phenotype in all strains. Their effect in the other 
phenotype was varied. 
 
6.2.1 Vacuole size 
The mean vacuole size of all the LSD strains (lvs1Δ, npc2Δ and sxa1Δ) after 
treatment with three compounds (alloxazine, E-64 and prochlorperazine 
dimaleate) was measured and compared to the same untreated strains and 
wild-type treated cells. All strains were also treated with DMSO (the carrier of 
the compounds) as a control. At least 500 vacuoles were measured for each 
compound in three independent experiments. 
Cells deleted for lvs1 have the largest vacuoles from all the strains that were 
analysed; the presence of all the three compounds reduced the vacuole size to 
a significantly smaller size, but still larger than in the wild-type strain (0.86 μm). 
After being treated with each compound, the mean vacuole size of the lvs1Δ 
strain, which models the Chédiak Higashi Syndrome, is significantly reduced: 
approximately 1.2 m compared to 1.62 m for lvs1 untreated cells. After 
measuring the vacuoles diameter in the npc2Δ cells, it was shown that all three 
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compounds are able to significantly rescue this phenotype. The vacuoles 
diameter in this strain is significantly reduced in the presence of the 
compounds: 1.03 μm for alloxazine, 0.97 μm for E-64 and prochlorperazine 
dimaleate, when compared to 1.06 μm for the npc2Δ strain. Finally, the 
vacuoles size of sxa1Δ cells was measured after treatment with all three 
compounds. Treated cells show significantly smaller vacuoles than the 
untreated strain (1.08 μm): 1 μm for alloxazine, 0.98 μm for E-64 and 
prochlorperazine dimaleate (Figure 6.2.1).  
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Figure 6.2.1. Effect of different compounds on the vacuole size 
of different lysosomal storage disorders yeast strains 
Alloxazine, E-64 and prochlorperazine dimaleate are able to rescue the enlarged vacuoles in 
yeast models of three lysosomal storage disorders lvs1Δ, npc2Δ and sxa1Δ. Graphs show the 
mean (±SEM) of the vacuoles diameter (in μm) of the lvs1Δ, npc2Δ and sxa1Δ strains treated 
with DMSO (control) and different compounds (10μM): alloxazine, E-64 and prochlorperazine 
dimaleate (proc). The average vacuole diameter of the wild-type strain treated with DMSO is 
represented by a grid line in all graphs (wt). Data was collected in three independent 
experiments. Statistical significances between each treatment were determined using a one-
way ANOVA with a Tukey’s multiple comparison post-test. Statistical significances between 
lvs1Δ, npc2Δ and sxa1Δ treated with DMSO and with the three compounds are represented in 
the graph above the compounds bars (****p= <0.0001). lvs1D – Chédiak-Higashi syndrome 
yeast model: lvs1Δ strain; npc2D – Niemann-Pick type C2 yeast model: npc2Δ strain; sxa1D – 
congenital CLN10 disease yeast model: sxa1Δ strain. All the strains were treated with DMSO. 
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6.2.2 Septation index 
It was previously shown that cells deleted for lvs1, npc2 and sxa1 have a 
significantly higher septation index than wild-type cells, similar to btn1Δ cells  
(section 6.1.2). Therefore, these strains were treated with the compounds 
alloxazine, E-64 and prochlorperazine dimaleate and the number of septated 
cells were counted for each treatment. At least 300 cells were counted for each 
compound in three independent experiments. All the compounds are able to 
rescue the high septation index in the lvs1Δ strain: 11.07%, 8.42% and 5.3% 
with alloxazine, E-64 and prochlorperazine dimaleate respectively, compared to 
20.12% in untreated cells. For the two remaining strains, only alloxazine and 
prochlorperazine dimaleate are able to significantly rescue the index in the 
npc2Δ (16.83% and 11.77% respectively, in comparison with 24.11% in 
untreated cells), and none of the compounds has any effect on the sxa1Δ strain 
(Figure 6.2.2). All strains were also treated with DMSO (the carrier of the 
compounds) as a control. Some of the compounds were able to rescue this 
phenotype to values even lower than the wild-type strain (12.68%).  
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Figure 6.2.2. Effect of different compounds on the septation 
index of other lysosomal storage disorders yeast strains 
Alloxazine, E-64 and prochlorperazine dimaleate are able to rescue the high septation index in 
the lvs1Δ strain. Alloxazine and prochlorperazine dimaleate are able to rescue the high 
septation index in the npc2Δ strain. Graphs shows the mean (±SEM) of septation index in the 
lvs1Δ, npc2Δ and sxa1Δ strains treated with DMSO (control) and different compounds (10μM): 
alloxazine, E-64 and prochlorperazine dimaleate (proc). The average septation index of the 
wild-type strain treated with DMSO is represented by a grid line in all graphs (wt). Septation 
index is the percentage of septated cells in total number of cells. Data was collected in three 
independent experiments. Statistical significances between each treatment were determined 
using a one-way ANOVA with a Tukey’s multiple comparison post-test. Statistical significances 
between lvs1Δ, npc2Δ and sxa1Δ treated with DMSO and with the three compounds are 
represented in the graph above the compounds’ bars (*p= <0.1;***p= <0.001; ****p= <0.0001). 
lvs1D – Chédiak-Higashi syndrome yeast model: lvs1Δ strain; npc2D – Niemann-Pick type C2 
yeast model: npc2Δ strain; sxa1D – congenital CLN10 disease yeast model: sxa1Δ strain. All 
the strains were treated with DMSO. 
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6.3 Summary 
The last part of the project consisted in the study and characterisation of fission 
yeast strains modelling three Lysosomal Storage Disorders: Chédiak Higashi 
Syndrome, Niemann-Pick disease type C2 and congenital CLN10 disease. The 
first step was to characterise the strains in terms of the phenotypes that had 
previously been observed in the yeast model of juvenile CLN3 disease, the 
btn1Δ strain. All three strains presented two of the five phenotypes that were 
explored. These strains have larger vacuoles and more septated cells than the 
wild-type strain. The phenotype of increased vacuole size was particularly 
evidenced in the lvs1Δ strain (model of the Chédiak Higashi Syndrome), whose 
name, given in previous work, reflects this phenotype (unpublished data): large 
vacuoles strain. On the other hand, the septation index phenotype was more 
apparent in the npc2Δ strain (model of the Niemann-Pick disease type C2).  
The drug screen that was carried out with the btn1Δ strain led to the 
identification of three compounds that are able to rescue several phenotypes 
associated with the loss of btn1 in fission yeast, including the enlarged vacuoles 
and the high septation index phenotypes. Therefore, the same compounds, 
alloxazine, E-64 and prochlorperazine dimaleate, were tested in the LSD strains 
(lvs1Δ, npc2Δ and sxa1Δ) to test whether they were also able to rescue the two 
phenotypes observed in these strains. All compounds showed significant 
rescue of the increased vacuoles size in all strains. As for the other phenotype, 
high septation index, all the compounds were able to rescue the phenotype in 
the lvs1Δ strain. In the npc2Δ strain, only alloxazine and prochlorperazine 
dimaleate were able to rescue the large number of septated cells. Finally, none 
of the compounds were able to rescue this phenotype in the sxa1Δ strain. 
Taken together these results show that, although some differences in terms of 
phenotypes were observed between the four LSD strains (btn1Δ, lvs1Δ, npc2Δ 
and sxa1Δ), they might be involved in common pathways, since similar effects 
were seen in the absence of these proteins. 
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7 Discussion 
 
The initial findings from this study show that distinct integrated mutations in the 
btn1 gene affect Btn1p function differently and, as a consequence, have varying 
effects on cell phenotypes. Varying levels of Btn1p expression can be related to 
the different phenotypes, since overexpression of btn1 leads to an over-
compensation of the tested phenotypes, when compared to wild-type cells. 
Furthermore, mutations in Btn1p seem to affect its expression levels (Chapter 
3.2.2). The endogenously expressed btn1 containing a deletion comparable to 
that of the common 1-kb intragenic deletion, present in the majority of juvenile 
NCL patients (Consortium 1995), was shown to retain partial function and 
prevent the appearance of some btn1Δ phenotypes almost as effectively as the 
full-length protein (Results Chapters 1 and 2). This observation corroborates 
previous studies where the ectopically expressed mutant Btn1p presented as a 
partially functional protein (Kitzmuller et al. 2008; Haines et al. 2009). The 
endogenous mutant protein expressing the p.E240K mutation prevented the 
appearance of all phenotypes that were tested in the first part of the project and 
didn’t seem to significantly change the Btn1p expression levels (Results 
Chapter 1), revealing that it does not affect Btn1p function to the same extent 
as the 1-kb deletion. These results are consistent with the fact that this mutation 
underlies the mildest form of juvenile NCL (Aberg et al. 2009). Finally, 
endogenous expression of the mutant protein containing the p.G136A mutation 
resembled complete deletion of btn1, with more phenotypes observed than the 
1-kb deletion mutant, and a decrease in the protein expression levels (Results 
Chapters 1 and 2). This supports the idea that p.G136A is a null mutation as 
previously suggested (Haines et al. 2009).  
Current therapeutic strategies for the types of neuronal ceroid lipofuscinosis 
caused by enzyme defects are not applicable to juvenile CLN3 disease. New 
tools or therapeutic strategies are urgently required for treatment of this 
disease. In this project the fission yeast Schizosaccharomyces pombe was 
used in an attempt to identify novel lead compounds suitable for the 
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development of potential therapeutic strategies for juvenile CLN3 disease. 
Many genes and cellular pathways are conserved between fission yeast and 
humans, and therefore compounds that revert JNCL-associated phenotypes in 
the yeast model may be relevant for patients. At present, readily detectable 
phenotypes suitable for high-throughput screening approaches have not been 
identified in mammalian cells. On the other hand, different marker phenotypes 
have been characterised in fission yeast. S. pombe is a genetically tractable 
model organism, already well established in juvenile NCL research that has less 
than a fifth of the number of human genes, and is therefore an ideal organism 
for performing a screen for potential therapeutic drugs for juvenile CLN3 
disease, even though some mammalian cellular pathways may not be present 
in this simpler organism. Moreover, an advantage of phenotypic screening is 
that the exact function of the protein (in this case CLN3 or Btn1p), or the 
molecular basis of the phenotype selected for the screen, does not need to be 
known in order to perform it. In this case, the drug will lead to a cellular effect, 
which cannot be guaranteed in a target-based screen. Results obtained in this 
study are complementary but potentially more far-reaching than currently 
available candidate approaches in mammalian cells or other model systems. 
Additionally, the compounds identified in the yeast drug screen were also tested 
in patient fibroblasts and a zebrafish model, and gave good results. This shows 
that it is possible to translate results obtained in S. pombe to human cells, 
relevant to juvenile CLN3 disease. This strategy could be adopted more widely 
in research to find new treatments for inherited diseases. 
The first step towards the development of the drug screen was to identify a 
robust and striking phenotype that was easily identified when rescued and 
significantly different between strains with and without btn1. btn1Δ cells show a 
growth sensitivity at 37°C in the presence of cyclosporine A, a calcineurin 
inhibitor (Results Chapter 2). Therefore, the viability of btn1Δ cells (compared to 
wild-type cells), after growing in these conditions, was selected as the marker 
phenotype, basis for the screen. This is an ideal phenotype for this purpose 
since it assesses something as basic as survival/death of the strains, where 
cells with no btn1 cannot survive as well as wild-type cells. This phenotype was 
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not suitable for mutation-specific screening, since strains with btn1 expressing 
two mutations (1-kb deletion and p.E240K missense mutation) were not 
sensitive to cyclosporine A. However, compounds that rescue phenotypes 
associated with the complete deletion of the gene are likely to be able to correct 
phenotypes in strains with more mild mutations, as seen with the cell curving 
phenotype. Nevertheless, it would be desirable to find other mutation-specific 
phenotypes suitable for a drug screen so that further compounds could be 
identified.  
The developed high-throughput screen was performed using the LoPac 
collection of 1280 FDA-approved compounds, and the six strongest hits were 
selected for further validation experiments. These compounds were manually 
retested in the same conditions as the automated drug screen in at least three 
independent experiments (Results Chapter 3). Three compounds that were able 
to consistently rescue the sensitivity of btn1Δ cells to cyclosporine A, without 
significantly affecting the viability of wild-type cells, were selected for further 
validation experiments: alloxazine, E-64 and prochlorperazine dimaleate. 
The final three compounds were then tested for their ability to rescue four other 
btn1Δ specific phenotypes: enlarged vacuoles, increased septation index, 
elevated number of curved cells and sensitivity to growth at high temperature 
(Results Chapter 3). All compounds were able to rescue the majority of the 
tested phenotypes. Finally, they were also tested in juvenile NCL patient 
fibroblasts and in a zebrafish disease model to verify their ability to rescue other 
phenotypes associated with mutated CLN3. All compounds were able to rescue 
at least one phenotype in zebrafish, and E-64 and prochlorperazine dimaleate 
showed a complete rescue of Golgi compactness in fibroblasts. Altogether 
these preliminary results are very encouraging, with respect to a potential 
juvenile CLN3 disease therapy. However, much future work is needed. First, to 
further clarify the mechanism of action of the compounds in fission yeast. 
Compounds can then be tested in higher organisms (such as mice) in order to 
determine their efficacy for therapeutic use. Toxicity should not be an issue for 
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future potential use in patients since all the compounds identified in this study 
are FDA-approved, and therefore known to be safe. 
The last part of this project was the study of three different fission yeast strains 
that model other lysosomal storage disorders (LSDs): Chédiak Higashi 
Syndrome, Niemann-Pick disease type C2 and congenital CLN10 disease. 
These strains were characterised particularly in terms of several phenotypes 
that are associated with the btn1Δ strain (Results Chapter 4). All three strains 
presented two of the five phenotypes that were explored: enlarged vacuoles 
and increased septation index, supporting a previously reported impairment of 
the lysosomal/vacuolar function in these strains (Faigle et al. 1998; Wang et al. 
2010; Kohan et al. 2011). After the characterisation, compounds that were 
efficacious in the btn1Δ strain were tested for their ability to rescue the newly 
described phenotypes associated with the three LSD strains. Notably, all three 
compounds showed significant rescue of the increased vacuole size in all 
strains. On the other hand, the effect of the compounds on the septation index 
phenotype was different among the strains. To summarise, the three tested 
compounds affected the function of Btn1p, Lvs1p, Npc2p and Sxa1p proteins 
differently. However, there were some overlapping phenotypes between the 
four strains, suggesting that some pathological mechanisms are common 
between them, and this should be further explored in the future in regards to a 
common therapeutic strategy for these and probably other LSDs. 
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7.1 CLN3 mutations affect the protein function in different 
manners 
It has been shown in this study and previous work in the S. pombe model of 
juvenile CLN3 disease (Haines et al. 2009) that some mutations in the btn1 
gene have different effects on the protein function. Whilst all the previous work 
done in S. pombe was based on the ectopic expression of mutated and non-
mutated Btn1p, this study investigated strains with endogenously expressed 
mutant protein, where the mutated versions of btn1 were integrated in the yeast 
genome under the control of the btn1 promoter. Three different strains 
expressing three different btn1 mutations were created: the 1-kb deletion 
equivalent to the one present in the majority of juvenile NCL patients 
(Consortium 1995); the p.E240K missense mutation equivalent to the one that 
underlies the mildest form of the juvenile CLN3 disease (Aberg et al. 2009) and 
the p.G136A mutation, reported to produce a nonfunctional protein which 
resembles the complete deletion of Btn1p in terms of phenotypes (Haines et al. 
2009). The 1-kb deletion and the p.E240K mutation are not complete null 
mutations, since strains with endogenous expression of these mutant proteins 
show less severe phenotypes compared to the btn1Δ strain, where btn1 is 
absent, and are more similar to the wild-type strain, even in terms of protein 
expression levels. On the other hand, cells expressing btn1 with the p.G136A 
mutation display all the phenotypes that are also observed in the btn1Δ cells 
and is sufficient to affect the levels of expression of Btn1p, suggesting that this 
is truly a null mutation. These observations also suggest that there are regions 
in the Btn1p protein that are more important for its function when compared to 
other regions.  
 
Discussion 
 
 161 
7.1.1 Level of expression of Btn1p is relevant to its function 
The results obtained in this study showed that the levels of expression of btn1 
influence the protein function the overall cell biology. When overexpressed, 
under the control of a full strength nmt1 p3 promoter, some phenotypes 
associated with the loss of btn1 are slightly different from the wild-type strain. 
For instance, the average diameter of vacuoles is smaller, and there is a slight 
reduction in the number of curved cells at 37°C when compared to the wild-type 
strain. Furthermore, there is, in fact, a significant difference between the wild-
type strain and the one under the control of the nmt1 p3 promoter in regards to 
the number of septated cells (Results Chapter 1). Furthermore, when 
expressed under the control of nmt1 p41 promoter (weaker than the p3 
promoter), the vacuole size and the number of septated and curved cells at 
37°C are similar to the wild-type strain. Similar effects were seen in previous 
studies, where both the overexpression and absence of Btn1p affected the 
Golgi compartments and trafficking (Codlin & Mole 2009) and increasing levels 
of Btn1p correlated with decreasing vacuolar size (Gachet et al. 2005). The 
expression of Btn1p appears to be slightly affected when tagged at its N-
terminal with GFP, under the control of its native promoter. GFP is a large tag 
and it is not unexpected for it to slightly affect the function of any tagged protein. 
The yeast strain with GFP-tagged Btn1p expressed from the btn1 native 
promoter showed slight but not significant differences in the phenotypes when 
compared to the wild-type strain: larger vacuoles, higher septation index but 
less curved cells. Thus, it is important to be aware of this, and to use both 
tagged and untagged forms when studying this protein. 
The integrated mutant strains explored in this study also seem to affect the 
Btn1p expression levels. The strain with the p.G136A mutation is the one that 
has the largest effect, decreasing these levels, whereas the p.E240K mutation 
shows similar levels to wild-type Btn1p (Chapter 3.2.1). This is expected since 
in human patients, the p.Glu295Lys mutation in CLN3 underlies the mildest 
form of the disease, and the yeast mutant strain has less phenotypes than the 
complete deletion of btn1. Moreover, the p.G136A mutation shows all the same 
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phenotypes than btn1Δ, and is predicted to be a null mutation. In summary, 
different mutations cause differences in the levels of GFP-tagged protein 
expression. This conclusion was based on a qualitative observation of the GFP 
signal produced by these mutant strains. Therefore, to confirm and quantify the 
differences in expression levels, a Western Blot assay must be performed. 
Together, these results support the hypothesis that the level of Btn1p 
expression is important for protein function, and that it is tightly regulated. This 
is in accordance with previous results that showed that the wild-type 
endogenous levels of expression of Btn1p are low (Codlin & Mole 2009).  
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7.1.2 Mapping functional domains of Btn1p 
In order to map functional domains of Btn1p, the position of different mutations 
in the predicted topology of the protein and the effect of these mutations were 
analysed.  
Two different mutations that share loss of a common amino acid (E240), 1kbΔ 
(102fsX5) and p.E240K, were both found to rescue the vacuole size, the 
septation index, the growth at high temperature, and growth in the presence of 
cyclosporine A defects. Furthermore, the 1kbΔ mutant Btn1p was also shown to 
be able to marginally improve the vacuole pH, and the p.E240K mutation 
significantly reduced the cell curving percentage after growth at 37°C. 
Altogether, these results demonstrate that the first 102 amino acids of Btn1p 
(equivalent to the first 153 amino acids in human CLN3) are sufficient to be 
functional in several pathways (maintenance of lysosomal size and pH, control 
of the cytokinetic process, resistance to cyclosporine A and to high 
temperature). This region of the protein includes the cytoplasmic N-terminal and 
two or three predicted transmembrane domains, depending on the topology that 
is considered (Nugent et al. 2008; Ratajczak et al. 2014). This N-terminal region 
is not conserved, contrary to the transmembrane regions, which suggests that 
the function of Btn1p (and CLN3) is exerted from within the membrane, or from 
the lumenal loops of the protein. The importance of the lumenal regions in the 
protein function has previously been reported (Haines et al. 2009). Similarly, the 
G to A point mutation of Btn1p affecting amino acid 136 (equivalent to 187 in 
CLN3), is also located either in the lumen or in the fourth transmembrane 
domain (according to the Nugent or Ratajczak topology, respectively), has great 
effect on the protein function, acting as a loss-of-function mutation. This finding 
supports the idea that this lumenal and/or transmembrane region of Btn1p (and 
CLN3) is crucial for its function in the cell. By extrapolation, the C-terminal 
region of CLN3 is not required at least for the functions mentioned above: 
lysosomal homeostasis, cytokinesis, resistance to high temperature and to 
cyclosporine A.  
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In the case of the curving defect, the region of the protein after the first 102 
amino acids (absent in the 1-kb-deleted protein), except when the amino acid 
E240 in the fifth transmembrane domain is altered, is sufficient to rescue this 
defect (Figure 1.1.1). This suggests that the region of the protein corresponding 
to the last four transmembrane domains and the amphipathic helix is important 
to regulate the function of Btn1p related to cytoskeleton and cell wall 
morphology. 
The 1-kb-deleted protein has been localised to the ER, both in yeast and 
human fibroblasts (Kitzmuller et al. 2008; Haines et al. 2009), which suggests 
that the truncated protein exerts some function from the ER or other early 
compartment, and not only from the lysosomes/vacuoles. However, any 
Btn1p/CLN3 functions associated with the cell cytoskeleton and cell wall 
composition may be exerted from a later compartment, being impaired when 
the protein is retained in the ER. The effect of mutated Btn1p/CLN3 on the 
lysosomes, exerted from its location in the ER, is similar to that observed for 
other NCL proteins, CLN6 and CLN8, which are both located in the ER and 
affect lysosomes (Mole et al. 2004; Vantaggiato et al. 2009). 
Whilst many functions arise from complete loss of btn1 function, not all the 
resultant phenotypes are affected by mutations in btn1 equivalent to those 
associated with juvenile CLN3 disease. Thus, therapy need to target only those 
pathways disrupted by the 1-kb deletion, present in the majority of patients, not 
all those affected by complete loss of CLN3 function. For instance, and since 
the 1-kb-deleted Btn1 protein seems to rescue all but the cell curving phenotype, 
therapeutic approaches that would target any pathway associated with the cell 
wall morphology or cytoskeleton in yeast, would be ideal. These pathways 
could then be extrapolated to mammalian cell biology. However, it is worth 
bearing in mind that 1-kb mutant mammalian cells have lysosomal defects 
(Sleat et al. 1998; Holopainen et al. 2001; Kitzmuller et al. 2008) and other 
defects that are less apparent in the yeast model but would need to be rescued 
in therapy. Focusing on one phenotype is important for the initial steps and 
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identification of potential therapeutic compounds, but it is crucial to further 
validate therapeutic strategies in a range of mutant backgrounds. 
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7.1.3 New insights into CLN3 function 
CLN3 has been reported to be localised in different regions in mammalian cells. 
Btn1p has been localised to the vacuoles and the Golgi complex (Gachet et al. 
2005; Codlin & Mole 2009). In this study, a similar observation was made: 
endogenously expressed GFP-Btn1p co-localises with the vacuole marker FM4-
64, but there is also some GFP signal elsewhere, which is likely to correspond 
with the Golgi (Chapter 3.1.2). This was the first study where the localisation of 
endogenously expressed Btn1p was analysed, since all previous results were 
performed with ectopically and overexpressed Btn1p.  
Furthermore, btn1 mutations affect the localisation of the protein. As previously 
reported, the 1-kb deletion changes the localisation of Btn1p to the ER (Haines 
et al. 2009), and mice studies have shown that mutant CLN3 cannot exit the ER 
due to misfolding or missing localisation signals (Järvelä et al. 1999). There are 
lysosomal targeting signals located at the C-terminal of the protein (Haines et al. 
2009) that are missing in the truncated Btn1p, which may also contribute to 
preventing exit of this mutant protein from the ER. A similar observation was 
made in cells with the mutant Btn1p containing the p.G136A mutation (Gachet 
et al. 2005). The amino acid Gly136 is thought to be localised either in a 
lumenal or transmembrane region of protein, and is thought to be essential for 
its function. Therefore when mutated, this amino acid might alter the correct 
conformation of Btn1p and lead to its retention in the ER, and possibly 
degradation. Finally, cells expressing Btn1p with the p.E240K mutation were 
reported to be localised in the vacuoles, but also present in pre-vacuolar 
compartments (Haines et al. 2009). Possibly, the region of the protein affected 
by this mutation (amino acid 240 in the fifth transmembrane domain) may affect 
the trafficking of the protein by affecting its conformational state, but not to the 
same extent as the two other mutations. 
It is known that CLN3 and Btn1p have an important role in lysosomal 
homeostasis. The lysosomal/vacuolar pH is less acidic in patient fibroblasts and 
btn1Δ cells (Holopainen et al. 2001; Gachet et al. 2005) (Chapter 4.1.3) and 
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these organelles are larger in CLN3-depleted HeLa cells and in btn1Δ cells 
(Gachet et al. 2005; Kitzmuller et al. 2008). A functional role of CLN3/Btn1p in 
lysosome/vacuole homeostasis was proposed to be exerted from a prevacuolar 
compartment in yeast cells, since the vacuole size in the btn1Δ/ypt7Δ double 
mutant was even bigger than in ypt7Δ mutant alone, where Btn1p is unable to 
traffic to the vacuoles (Gachet et al. 2005). This is in accordance with the 
observation that CLN3/Btn1p is located in the Golgi and other prevacuolar 
compartments. Alterations in vacuole pH, and consequently in the activity of the 
v-ATPase, have been shown to affect the composition of the cell wall in fission 
yeast, similar to that observed in btn1Δ cells (Codlin et al. 2008a). This 
observation, together with the vast array of other phenotypes observed in cells 
with defective CLN3/Btn1p, suggest that a defective activity of the v-ATPase 
may have an effect on the trafficking of many other proteins in the endocytic 
pathway, and possibly other pathways. Furthermore, the v-ATPase plays an 
important role in the transport of neurotransmitters into vesicles in the brain 
(Cousin & Nicholls 1997), and therefore when v-ATPAse function is affected 
there could be a great impact on neuronal transmission potentially leading to 
neurodegeneration, the hallmark of juvenile CLN3 disease.  
Similar to the observations made in this study, as well as in previous works, 
where btn1Δ cells have an abnormally curved morphology suggesting defects in 
microtubules or their related molecules (Haines et al. 2009) (Chapter 3.3.3), the 
CLN3 protein function has been associated with the organisation and regulation 
of cytoskeleton (Uusi-Rauva et al. 2008). This cytoskeletal disorganisation may 
affect intracellular transport, once again causing a panoply of cellular defects. 
For example, it is possible that trafficking of different transporters (like the v-
ATPase) through actin is impaired when CLN3 is defective. In yeast, the correct 
polarization of actin is dependent on the endocytic process (Smythe & 
Ayscough 2006), suggesting that the actin depolarisation of btn1Δ cells (Codlin 
et al. 2008b) is intimately linked with defects in membrane trafficking. It is also 
known that the activity of v-ATPase is linked to the actin cytoskeleton (Vitavska 
et al. 2003), which can explain the presence of phenotypes affecting both 
pathways in CLN3/Btn1p-deficient cells. Furthermore, the dynactin complex, 
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activator of microtubule motor protein dynein, has been reported to be 
downregulated in a Cln3 knockout mouse (Luiro et al. 2006) validating the 
hypothesis of a link between CLN3 and microtubule transport.  
The defect in cytokinesis of btn1Δ cells is independent of the defect in v-
ATPase activity, since it is not rescued by the growth of cells in acidic media 
(Codlin et al. 2008a). This defect may be due to a defective exocyst pathway, 
which is known to regulate the cell separation at the septum during the division 
process (Wang et al. 2002). However, the exact cause of this phenotype 
remains to be defined. More interestingly, it is known that correct localisation of 
exocyst proteins in the medial area of dividing cells is actin-dependent. This 
establishes a link between cytokinesis and the cytoskeleton phenotypes both 
observed in btn1Δ cells. Moreover, the fact that both mutant proteins containing 
either the 1-kb deletion or the p.E240K mutation are able to rescue the vacuole 
size defect, the high septation index and the growth at high temperature 
suggests a possible link between these three phenotypes. In a previous study, 
all mutants that were able to rescue the enlarged vacuoles in btn1Δ cells 
equally rescued the number of septated cells, reinforcing the idea that these 
two pathways are linked in some way (Haines et al. 2009). 
As discussed in the Introduction Chapter, Btn1p (and by inference, CLN3) is 
thought to be exerting its function in the Golgi apparatus compartments, 
affecting multiple downstream pathways. Therefore, when this function is 
disturbed, it eventually leads to defects at the vacuole level, as well as in the 
processes of cell growth, division, morphology and stress response. It is likely 
that Btn1p/CLN3 is required for the regulation of membrane trafficking to the 
lysosomes, the sorting and activity of different transporters and channels and 
the endocytic process. In fact, the involvement of CLN3/Btn1p in post-Golgi 
sorting and trafficking of proteins and in endocytosis has previously been 
reported and is detailed in the Introduction Chapter (Luiro et al. 2004; Metcalf et 
al. 2008; Codlin & Mole 2009). 
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7.1.3.1  CLN3: a potential channel? 
The fact that CLN3 is highly conserved across several species suggests that it 
plays a pivotal cellular role. It is likely that its complete loss of function may 
underlie a more severe disease than juvenile CLN3 disease, where partial 
function of the protein remains (see above in this chapter). The yeast 
orthologue of CLN3, btn1, is essential for correct cellular growth and division, 
especially at high temperature, proposing an essential role in this organism. 
As mentioned above, Btn1p is important for vacuole acidification. Although it is 
possible that this effect is indirect via the correct sorting of v-ATPase, it is also 
possible that Btn1p is acidifying the vacuoles directly. Btn1p may be a channel 
or ion transporter, and there are several lines of evidence that support this 
hypothesis.  First, CLN3 and Btn1p are known to be involved in the transport of 
arginine into the vacuole and in cerebellar cells (Kim et al. 2003; Ramirez-
Montealegre & Pearce 2005; Chan et al. 2009). Second, phenotypes observed 
in a knockout mouse model of juvenile NCL resemble those seen in a chloride 
channel CLC-3-deficient mouse (Mitchison et al. 1999). Third, the sequence of 
CLN3 is distant but significantly similar to the equilibrative nucleoside 
transporter hENT1 (Baldwin et al. 2004), and according to Pfam (a Wellcome 
Trust Sanger Institute database of protein families, http://pfam.xfam.org/) CLN3 
is a member of the major facilitator superfamily (MFS), a membrane transporter 
superfamily (Pao et al. 1998). Finally, it is also known that CLN3 regulates the 
intracellular levels of cytosolic free calcium (Ca2+) in SH-SY5Y cells (Chang et 
al. 2007) and a calcium channel antagonist, amlodipine, was reported as being 
able to reverse the elevated intracellular calcium levels seen in rat cortical 
neurons treated with CLN3 siRNA (Warnock et al. 2013). CLN3 may be a 
lysosomal calcium channel. These type of channels are responsible for 
maintaining the lysosomal calcium content at a specific concentration (Lemons 
& Thoene 1991) and therefore, when defective, lead to alterations of calcium 
levels in these organelles and consequently in the cytosol. Furthermore, 
dysregulated calcium levels in lysosomes greatly affects the endocytic transport 
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(Kiselyov et al. 2010), which could explain the fact that several cellular proteins 
are affected in the absence of CLN3/Btn1p.  
Changes in intracellular levels of calcium and dysfunction of lysosomal calcium 
channels have a great effect on crucial processes in nerve cells, and calcium  
overload eventually leads to cell death, neurodegeneration (Siesjo et al. 1986; 
Heizmann & Braun 1992; Kiselyov et al. 2010), a common feature of lysosomal 
storage disorders (Jeyakumar et al. 2005; Kiselyov et al. 2010; Lloyd-Evans & 
Platt 2011). Calcium homeostasis is also linked to mitochondrial function 
(Duchen et al. 2008) and mitochondrial defects have been reported in CLN3 
disease (Fossale et al. 2004; Luiro et al. 2006; Lojewski et al. 2014), suggesting 
that these defects may be leading to dysregulation of calcium levels in these 
diseases.  
Yeast vacuoles are the major site of intracellular calcium storage (Denis & Cyert 
2002). The regulation of intracellular calcium levels in yeast is crucial for several 
cellular functions to be carried out appropriately: cytokinesis, cytoskeletal 
organization and cell wall integrity. All of these pathways are regulated by 
calcium signalling pathways, which in turn are mediated by calcium channels, 
pumps and transporters (Cortes et al. 2004). These channels and transporters 
are responsible for the uptake and release of calcium into or out of the 
cell/organelles via the respective membranes. Btn1p may be acting as a 
vacuolar channel in yeast regulating calcium levels in these organelles and 
cells. 
 
7.1.3.2  Btn1p and TOR signalling pathway 
Btn1p is also linked to the target of rapamycin (TOR) signalling pathway and 
other connected pathways in yeast. In response to glucose limitation, fission 
yeast appropriately represses TORC1, and activates TORC2 to maintain 
viability until glucose becomes available (Ikai et al. 2011). The TORC2 pathway 
is also involved in a correct response to exogenous stress, whereas TORC1 
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represses this stress response (Ikeda et al. 2008). Work performed by Dr 
Michael Bond (unpublished data) showed that btn1Δ cells are unable to 
correctly respond to limited nutrient conditions and high temperature (due to a 
reduced signalling in the TORC2 pathway) which could be rescued by reducing 
TORC1 or increasing TORC2 function. This inability to respond to stress is 
consistent with the phenotypes seen at 37°C, such as reduced viability, cell 
curving and sensitivity to cyclosporine A. Furthermore, a role for the mammalian 
TOR (mTOR) pathway in regulating microtubule-dependent protein transport 
was identified in rat fibroblasts (Jiang & Yeung 2006) suggesting that there is a 
link between this signalling pathway, the cytoskeleton organization (known to be 
disrupted in CLN3- and btn1-depleted cells) and the defective transport of 
certain proteins.  
There are a lot of similarities between the processes regulated by Btn1p and a 
small GTPase Ypt3p, the yeast orthologue of the mammalian Rab11, proposing 
that they might share a similar function. Ypt3p is localised in the Golgi and 
endosomes, similarly to Btn1p (He et al. 2006); and cells with mutated ypt3 
show similar phenotypes to btn1Δ: defects in the cell wall composition, 
cytokinesis and vacuolar fusion processes, and aberrant Golgi compartments 
(Cheng et al. 2002). Furthermore, Gad8p, a kinase lying downstream of TORC2 
in the TORC2 signalling cascade, is affected in both Ypt3p and Btn1p mutant 
cells (Tatebe et al. 2010) (Mike Bond, unpublished data). Ypt3p has been 
reported to interact with calcineurin, a Ca2+-dependent phosphatase that 
negatively regulates and is regulated by TORC2 (Cheng et al. 2002). Ypt3p 
mutants require calcineurin activity for vegetative growth and double mutants 
(Ypt3p and calcineurin) are synthetically lethal, suggesting that these proteins 
have overlapping functions. Since btn1Δ cells are sensitive to growth in the 
presence of cyclosporine A, an inhibitor of calcineurin, it is likely that Btn1p 
function is linked to the calcineurin pathway. For instance, Btn1p may have an 
overlapping function with calcineurin, similarly to Ypt3p. Furthermore, Ypt3p 
was reported to be involved in the transport of proteins from the Golgi 
compartments and in the exocytic pathway, and calcineurin was proposed to 
regulate these events (Cheng et al. 2002). If this is the case, the role in protein 
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transport may be the overlapping function between Btn1p and calcineurin. 
Future work has to be done in order to further elucidate the interplay between 
Btn1p and calcineurin, and also to better understand the reported similarities 
between Btn1p and Ypt3p. 
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7.2 Using a drug screen approach in a yeast model to develop 
therapy for juvenile CLN3 disease 
The choice of using a S. pombe model of juvenile CLN3 disease to perform a 
drug screen is due to the fact that fission yeast is easy to genetically manipulate, 
grows rapidly, and has a high degree of conservation of genes and molecular 
pathways with mammalian cells. S. pombe is a good model for the study of 
lysosomal storage disorders since it contains numerous vacuoles, the yeast 
equivalent to lysosomes (Bone et al. 1998). Furthermore, yeast has been 
established as a good model for the study of neurodegeneration (Khurana & 
Lindquist 2010), and for drug discovery (Howitz et al. 2003; Hoon et al. 2008; 
Su et al. 2010). These drugs act on targets that are highly conserved and are 
able to rescue disease pathology not only in yeast but also in neurons (Su et al. 
2010), demonstrating that drugs identified in yeast can act on highly conserved 
biological processes and be translated into higher organisms. In fact, there are 
reports that show a translation from concept to drugs in the clinic in less than 3 
years (Howitz et al. 2003). There are disadvantages in using S. pombe as a 
model for high-throughput drug screening that could be used for human disease 
therapies: the possibility of a drug not being permeable to the yeast cell wall or 
not being soluble in the yeast growing medium giving rise to false negative 
results, and the obvious fact that several cellular pathways existent in human 
are not conserved in fission yeast, and therefore drugs acting in these pathways 
cannot be detected in this organism. However, S. pombe has been previously 
used in high-throughput screening in a successful manner (Yashiroda et al. 
2010; Demirbas et al. 2013). Fission yeast can, in fact, be powerful tools for fast 
drug discovery in neurodegenerative diseases, such as juvenile CLN3 disease. 
The efficacy of screen hit compounds can be quickly verified in other model 
organisms, such as zebrafish or mammalian cells (as it was done in this study), 
a crucial step before the preclinical trials are carried out in mouse models, for 
example.  
Currently, there are no readily detectable phenotypes suitable for high-
throughput screening for NCL diseases in mammalian cells. On the other hand, 
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multiple marker phenotypes have been characterised in fission yeast, which 
also indicates that Btn1p (just like CLN3) has a complex function that affects 
different pathways in the cell. It is important to gain more information about the 
pathways where Btn1p/CLN3 is involved, to further understand the molecular 
mechanisms of juvenile CLN3 disease. This type of information can be inferred 
from the results obtained in the drug screen, if one considers the typical targets 
of the compounds that were identified. 
The phenotype chosen as the basis for the drug screen was the growth at 37°C 
in the presence of cyclosporine A, since there is a very significant difference in 
the viabilities of wild-type and btn1Δ cells when grown in these conditions. The 
viability can be easily measured by the presence of propidium iodide inside the 
dead cells. 1280 FDA-approved compounds were tested for their ability to 
rescue the percentage of dead btn1Δ cells to levels similar to wild-type cells. 
Three compounds that strongly rescued the viability of the btn1Δ strain were 
first validated and then selected for further experiments to assess their ability of 
rescuing other phenotypes associated with the loss of btn1 or CLN3. All three 
compounds were able to rescue other phenotypes in btn1Δ cells, and some of 
them in juvenile NCL patient fibroblasts and in a zebrafish disease model. Each 
compound will be discussed in the sections below, as well as the possible role 
of calcineurin and the TOR pathway in juvenile CLN3 disease.  
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7.2.1 Calcineurin and TOR signalling pathway 
Calcineurin is a serine/threonine phosphatase that is regulated by the 
Ca2+/calmodulin-dependent signalling pathway (Klee et al. 1979). In yeast, 
calcineurin stimulates cell survival upon exogenous stress (Cyert 2003). In 
response to stress, calcineurin dephosphorylates transcription factors (such as 
Crz1p) that then activates target genes involved in pathways such as vesicular 
transport, ion homeostasis and cell wall maintenance. Calcineurin is also 
responsible for the actin cytoskeleton depolarization and delay in the cell cycle 
upon stress (Mizunuma et al. 1998; Shitamukai et al. 2004). Calcineurin-null 
yeast cells show a delay in cytokinesis (Yoshida et al. 1994). 
In S. cerevisiae, calcineurin negatively regulates TORC2 signalling and TORC2 
negatively regulates calcineurin via the Slm proteins (Mulet et al. 2006). There 
are some differences in S. pombe: the growth of cells lacking tor1, the Tor 
kinase in TORC2 is strongly inhibited by cyclosporine A, the inhibitor of 
calcineurin (Kawai et al. 2001). Furthermore, in budding yeast calcineurin-null 
cells are resistant to the presence of calcium and grow better in these 
conditions, whereas fission yeast cells null for calcineurin are highly sensitive to 
calcium (Hirayama et al. 2003). Therefore, the function of calcineurin is likely to 
be different in the two types of yeast, and probably the function in fission yeast 
is more equivalent to mammalian cells. Evidence from this study supports this 
idea, since btn1Δ calcineurin-null cells are not able to survive, and as 
mentioned above, it is known that in btn1Δ cells TORC2 activity is affected and 
that CLN3-deficient cells have increased levels of intracellular calcium. 
According to results presented in this work and elsewhere, it is proposed that 
Btn1p/CLN3 and calcineurin have an overlapping function. Several lines of 
evidence support this hypothesis: 1) as mentioned above (1.1.3.2) vegetative 
growth of Ypt3p mutant cells is calcineurin-dependent, Ypt3p was proposed as 
having overlapping function with calcineurin and Ypt3p mutant cells show 
several common phenotypes to btn1Δ cells; 2) both calcineurin and CLN3 have 
been reported to regulate intracellular calcium levels (Klee et al. 1979; Chang et 
al. 2007) and calcineurin-null cells are sensitive to high calcium levels 
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(Hirayama et al. 2003), which are known to be present in SH-SY5Y cells treated 
with CLN3 siRNA (An Haack et al. 2011); 3) Cni1p, a calcineurin-binding 
protein, promotes growth of fission yeast cells at high pH (Cyert 2003), and 
defects in btn1Δ cells are known to be rescued by growth in acidic media, 
suggesting that when both Btn1p and calcineurin are defective, yeast cells are 
unable to survive; 4) a yeast orthologue of a mammalian subunit of the clathrin-
associated adaptor protein complex, Apm1p, and calcineurin double mutant 
cells are synthetically lethal, and apm1Δ cells show similar phenotypes to btn1Δ 
cells: temperature sensitivity, tacrolimus (a calcineurin inhibitor) sensitivity, 
cytokinesis and vacuole fusion defects and larger Golgi stacks, all of these 
accentuated by a temperature up-shift (Kita et al. 2004). Apm1p is also 
localised to the Golgi and endosomes, and its role was proposed to be 
associated with a function in these organelles that will affect several cellular 
processes, analogously to what is suggested for Btn1p; 5) calcineurin may be 
associated with the release and action of neurotransmitters due to the fact that 
it regulates the levels of calcium in the nervous system and this are known to 
play a crucial role in neuronal transmitters at the synaptic terminals (Klee et al. 
1979). Similarly, v-ATPase, known to be defective in CLN3-deficient cells, was 
reported to play a role in neurotransmitters transport in the brain (Cousin & 
Nicholls 1997). Therefore, when btn1 and calcineurin are defective, this could 
affect neuronal transmission and potentially lead to neurodegeneration.  
After the realization that Btn1p function was related to the TORC2 pathway, and 
in order to identify a robust phenotype for the screen, btn1∆ cells were tested 
for their ability to withstand a pharmacological treatment that other TORC2 
mutants have been shown to be sensitive to: the presence of cyclosporine A. 
The CsA sensitivity of btn1∆ cells was only present when cells were grown at 
the non-permissive temperature of 37°C which may suggest CsA acts by 
exacerbating the underlying temperature sensitivity of these strains (or vice 
versa). 
 
Discussion 
 
 177 
 7.2.2 Alloxazine 
Alloxazines are degradation products of flavocoenzymes, proteins containing 
riboflavin, a crucial constituent of all living cells and organisms (Ferreira et al. 
2014). Alloxazine is an antagonist of the adenosine A2b receptor (Brackett & 
Daly 1994) and was also reported as being able to inhibit the splicing process 
(Kim & Park 2000). 
The adenosine A2b receptor has been implicated in several biological functions, 
from regulation of neuroglia function to calcium homeostasis (Fiebich et al. 
1996; Pilitsis & Kimelberg 1998). Although the biological roles of adenosine and 
adenosine A2b receptor, target of alloxazine, are well known, the target of 
alloxazine in yeast is still unclear, since these receptors are not present in this 
organism. It is not possible to effectively speculate on what alloxazine action is 
in yeast based on the evidence from this study. However, there are examples of 
drugs with a known target in humans that were shown to have a different target 
in yeast. For example, Guanabenz, an antihypertensive drug and an agonist of 
α2-adrenergic receptors, has an antiprion activity in yeast cells (Tribouillard-
Tanvier et al. 2008).  
Despite encouraging results obtained in fission yeast, the use of alloxazine as a 
template for a therapeutic drug for juvenile CLN3 disease might be unrealistic. 
First, because the results obtained with alloxazine treatment in patient 
fibroblasts were not encouraging: the compound was not able to rescue the 
Golgi phenotype (Chapter 5.3.1). Moreover, work done by Yamagata et al 
(2007) reported that adenosine when bound to the adenosine A2b receptor 
induce the expression of glial cell line-derived neurotrophic factor (GDNF) and 
this is repressed by alloxazine (Yamagata et al. 2007). The fact that GDNF 
promotes the survival of neurons, and neurodegeneration is a hallmark of 
juvenile NCL, discredits the possibility of using alloxazine towards a therapeutic 
goal. 
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7.2.3 E-64 
L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane, commonly known as E-
64, is an irreversible and potent inhibitor of several cysteine peptidases, such 
as papain, actinidin, cathepsins B, H and L, among others  (Hashida et al. 1980; 
Barrett et al. 1982; Varughese et al. 1989; Matsumoto et al. 1999). E-64 is also 
able to strongly inhibit trypsin-catalysed hydrolysis, and trypsin is the only 
serine protease that E-64 has an effect on (Sreedharan et al. 1996). E-64 is 
widely used in vivo and as a potential template for drugs used in disease 
treatment mainly due to its specificity, cell permeability, ease of synthesis, 
stability and low toxicity (Katunuma & Kominami 1995).  
Since it is able to inhibit several cysteine peptidases involved in different 
biochemical processes in the cell, E-64 action directly influences multiple 
cellular pathways. It has been shown to inhibit neutrophil chemotaxis (Barna & 
Kew 1995) and invasion of human bladder carcinoma cells through basement 
membranes via cathepsin B inhibition (Redwood et al. 1992); it has antiparasitic 
properties (Carvalho et al. 2014; Wadhawan et al. 2014); and it has been 
reported to delay muscular dystrophy progression in mice (Komatsu et al. 
1986). Furthermore, E-64 also inhibits the chicken calcium-activated neutral 
protease (Sugita et al. 1980), establishing an indirect link with calcium 
homeostasis. The inhibition of the calcium-dependent cysteine protease calpain 
by E-64 has varying effects on several cellular pathways. For example, the 
development of Th17 cells is impaired (Iguchi-Hashimoto et al. 2011), together 
with apoptosis triggered by the T-cell receptor complex (Sarin et al. 1993), and 
the IL-6 and IL-1β cytokines production is inhibited, which leads to an 
amelioration of rheumatoid arthritis (Yoshifuji et al. 2005). Calpain is also 
involved in the processing of amyloid precursor protein (APP) (Tanabe et al. 
2013). APP when cleaved by β- or γ-secretases originates amyloid-β, the 
protein that accumulates in Alzheimer’s disease. On the other hand, when 
cleaved by α-secretases, APP produces a soluble form (sAPPα) that has 
neuroprotective properties. When there is an increased production of amyloid-β, 
there is no secretion of sAPPα, a phenotype observed in Alzheimer’s patients. 
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Calpain inhibition by E-64 is able to revert the reduced secretion of sAPPα, 
suggesting a neuroprotective role for E-64 and a potential for treatment of 
Alzheimer’s disease based on this compound. As Alzheimer’s is a 
neurodegenerative disease like juvenile CLN3 disease, and that amyloid-β 
processing is also altered in juvenile NCL (Kitaguchi et al. 1990), the same 
treatment may work for both. 
The fact that E-64 is able to reduce apoptosis in a mouse hybridoma (Sarin et 
al. 1993) makes this compound a good candidate for the development of 
therapy for juvenile CLN3 disease. The analgesic flupirtine, which has been 
reported to slow disease progression and clinically benefit juvenile NCL 
patients, is also able to reduce apoptosis in patient lymphoblasts and neurons 
(Dhar et al. 2002). Apoptosis has been reported as one of the mechanisms of 
neurodegeneration in juvenile NCL (Lane et al. 1996), and CLN3 also exerts an 
anti-apoptotic role (Puranam et al. 1999; Narayan et al. 2006a).  
E-64 has at least one identified target in S. cerevisiae, Ycp1p, a cysteine 
protease (Pei et al. 1995), suggesting that it may have at least one target in S. 
pombe. In fact, there are several cysteine peptidases in fission yeast, and 
although none of these were identified as E-64 targets to date, it is possible that 
E-64 exerts its action through one or all of them. Potential targets of E-64 in 
fission yeast, all of them cysteine proteases are listed below: 
1) Pca1p, a caspase-like protein involved in lipid-induced apoptosis (Low & 
Yang 2008). As discussed above, apoptosis is the main cause of 
neurodegeneration in juvenile CLN3 disease. 
2) Cut1p, a separase that is involved in several cellular roles. For example, 
it is involved in the cytokinetic process, more specifically in the 
separation of sister chromatids (Funabiki et al. 1996). Cytokinesis is 
known to be affected in btn1Δ cells (as previously discussed throughout 
this work), suggesting a link between Btn1p function and Cut1p, and 
possibly E-64 inhibitory action on the latter. Cut1p also represses the 
TORC2 pathway (Yuasa et al. 2004). Since the signalling in this pathway 
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is already affected in btn1Δ cells, E-64 may be targeting Cut1p and 
releasing TORC2 pathway from inhibition. In fact, it was reported that 
unbalanced high levels of Cut1p seem to be harmful for TORC2, when 
its activity is diminished (Ikai et al. 2011). This is also consistent with the 
sensitivity that btn1Δ cells show to CsA, an inhibitor of calcineurin, a 
component of the TORC2 pathway.  
3) Some deubiquitinating enzymes (like Ubp9p) involved in signalling 
pathways that regulate cell polarity and endocytosis (Kouranti et al. 
2010). These mechanisms are known to be deregulated in juvenile CLN3 
disease (Chapter 1.1.2). 
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7.2.4 Prochlorperazine dimaleate 
Prochlorperazine dimaleate or 2-Chloro-10-[3[(4-methyl-1-piperazinyl)propyl]-
10H-phenothiazine dimaleate is a salt composed of prochlorperazine and two 
molecules of maleate. Prochlorperazine is a phenothiazine (Lummis & Baker 
1997) and a D2 dopamine receptor antagonist (Creese et al. 1976) that also 
interacts directly with 5-hydroxytryptamine3 (5-HT3) receptors (Lummis & Baker 
1997), which are responsible for several roles mainly in the central nervous 
system (Kilpatrick et al. 1990). Prochlorperazine is also able to promote the 
release of the neurotransmitter acetylcholine  (ACh) in the cerebral cortex 
(Ghelardini et al. 2004).  
Prochlorperazine has antipsychotic, antiemetic and antinociceptive activity in 
vivo. The first to be discovered was the antiemetic ability of prochlorperazine 
(Moertel et al. 1963); this drug is able to stop nausea and vomiting. 
Prochlorperazine was also reported to increase the pain threshold in mice, 
exerting an antinociceptive effect, mediated by release of ACh (Ghelardini et al. 
2004). Furthermore, prochlorperazine is effective in the treatment of acute 
migraines, namely by alleviating pain and nausea (Tanen et al. 2003).  
Action of prochlorperazine affects several proteins in different manners. It was 
reported to increase the activity of integral membrane enzymes uridine 5'-
diphospho-glucuronosyltransferase and glucose-6-phosphatase in microsomes, 
via disruption of organized lipid-protein interactions (Dannenberg & Zakim 
1988). Prochlorperazine was also proposed to affect clathrin distribution, which 
led to an antiviral effect against the dengue virus (Simanjuntak et al. 2014). 
Furthermore, prochlorperazine modulates the human P2X7 receptor, an ATP 
cation channel involved in immune cell activation and neurological disorders 
such as Alzheimer’s disease and schizophrenia (Skaper et al. 2009). In this 
case, prochlorperazine acts as an open pore blocker and inhibits calcium entry 
into the cell (Hempel et al. 2013). This establishes a link between this 
compound’s action, neurodegeneration and calcium homeostasis. Other 
example of its link to calcium is the fact that prochlorperazine is able to inhibit 
growth of Acanthamoeba castellanii, the causative agent of blinding keratitis, by 
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an inhibitory action on amoeba calcium-regulatory proteins or by disruption of 
the amoeba plasma membrane (Baig et al. 2013). Moreover, prochlorperazine 
inhibits release of pro-inflammatory mediators from human mast cells, probably 
by decreasing the levels of intracellular calcium (Clemons et al. 2011). From all 
these roles and processes, only some are relevant to yeast and could be the 
underlying mechanism of drug action in this organism: disruption of lipid-protein 
interactions or pore blocking activity. Although the other processes are not 
relevant to yeast work, it is important to bear them in mind in order to avoid 
potential side effects or potential synergistic effects when translated to other 
organisms. 
Although prochlorperazine (dimaleate) and its action have not been associated 
with fission yeast, and there is no identified targeted yeast protein, it is possible 
that this compound has a target in these cells that is different from its original 
one. It is possible that this compound is in some way involved in a calcium 
homeostasis pathway in yeast, since it has been associated with it in several 
studies conducted in human cells, as mentioned above, and that this pathway is 
known to be disrupted in juvenile CLN3 disease and supposedly in btn1Δ cells. 
Further work needs to be done in order to identify and clarify the action of 
prochlorperazine in S. pombe.  
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7.2.5 Summary of all compounds 
The three compounds that were identified in the drug screen and that were 
subsequently validated (alloxazine, E-64 and prochlorperazine dimaleate) do 
not have any reported targets in fission yeast. For instance, adenosine and 
dopamine receptors, the principal human targets of alloxazine and 
prochlorperazine respectively, do not exist in this unicellular organism. This 
suggests that these two compounds are probably acting in a different manner, 
targeting another yeast pathway(s). Regarding the other compound, E-64, its 
targets are cysteine protease and there are several in S. pombe. Therefore, it is 
plausible that E-64 is exerting its inhibitory effect on one or more of them.  
Alloxazine is the only one among the three compounds able to rescue the 
temperature sensitivity phenotype of btn1Δ cells, both in liquid media and in 
spot assays (Chapter 5.2.4). This temperature sensitivity is related to the 
inability that btn1Δ cells have of adequately responding to different types of 
stress, which in turn, is linked to disruption in the TORC2 pathway (see above, 
section 7.2.1). This suggests that alloxazine may be involved in stress response 
pathways. On the other hand, alloxazine does not rescue the Golgi 
compactness phenotype in juvenile NCL patient fibroblasts, which may mean 
that it cannot be used with a therapeutic purpose for juvenile CLN3 disease.  
As mentioned above (section 7.2.3), E-64 may be inhibiting any cysteine 
protease activities in S. pombe. Different cysteine peptidases have been 
described in these cells, involved in different cellular processes, some of which 
that have been associated with Btn1p: autophagy, cytokinesis, endocytosis, cell 
polarity, vacuolar function (Funabiki et al. 1996; Low & Yang 2008; Kouranti et 
al. 2010; Mikawa et al. 2010; Sun et al. 2013) and most importantly the TORC2 
pathway (Yuasa et al. 2004). Consistent with its Cut1p protease inhibitory 
action, and its involvement in the TORC2 pathway, is the observation that E-64 
was the compound that most efficiently rescued the CsA sensitivity phenotype 
in btn1Δ cells out of the three compounds (Chapter 5.1). It was also the one 
that elicited the strongest rescue of the btn1Δ cell curving phenotype, the 
juvenile NCL fibroblasts’ less compact Golgi, and the activity and survival of the 
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Cln3 MO zebrafish. E-64 was also able to rescue all the other tested 
phenotypes in btn1Δ cells, except the defective growth at 37°C (Results 
Chapter 3). All of these results indicate that E-64 may be very useful for the 
development of new therapeutic tools towards juvenile CLN3 disease. 
Furthermore, E-64 has previously been reported as having a neuroprotective 
role in Alzheimer’s disease (Tanabe et al. 2013), and decreasing apoptosis 
(Sarin et al. 1993), one of the mechanisms of neurodegeneration in juvenile 
NCL (Lane et al. 1996).  
Prochlorperazine (dimaleate) action has not been previously associated with 
fission yeast; its known targets are not present in these cells (D2 dopamine 
receptor, 5-HT3 receptors and ACh); and its well-known use as an 
antipsychotic, antiemetic and antinociceptive drug is not relevant for yeast work. 
However, juvenile NCL patients do suffer from severe psychotic episodes as 
the disease advances (Mole et al. 2011), so a drug that addresses the 
underlying cause may be a very helpful component of juvenile NCL therapy. It is 
possible that this drug is acting in a different manner in yeast, maybe in a 
calcium-related pathway, due to its reported link to calcium, more specifically by 
potentially decreasing its intracellular levels (Clemons et al. 2011). 
Prochlorperazine dimaleate rescues all tested phenotypes in btn1Δ cells, 
except defective growth at 37°C, similarly to E-64 (Results Chapter 3). It is also 
able to rescue the tested phenotypes in juvenile NCL patient fibroblasts and in 
Cln3 MO zebrafish (tail flicking activity), which strongly supports its ability to 
revert or complement the lack of Btn1p in fission yeast cells, and probably 
dysfunctional CLN3 in human cells and fish. 
To conclude, all three compounds seem to be acting differently in the btn1Δ 
strain. However, two of them share some common features, for example their 
link to calcium: prochlorperazine decrease intracellular calcium levels (Pilitsis & 
Kimelberg 1998; Clemons et al. 2011) and E-64 inhibits calcium-dependent 
proteins (Sugita et al. 1980; Iguchi-Hashimoto et al. 2011). This could be a 
plausible explanation for their ability to rescue disease-related phenotypes, 
since CLN3 is known to regulate the intracellular levels of free calcium in SH-
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SY5Y cells (Chang et al. 2007). Furthermore, a study reported the ability of 
amlodipine, a calcium channel antagonist, to decrease the calcium levels in 
CLN3 siRNA–treated neurons (Warnock et al. 2013). As mentioned above 
(section 7.1.3.1), CLN3 may be working as a calcium channel, maintaining 
intracellular calcium levels, an important condition for several proteins to carry 
out their functions correctly. It is important to elucidate the role of Btn1p as a 
potential calcium channel. 
E-64 appears to be the most promising compound for the development of 
therapeutic tools for juvenile CLN3 disease, since it was able to rescue all the 
tested phenotypes (except one) in different models, and its action spectrum is 
broad. However, future work must be conducted regarding all three compounds 
in order to further clarify their mechanisms of action in fission yeast, and 
consequently in human cells.  
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7.3 Insights into therapy of other lysosomal storage disorders 
Fission yeast models of three lysosomal storage disorders, Chédiak Higashi 
syndrome, Niemann-Pick disease type C2 and congenital CLN10 disease, were 
characterised and further explored in the last part of this work. Considerations 
about their mechanism of action and potential therapy will be discussed below.  
The S. pombe strain modelling CHS is the lvs1Δ strain. This strain is 
characterised by the presence of exceptionally large vacuoles, and according to 
this work, a higher septation index when compared to a wild-type strain 
(Chapter 6.1.2). Alloxazine, E-64 and prochlorperazine dimaleate were able to 
rescue both these phenotypes in these cells, suggesting that these compounds 
should be considered for further studies concerning therapeutic alternatives for 
CHS. Similar to juvenile CLN3 disease, calcium homeostasis is also disrupted 
in CHS, where the levels of lysosomal calcium are elevated in neutrophils, due 
to an hyperactivation of the calcium uptake process (Styrt et al. 1988). This 
observation establishes a possible link between this disorder, calcium 
homeostasis and action of E-64 and prochlorperazine dimaleate compounds 
(see the section above). 
E-64 has been shown to rescue several phenotypes in the mouse model of 
CHS, the beige mouse, and in patient cell lines: decreased activity of natural 
killer cells, increased concanavalin A-induced cap formation, formation of giant 
granules, reduced cathepsin G and lysosomal elastase activities, susceptibility 
to bacterial infection; all due to its effect on reversing the decline of protein 
kinase C activity, by preventing its calpain-mediated proteolysis (Ito et al. 1989; 
Sato et al. 1990; Tanabe et al. 2000; Cui et al. 2001; Morimoto et al. 2007; 
Tanabe et al. 2009). These observations suggest that E-64 is a good candidate 
for the development of a CHS therapeutic drug.  
Niemann-Pick type C2 protein is conserved in fission yeast. The npc2Δ strain 
was characterised in this work (Results Chapter 4). This strain contains large 
vacuoles and an increased number of septated cells. The first phenotype was 
rescued by alloxazine, E-64 and prochlorperazine dimaleate, whereas the 
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septation index was only decreased after treatment with alloxazine and 
prochlorperazine. However, and in contrast with these results, E-64 seems to 
be the most promising compound regarding therapy of NPC. Levels and activity 
of cathepsin B are increased in the brains of NPC mutant mice (Liao et al. 
2007). Cathepsin B is a target of E-64, and therefore this compound may be 
able to revert some phenotypes associated with the increased levels of this 
lysosomal enzyme in NPC. In fact, this increase has been associated with 
neurodegeneration in NPC (Amritraj et al. 2009), and therefore the action of E-
64 may be relevant for therapy attenuating NPC pathology. Further supporting 
this hypothesis is the observation that cathepsins B and L are involved in 
secretion of NPC2, and treatment with E-64 (inhibitor of these cathepsins) 
increases the intracellular levels of NPC2, by blocking its secretion (Hannaford 
et al. 2013). Similarly to juvenile CLN3 disease, mitochondrial defects have 
been reported in NPC (Vilaca et al. 2014), and mitochondrial function is linked 
to calcium homeostasis (Duchen et al. 2008), suggesting that there is a link 
between dysregulation of calcium levels in these diseases and the mechanisms 
of action of E-64 and prochlorperazine dimaleate. 
The sxa1Δ S. pombe strain models congenital CLN10 disease. This strain, 
similar to the other two LSD strains, is characterised by enlarged vacuoles and 
a high septation index. Treatment with alloxazine, E-64 and prochlorperazine 
dimaleate rescued the vacuoles size but not the number of septated cells in this 
strain. Total activity of cathepsin D (deficient in CLN10) is increased in E-64-
treated fibroblasts (Samarel et al. 1989); however, this compound is known to 
affect the proteolytic maturation of procathepsin D (Ishidoh et al. 1999), leading 
to accumulation of the processing intermediates (Laurent-Matha et al. 2006). 
This effect of E-64 on cathepsin D is not relevant to treatment as cathepsin D is 
essentially null in congenital CLN10 disease. As long as E-64 is known to have 
a positive effect on parallel pathways (as the vacuoles size rescue data 
mentioned above suggests, Results Chapter 4), it could still be useful for the 
development of CLN10 disease therapeutic tools. 
Discussion 
 
 188 
Results obtained in this work with the LSD yeast strains are preliminary, since 
these strains were characterised in terms of the phenotypes that were 
previously associated with the loss of btn1 in the yeast strain modelling juvenile 
CLN3 disease. Work to confirm a direct link between the phenotypes and the 
deleted LSD gene (for example, expression of the respective genes in the 
deletion strains in order to verify if they were able to rescue the phenotypes) still 
needs to be done. Furthermore, the compounds tested in these strains were the 
ones identified in the drug screen performed with btn1Δ cells, and not specific 
to the other three LSD strains. Therefore, the results obtained here must be 
regarded as preliminary; additional work must be done in order to further 
elucidate the disease pathways involved in these S. pombe disease strains as 
well as the action of compounds in these pathways. Nevertheless, it may be 
that these diseases share common downstream disease phenotypes, such as 
vacuole homeostasis, in which case a compound addressing these could be 
efficacious for more than one disease. 
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7.4 Conclusions and Future Work 
The principal aims of this project were to study the impact of different mutations 
on the function of fission yeast Btn1p and to identify novel lead compounds that 
can be developed to treat juvenile CLN3 disease as a first stage to new 
therapeutic development. In the first part of this work, it was confirmed that 
different mutations in the btn1 gene have different effects on the protein 
function, affecting its expression and cell phenotypes. According to the results 
obtained with strain expressing different mutant Btn1p, it is proposed that its 
lumenal and/or transmembrane regions are particularly important for its function. 
Furthermore, the levels of btn1 expression influence its function, suggesting 
that this is important and tightly regulated. New insights regarding the function 
of Btn1p (and CLN3) were gained. These orthologue proteins are known to 
affect the function of several proteins involved in different cellular pathways. 
Their effect may be exerted from the Golgi compartments, by affecting the 
sorting and activity of several proteins and downstream pathways. On the other 
hand, it is also possible that Btn1p (and CLN3) is acting as a channel or ion 
transporter, and that its dysfunction affects the endocytic transport, which would 
affect many cellular proteins. Furthermore, Btn1p function is related to the 
TORC2 signalling pathway, most likely via its link to calcineurin. It is possible 
that Btn1 has an overlapping function with calcineurin. Conclusions obtained 
regarding the potential therapeutic compounds identified in this study, are 
discussed in detail below (section 7.4.2). Beforehand, suggestions on future 
work that need to be done are presented. 
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7.4.1 Future work  
Further work is needed to conclude the work started of this study. Below is a list 
of some experiments that will be useful to fully comprehend and complement 
the findings made in this study.  
1) Further clarify the action mechanism of calcineurin in wild-type and btn1Δ 
cells – for example, the creation of a calcineurin and Btn1p double mutant to 
verify its viability or synthetic lethality (if these proteins have, in fact, an 
overlapping function);  
2) Determine if btn1Δ cells are sensitive to growth in the presence of another 
calcineurin inhibitor, FK506, to ensure that the sensitivity of these cells is 
related to the absence of calcineurin;  
3) Investigate the relationship between Btn1p and Ypt3p, to verify if they have 
common functions, as suggested by the results from several studies;  
4) Further clarify the role of calcium homeostasis in disease pathology and in 
the fission yeast model, by measuring calcium cytosolic and vacuolar levels in 
wild-type and btn1Δ cells; and testing whether any calcium channel antagonists 
are able to reverse phenotypes in btn1Δ (and mammalian cells). 
5) Perform a drug screen with the same library using one or more btn1-mutated 
S. pombe strains, after identification of a mutation-specific phenotype in these 
cells; 
6) Test the ability of alloxazine, E-64 and prochlorperazine dimaleate to rescue 
more phenotypes of CLN3-depleted/deficient mammalian cells; 
7) Perform a dose response assay for alloxazine, E-64 and prochlorperazine 
dimaleate;  
8) Test other positive hits from the drug screen already performed, that showed 
a less significant rescue than the six that were followed up; 
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9) Test the three initial hit compounds (atenolol, etoposide and daphnetin) that 
were excluded from the yeast work due to their toxicity in wild-type yeast cells, 
in mammalian cells/models where their action could be beneficial;  
9) Test the effect of other compounds structurally similar to the ones studied 
here in btn1Δ cells;  
10) A great amount of work for the CHS, NPC and CLN10 yeast strains: 
characterising them in terms of phenotypes, performing a drug screen with the 
same library (or a different one) using each strain, further analysing the effect 
that alloxazine, E-64 and prochlorperazine dimaleate (and potential newly 
identified compounds) have in their phenotypes; 
 
Discussion 
 
 192 
7.4.2 Potential therapeutic compounds for juvenile CLN3 disease 
Three compounds were identified in a drug screen with btn1Δ cells: alloxazine, 
E-64 and prochlorperazine dimaleate. All three compounds seem to be acting 
differently in the btn1Δ strain, and none of their targets have been identified in 
fission yeast. The exact mechanism of action of alloxazine in yeast cannot be 
inferred from the results that were obtained. The same statement is valid for 
prochlorperazine dimaleate, although this compound may be affecting calcium-
related pathways, along with regulating calcium intracellular levels. In fact, this 
compound shares a common link with CLN3/Btn1p and E-64 to calcium-related 
pathways and proteins. 
Many yeast pathways are conserved in human and other eukaryotic organisms, 
therefore pathways targeted by these compounds in yeast are probably present 
in human cells, even though it is already known that these compounds work on 
different targets in humans. Actions of the three compounds are unlikely to be 
yeast-specific as they were able to successfully rescue phenotypes in a 
zebrafish disease model. 
E-64 seems to be the compound with the most potential for development of 
therapeutic tools for juvenile CLN3 disease, since it was able to rescue all 
(except one) phenotypes in fission yeast, zebrafish disease models and patient 
fibroblasts. Furthermore, this compound has been previously reported to rescue 
several phenotypes in the CHS mouse model and in CHS patient cell lines, 
suggesting that it could be used as a template for a CHS therapeutic drug. A 
similar conclusion can be drawn regarding NPC, since E-64 is able to decrease 
high levels of cathepsin B in brains of NPC mice models. These observations 
may be linked to the fact that E-64 is the compound with the largest pattern of 
action from the three that were tested. This makes it a good candidate as a 
template for the development of drugs that will target specific proteins in 
different diseases. However, it is very important to achieve an acceptable safety 
profile, in order to avoid side effects. 
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